Compositions and methods for modulating CXCL
By combining expression repressors of targeted parts and effector parts in the CXCL locus, the expression of CXCL and IL-8 is solved, and the problem of difficult to regulate the expression of multiple related genes in the prior art is achieved, and multiple CXCLs are achieved Effective regulation of genes has the potential to treat inflammatory diseases and cancer.
Patent Information
- Application Number
- CN202380031799.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-01-06
- Filing Date
- 2023-03-29
- Publication Date
- 2024-11-26
AI Technical Summary
The prior art is difficult to effectively regulate the expression of multiple related genes, especially within the CXCL locus, resulting in the occurrence and development of diseases.
Provides expression repressors containing targeting moieties and effector moieties that reduce expression of CXCL genes, including target sites of the IL-8 promoter, by binding to cis-acting regulatory elements of the CXCL locus, using specific nucleosides Sequence and amino acid sequence, combined with functional variants such as CRISPR-Cas domain and DNA methyltransferase, realize the expression regulation of multiple CXCL genes.
Reduced expression of CXCL genes and IL-8 was achieved, reducing the expression levels of multiple CXCL genes, providing a new system of tools to regulate gene expression, potentially for the treatment of inflammatory diseases and cancers.
Smart Images

Figure BDA0005066765170001091 
Figure BDA0005066765170001101 
Figure BDA0005066765170001111
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to U.S. Provisional Application No. 63 / 325,524 filed on March 30, 2022, U.S. Provisional Application No. 63 / 379,849 filed on October 17, 2022, and U.S. Provisional Application No. 63 / 478,855 filed on January 6, 2023, the entire contents of which are hereby incorporated by reference.
[0003] Sequence Listing
[0004] This application contains a sequence listing, which has been submitted electronically in XML format and is hereby incorporated by reference in its entirety. The XML copy was created on March 28, 2023, is named O2057-7032WO_SL, and is 661,150 bytes in size. Background Art
[0005] Misregulation of gene expression is the root cause of many diseases (e.g., in mammals, such as humans). Many diseases and conditions are associated with multiple related genes. New tools, systems, and methods are needed to alter (e.g., reduce) the expression of multiple related genes. Summary of the Invention
[0006] The present disclosure provides, inter alia, expression repressors or systems comprising expression repressors that can be used to modulate (e.g., reduce) the expression of one or more target genes (e.g., one or more CXCL genes) located within a CXCL locus that includes cis-acting regulatory elements.
[0007] In one aspect, the present disclosure provides an expression repressor comprising:
[0008] a first targeting moiety that binds to a target site comprising a cis-acting regulatory element, such as an enhancer (e.g., an enhancer of the CXCL gene); and
[0009] First effector moiety.
[0010] In one aspect, the present disclosure provides an expression repressor comprising:
[0011] a first targeting moiety that binds to a target site, wherein the target site is within a cis-acting regulatory element of the CXCL locus, and
[0012] Optionally, the first effector moiety,
[0013] The expression inhibitor can reduce the expression of the CXCL gene.
[0014] In one aspect, the present disclosure provides an expression repressor comprising:
[0015] a first targeting moiety that binds to a target site comprising an IL-8 promoter; and
[0016] First effector moiety.
[0017] In one aspect, the present disclosure provides an expression repressor comprising:
[0018] a first targeting moiety that binds to a target site, wherein the target site is within an El cis-acting regulatory element of the CXCL locus or within an E2 cis-acting regulatory element of the CXCL locus, and
[0019] Optionally, the first effector moiety,
[0020] The expression inhibitor can reduce the expression of the CXCL gene.
[0021] In some embodiments, the target site is within genomic coordinates chr4:74591400-74593000 or chr4:74982639-74983600 (based on the hg19 human genome reference assembly).
[0022] In one aspect, the present disclosure provides an expression repressor comprising:
[0023] a first targeting moiety that binds to a target site within genomic coordinates chr4:74591400-74593000 or chr4:74982639-74983600 (based on the hg19 human genome reference assembly), and
[0024] Optionally, the first effector moiety,
[0025] The expression inhibitor can reduce the expression of the CXCL gene.
[0026] In some embodiments, the target site is selected from:
[0027] a) GRCh37: chr4:74591777-74591797;
[0028] b)GRCh37:chr4:74591834-74591854;
[0029] c)GRCh37:chr4:74591896-74591916;
[0030] d)GRCh37:chr4:74592082-74592102;
[0031] e)GRCh37:chr4:74592107-74592127;
[0032] f)GRCh37:chr4:74592156-74592176;
[0033] g)GRCh37:chr4:74592210-74592230;
[0034] h)GRCh37:chr4:74592057-74592077;
[0035] i)GRCh37:chr4:74591977-74591997;
[0036] j)GRCh37:chr4:74591856-74591876;
[0037] k)GRCh37:chr4:74591768-74591790;
[0038] l)GRCh37:chr4:74591844-74591866;
[0039] m)GRCh37:chr4:74591892-74591914;
[0040] n)GRCh37:chr4:74592088-74592110;
[0041] o)GRCh37:chr4:74982748-74982770;
[0042] p)GRCh37:chr4:74982841-74982863;
[0043] q)GRCh37:chr4:74982882-74982904;
[0044] r)GRCh37:chr4:74982960-74982982;
[0045] s)GRCh37:chr4:74983108-74983130; and
[0046] t)GRCh37:chr4:74983181-74983203.
[0047] In certain embodiments, the first targeting moiety binds within 500, 300, 200, 100, or 50 nucleotides upstream or downstream of a target site selected from:
[0048] a) GRCh37: chr4:74591777-74591797;
[0049] b)GRCh37:chr4:74591834-74591854;
[0050] c)GRCh37:chr4:74591896-74591916;
[0051] d)GRCh37:chr4:74592082-74592102;
[0052] e)GRCh37:chr4:74592107-74592127;
[0053] f)GRCh37:chr4:74592156-74592176;
[0054] g)GRCh37:chr4:74592210-74592230;
[0055] h)GRCh37:chr4:74592057-74592077;
[0056] i)GRCh37:chr4:74591977-74591997;
[0057] j)GRCh37:chr4:74591856-74591876;
[0058] k)GRCh37:chr4:74591768-74591790;
[0059] l)GRCh37:chr4:74591844-74591866;
[0060] m)GRCh37:chr4:74591892-74591914;
[0061] n)GRCh37:chr4:74592088-74592110;
[0062] o)GRCh37:chr4:74982748-74982770;
[0063] p)GRCh37:chr4:74982841-74982863;
[0064] k)GRCh37:chr4:74982882-74982904;
[0065] r)GRCh37:chr4:74982960-74982982;
[0066] s)GRCh37:chr4:74983108-74983130; and
[0067] t)GRCh37:chr4:74983181-74983203.
[0068] In one aspect, the present disclosure provides an expression repressor comprising:
[0069] a first targeting moiety that binds to a target site, the first targeting moiety comprising at least 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, or 29 nucleotides of a sequence of any one of SEQ ID NO: 163 or 164, or a sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical thereto, or a sequence that differs therefrom at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 position, and
[0070] Optionally, the first effector moiety,
[0071] The expression inhibitor can reduce the expression of the CXCL gene.
[0072] In one aspect, the present disclosure provides an expression repressor comprising:
[0073] a first targeting moiety that binds to a target site, wherein the target site is within the IL-8 promoter, and
[0074] Optionally, the first effector moiety,
[0075] The expression inhibitor can reduce the expression of IL-8.
[0076] In some embodiments, the target site (e.g., a target site within the IL8 promoter) is within genomic coordinates chr4:74606112-74606462 (hg19). In some embodiments, the target site (e.g., a target site within the IL8 promoter) is located within 1 kb of chr:74606112-74606462 (e.g., chr4:74606112-74606662, chr4:74606112-74606862, chr4:74606112-74607062, chr4:74606112-74607262, chr4:74606112-74607462, chr4:74605912-74606462, chr4:74605712-74606862 4606462, chr4:74605512-74606462, chr4:74605312-74606462, chr4:74605112-74606462, chr4:74605912-74606662, chr4:7460 5912-74606862, chr4:74605912-74607062, chr4:74605912-74607262, chr4:74605912-74607462, chr4:74605712-74606662, chr 4:74605712-74606862, chr4:74605712-74607062, chr4:74605712-74607262, chr4:74605712-74607462, chr4:74605512-74606 662, chr4:74605512-74606862, chr4:74605512-74607062, chr4:74605512-74607262, chr4:74605512-74607462, chr4:74605312 In certain embodiments, the target site (e.g., a target site within the IL8 promoter) is located 500 bp upstream of the transcription start site.In certain embodiments, the target site (e.g., a target site within the IL8 promoter) is located at chr4:74605723-74606223. In certain embodiments, the target site (e.g., a target site within the IL8 promoter) is located at chr4:74605723-74606426, chr4:74605723-74606626, chr4:74605723-74606826, chr4:74605723-74607026, chr4:74605723-74607226, chr4:74605523-74606226, chr4:74605323-74606226, chr4:74605123-74606426. 6226, chr4:74604923-74606226, chr4:74604723-74606226, chr4:74605523-74606426, chr4:74605523-74606626, chr4:74 605523-74606826, chr4:74605523-74607026, chr4:74605523-74607226, chr4:74605323-74606426, chr4:74605323-746066 26. chr4:74605323-74606826, chr4:74605323-74607026, chr4:74605323-74607226, chr4:74605123-74606426, chr4:7460 5123-74606626, chr4:74605123-74606826, chr4:74605123-74607026, chr4:74605123-74607226, chr4:74604923-7460642 6. chr4:74604923-74606626, chr4:74604923-74606826, chr4:74604923-74607026, chr4:74604923-74607226, chr4:74604723-74606426, chr4:74604723-74606626, chr4:74604723-74606826, chr4:74604723-74607026, or chr4:74604723-74607226. In some embodiments, the target site (e.g., a target site within the IL8 promoter) is located 1000 bp upstream of the transcription start site. In certain embodiments, the target site (e.g., a target site within the IL8 promoter) is located at chr4:74605223-74606223.In some embodiments, the target site (e.g., a target site within the IL8 promoter) is located at chr4:74605226-74606426, chr4:74605226-74606626, chr4:74605226-74606826, chr4:74605226-74607026, chr4:74605226-74607226, chr4:74605026-74606226, chr4:74604826-74606226, chr4:74604626-7460 6226, chr4:74604426-74606226, chr4:74604226-74606226, chr4:74605026-74606426, chr4:74605026-74606626, chr4:74 605026-74606826, chr4:74605026-74607026, chr4:74605026-74607226, chr4:74604826-74606426, chr4:74604826-746066 26. chr4:74604826-74606826, chr4:74604826-74607026, chr4:74604826-74607226, chr4:74604626-74606426, chr4:7460 4626-74606626, chr4:74604626-74606826, chr4:74604626-74607026, chr4:74604626-74607226, chr4:74604426-7460642 6. chr4:74604426-74606626, chr4:74604426-74606826, chr4:74604426-74607026, chr4:74604426-74607226, chr4:74604226-74606426, chr4:74604226-74606626, chr4:74604226-74606826, chr4:74604226-74607026 or chr4:74604226-74607226.
[0077] In one aspect, the present disclosure provides an expression repressor comprising:
[0078] a first targeting moiety that binds to a target site within the following genomic coordinates: GRCh37:chr4:74606162-74606184, GRCh37:chr4:74605723-74606223, or GRCh37:chr4:74605223-74606223 (based on the hg19 human genome reference assembly); and
[0079] Optionally, the first effector moiety,
[0080] The expression inhibitor can reduce the expression of IL-8.
[0081] In some embodiments, the target site to which the expression repressor binds is selected from:
[0082] i)GRCh37:chr4:74605780-74605800;
[0083] ii) GRCh37: chr4:74605961-74605981;
[0084] iii) GRCh37: chr4:74606122-74606142;
[0085] iv)GRCh37:chr4:74605955-74605975;
[0086] v)GRCh37:chr4:74605842-74605862;
[0087] vi)GRCh37:chr4:74606145-74606165;
[0088] vii)GRCh37:chr4:74606039-74606056;
[0089] viii)GRCh37:chr4:74606113-74606130;
[0090] ix)GRCh37:chr4:74606137-74606154;
[0091] x)GRCh37:chr4:74606150-74606167;
[0092] xi)GRCh37:chr4:74591882-74591899;
[0093] xii) GRCh37:chr4:74591923-74591940;
[0094] xiii) GRCh37: chr4:74591897-74591914; and
[0095] xiv) GRCh37:chr4:74591873-74591890.
[0096] In certain embodiments, the first targeting moiety binds within 500, 300, 200, 100, or 50 nucleotides upstream or downstream of a target site selected from:
[0097] i)GRCh37:chr4:74605780-74605800;
[0098] ii) GRCh37: chr4:74605961-74605981;
[0099] iii) GRCh37: chr4:74606122-74606142;
[0100] iv)GRCh37:chr4:74605955-74605975;
[0101] v)GRCh37:chr4:74605842-74605862;
[0102] vi)GRCh37:chr4:74606145-74606165;
[0103] vii)GRCh37:chr4:74606039-74606056;
[0104] viii)GRCh37:chr4:74606113-74606130;
[0105] ix)GRCh37:chr4:74606137-74606154;
[0106] x)GRCh37:chr4:74606150-74606167;
[0107] xi)GRCh37:chr4:74591882-74591899;
[0108] xii) GRCh37:chr4:74591923-74591940;
[0109] xiii) GRCh37: chr4:74591897-74591914; and
[0110] xiv) GRCh37:chr4:74591873-74591890.
[0111] In some embodiments, the first effector portion comprises an effector described herein, e.g., KRAB, MQ1, DNMT1, DNMT3A1, DNMT3A2, DNMT3B1, DNMT3B2, DNMT3B3, DNMT3B4, DNMT3B5, DNMT3B6, DNMT3L, EZH2, HDAC8, MeCP2, HP1, RBBP4, REST, FOG1, SUZ12, SETDB1, SETDB2, EHMT2 (i.e., G9A), EHMT1 (i.e., GLP), SUV39H1, HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, HDAC10, HDAC11, SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, SIRT7, SIRT8, SIRT9, EZH1, SUV39H2, SETD8, SUV420H1, SUV420H2 or DNMT3, or a functional variant or fragment of any one thereof.
[0112] In certain embodiments, the first effector moiety is connected to the targeting moiety by a linker. In certain embodiments, the linker is a peptide linker. In certain embodiments, the length of the linker can be between 2-30, 5-30, 10-30, 15-30, 20-30, 25-30, 2-25, 5-25, 10-25, 15-25, 20-25, 2-20, 5-20, 10-20, 15-20, 2-15, 5-15, 10-15, 2-10, 5-10, or 2-5 amino acids, or a length greater than or equal to 2, 5, 10, 15, 20, 25, or 30 amino acids (and optionally, a length of up to 50, 40, 30, 25, 20, 15, 10, or 5 amino acids).
[0113] In some embodiments, the first effector moiety is C-terminal to the targeting moiety.
[0114] In certain embodiments, the first effector moiety is N-terminal to the targeting moiety.
[0115] In some embodiments, the first effector portion is encoded by a nucleotide sequence selected from any one of SEQ ID NOs: 10, 14, 16, 18, 66, 68, or a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical thereto, or differs therefrom at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 position.
[0116] In certain embodiments, the first effector portion comprises an amino acid sequence according to any one of SEQ ID NOs: 11, 12, 13, 15, 17, 19, 67, or a sequence that is at least 80%, 85%, 90%, 95%, 99% or 100% identical thereto, or differs therefrom at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 position.
[0117] In some embodiments, the first effector moiety is MQ1 or a functional variant or fragment thereof, for example, wherein the first effector moiety comprises the amino acid sequence of SEQ ID NO: 11 or 12, or a sequence that is at least 80%, 85%, 90%, 95%, 99% or 100% identical thereto, or differs therefrom at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 position, wherein optionally the first effector moiety is at the C-terminal end of the first targeting moiety.
[0118] In certain embodiments, the first effector moiety is KRAB or a functional variant or fragment thereof, e.g., wherein the first effector moiety comprises the amino acid sequence of SEQ ID NO: 13, or a sequence that is at least 80%, 85%, 90%, 95%, 99% or 100% identical thereto, or differs therefrom at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 position, wherein optionally the first effector moiety is C-terminal to the first targeting moiety.
[0119] In some embodiments, the first effector moiety is DNMT3a / 3L or a functional variant or fragment thereof, e.g., wherein the first effector moiety comprises the amino acid sequence of SEQ ID NO: 15, or a sequence that is at least 80%, 85%, 90%, 95%, 99% or 100% identical thereto, or differs therefrom at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 position, wherein optionally the first effector moiety is at the C-terminal end of the first targeting moiety.
[0120] In certain embodiments, the first effector portion is EZH2 or a functional variant or fragment thereof, for example, wherein the first effector portion comprises the amino acid sequence of SEQ ID NO: 17, or a sequence that is at least 80%, 85%, 90%, 95%, 99% or 100% identical thereto, or differs therefrom at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 position.
[0121] In some embodiments, the first effector moiety is HDAC8 or a functional variant or fragment thereof, e.g., wherein the first effector moiety comprises the amino acid sequence of SEQ ID NO: 19, or a sequence that is at least 80%, 85%, 90%, 95%, 99% or 100% identical thereto, or differs therefrom at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 position, wherein optionally the first effector moiety is at the C-terminal end of the first targeting moiety.
[0122] In certain embodiments, the first effector moiety is G9A or a functional variant or fragment thereof, for example, wherein the first effector moiety comprises the amino acid sequence of SEQ ID NO: 67, or a sequence that is at least 80%, 85%, 90%, 95%, 99% or 100% identical thereto, or differs therefrom at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 position, wherein optionally the first effector moiety is N-terminal to the first targeting moiety.
[0123] In some embodiments, the effector moiety comprises a DNA methyltransferase, eg, MQ1, or a fragment or variant thereof.
[0124] In certain embodiments, the effector moiety comprises a transcriptional repressor, eg, comprises KRAB or a fragment or variant thereof.
[0125] In some embodiments, the target site has a length of 15-20, 20-25, 25-30, or 30-35 nucleotides.
[0126] In some embodiments, the first targeting moiety comprises a zinc finger domain.
[0127] In certain embodiments, the zinc finger domain comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 zinc fingers (and optionally no more than 11, 10, 9, 8, 7, 6, or 5 zinc fingers).
[0128] In some embodiments, the zinc finger domain comprises 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 2-10, 2-9, 2-8, 2-7, 2-6, 2-5, 2-4, 2-3, 3-10, 3-9, 3-8, 3-7, 3-6, 3-5, 3-4, 4-10, 4-9, 4-8, 4-7, 4-6, 4-5, 5-10, 5-9, 5-8, 5-7, 5-6, 6-10, 6-9, 6-8, 6-7, 7-10, 7-9, 7-8, 8-10, 8-9, or 9-10 zinc fingers.
[0129] In some embodiments, the zinc finger domain comprises 3, 7, or 9 zinc fingers. In some embodiments, the zinc finger domain targets a site comprising 21 nucleotides.
[0130] In certain embodiments, the first targeting moiety comprises a CRISPR-Cas domain.
[0131] In certain embodiments, the expression inhibitors described herein can reduce the expression of multiple CXCL genes (e.g., 2, 3, 4, 5, 6, 7, or 8 CXCL genes). In certain embodiments, the expression inhibitors described herein can reduce the expression of one or more (e.g., 2, 3, 4, 5, 6, 7, or 8) of CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, or IL-8.
[0132] In certain embodiments, the first effector moiety is a persistent effector moiety or a transient effector moiety.
[0133] In some embodiments, the first targeting moiety comprises a zinc finger domain and the first effector moiety comprises a transcriptional repressor, eg, KRAB or a fragment or variant thereof.
[0134] In some embodiments, the first targeting moiety comprises a zinc finger domain and the first effector moiety comprises an epigenetic modifying moiety, e.g., a DNA methyltransferase, e.g., MQ1 or a fragment or variant thereof.
[0135] In some embodiments, the expression repressor comprises the amino acid sequence of any one of SEQ ID NOs: 152-161, or a sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical thereto, or a sequence that differs therefrom at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 position.
[0136] In some embodiments, an expression repressor described herein: (i) comprises one or more nuclear localization signal sequences (NLS), or (ii) does not comprise an NLS.
[0137] In some embodiments, the expression repressors described herein comprise a first NLS at the N-terminus, eg, wherein the first NLS has the sequence of SEQ ID NO: 63 or 64.
[0138] In some embodiments, the expression repressors described herein comprise an NLS located at the C-terminus, such as a second NLS, such as a sequence having SEQ ID NO: 63 or 64.
[0139] In some embodiments, the first and second NLS have the same sequence. In certain embodiments, the first and second NLS have different sequences.
[0140] In certain embodiments, binding of the expression repressor to the target site increases methylation at a site in the CXCL locus, such as increased methylation at an El cis-acting regulatory element of the CXCL locus or an E2 cis-acting regulatory element of the CXCL locus.
[0141] In one aspect, the present disclosure provides a system comprising:
[0142] a) the first expression repressor according to any preceding embodiment, and
[0143] b) a second expression suppressor, for example, a second expression suppressor that reduces expression of a CXCL gene.
[0144] In some embodiments, the second expression repressor comprises:
[0145] a second targeting moiety that binds to a second target site within the CXCL locus, and
[0146] Optionally, a second effector moiety.
[0147] In certain embodiments, the second expression repressor binds to the El cis-acting regulatory element of the CXCL locus, the E2 cis-acting regulatory element of the CXCL locus, or the IL8 promoter.
[0148] In certain embodiments, the second target site is within the following coordinates: GRCh37: chr4:74606162-74606184, GRCh37: chr4:74605723-74606223 or GRCh37: chr4:74605223-74606223. In some embodiments, the second target site is within the following coordinates:
[0149] a) chr4: 74606112 - 74606462, chr4: 74606112 - 74606662, chr4: 74606112 - 74606862, chr4: 74606112 - 74607062, chr4: 74606112 - 74607262, chr4: 74606112 - 74607462, chr4: 74605912 - 74606462, chr4: 74605712 - 74606462, chr4: 74605512 - 74606462, chr4: 74605312 - 74606462, chr4: 74605112 - 74606462, chr4: 74605912 - 74606662, chr4: 74605912 - 74606862, chr4: 74605912 - 74607062, chr4: 74605912 - 74607262, chr4: 74605912 - 74607462, chr4: 74605712 - 74606662, chr4: 74605712 - 74606862, chr4: 74605712 - 74607062, chr4: 74605712 - 74607262, chr4: 74605712 - 74607462, chr4: 74605512 - 74606662, chr4: 74605512 - 74606862, chr4: 74605512 - 74607062, chr4: 74605512 - 74607262, chr4: 74605512 - 74607462, chr4: 74605312 - 74606662, chr4: 74605312 - 74606862, chr4: 74605312 - 74607062, chr4: 74605312 - 74607262, chr4: 74605312 - 74607462, chr4: 74605112 - 74606662, chr4: 74605112 - 74606862, chr4: 74605112 - 74607062, chr4: 74605112 - 74607262 or chr4: 74605112 - 74607462;
[0150] b) chr4: 74605723 - 74606223, chr4: 74605723 - 74606426, chr4: 74605723 - 74606626, chr4: 74605723 - 74606826, chr4: 74605723 - 74607026, chr4: 74605723 - 74607226, chr4: 74605523 - 74606226, chr4: 74605323 - 74606226, chr4: 74605123 - 74606226, chr4: 74604923 - 74606226, chr4: 74604723 - 74606226, chr4: 74605523 - 74606426, chr4: 74605523 - 74606626, chr4: 74605523 - 74606826, chr4: 74605523 - 74607026, chr4: 74605523 - 74607226, chr4: 74605323 - 74606426, chr4: 74605323 - 74606626, chr4: 74605323 - 74606826, chr4: 74605323 - 74607026, chr4: 74605323 - 74607226, chr4: 74605123 - 74606426, chr4: 74605123 - 74606626, chr4: 74605123 - 74606826, chr4: 74605123 - 74607026, chr4: 74605123 - 74607226, chr4: 74604923 - 74606426, chr4: 74604923 - 74606626, chr4: 74604923 - 74606826, chr4: 74604923 - 74607026, chr4: 74604923 - 74607226, chr4: 74604723 - 74606426, chr4: 74604723 - 74606626, chr4: 74604723 - 74606826, chr4: 74604723 - 74607026 or chr4: 74604723 - 74607226; or
[0151] c)chr4:74605223-74606223, chr4:74605226-74606426, chr4:74605226-74606626, chr4:74605226-74606826, chr4:7460 5226-74607026, chr4:74605226-74607226, chr4:74605026-74606226, chr4:74604826-74606226, chr4:74604626-7460622 6. chr4:74604426-74606226, chr4:74604226-74606226, chr4:74605026-74606426, chr4:74605026-74606626, chr4:74605 026-74606826、chr4:74605026-74607026、chr4:74605026-74607226、chr4:74604826-74606426、chr4:74604826-74606626 , chr4:74604826-74606826, chr4:74604826-74607026, chr4:74604826-74607226, chr4:74604626-74606426, chr4:74604 626-74606626、chr4:74604626-74606826、chr4:74604626-74607026、chr4:74604626-74607226、chr4:74604426-74606426 , chr4:74604426-74606626, chr4:74604426-74606826, chr4:74604426-74607026, chr4:74604426-74607226, chr4:74604226-74606426, chr4:74604226-74606626, chr4:74604226-74606826, chr4:74604226-74607026 or chr4:74604226-74607226.
[0152] In certain embodiments, the second target site is within: GRCh37: chr4:74606162-74606184.
[0153] In some embodiments, the second target site is selected from:
[0154] i)GRCh37:chr4:74605780-74605800;
[0155] ii) GRCh37: chr4:74605961-74605981;
[0156] iii) GRCh37: chr4:74606122-74606142;
[0157] iv)GRCh37:chr4:74605955-74605975;
[0158] v)GRCh37:chr4:74605842-74605862;
[0159] vi)GRCh37:chr4:74606145-74606165;
[0160] vii)GRCh37:chr4:74606039-74606056;
[0161] viii)GRCh37:chr4:74606113-74606130;
[0162] ix)GRCh37:chr4:74606137-74606154;
[0163] x)GRCh37:chr4:74606150-74606167;
[0164] xi)GRCh37:chr4:74591882-74591899;
[0165] xii) GRCh37:chr4:74591923-74591940;
[0166] xiii) GRCh37: chr4:74591897-74591914; and
[0167] xiv) GRCh37:chr4:74591873-74591890.
[0168] In certain embodiments, the second target site is located within 500, 300, 200, 100, or 50 nucleotides upstream or downstream of a target site selected from:
[0169] i)GRCh37:chr4:74605780-74605800;
[0170] ii) GRCh37: chr4:74605961-74605981;
[0171] iii) GRCh37: chr4:74606122-74606142;
[0172] iv)GRCh37:chr4:74605955-74605975;
[0173] v)GRCh37:chr4:74605842-74605862;
[0174] vi)GRCh37:chr4:74606145-74606165;
[0175] vii)GRCh37:chr4:74606039-74606056;
[0176] viii)GRCh37:chr4:74606113-74606130;
[0177] ix)GRCh37:chr4:74606137-74606154;
[0178] x)GRCh37:chr4:74606150-74606167;
[0179] xi)GRCh37:chr4:74591882-74591899;
[0180] xii) GRCh37:chr4:74591923-74591940;
[0181] xiii) GRCh37: chr4:74591897-74591914; and
[0182] xiv) GRCh37:chr4:74591873-74591890.
[0183] In certain embodiments, the second targeting moiety is a clustered regulatory interspaced short palindromic repeats (CRISPR) Cas domain.
[0184] In one aspect, the disclosure provides nucleic acids encoding the expression repressors described herein.
[0185] In one aspect, the disclosure provides nucleic acids encoding a first expression repressor and a second expression repressor of any one described herein, eg, a second expression repressor that reduces expression of a CXCL gene, eg, an expression repressor of the system of any one of the foregoing aspects of the embodiments.
[0186] In one aspect, the present disclosure provides a nucleic acid system comprising:
[0187] a) a first nucleic acid encoding a first expression repressor as described herein, and
[0188] b) a second nucleic acid encoding a second expression suppressor, eg, a second expression suppressor that reduces expression of a CXCL gene, eg, the expression suppressor of the system of any one of the preceding aspects of the embodiments.
[0189] In some embodiments, the nucleic acid or nucleic acid system comprises a region encoding a first targeting moiety, wherein the region encoding the first targeting moiety comprises a nucleotide sequence of any one of SEQ ID NOs: 122-131, or a sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical thereto.
[0190] In some embodiments, the nucleic acid or nucleic acid system comprises a region encoding a first targeting moiety, wherein the region encoding the first targeting moiety comprises a nucleotide sequence of any one of SEQ ID NOs: 194-199, 248-253, or 276-291, or a sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical thereto.
[0191] In some embodiments, the nucleic acid or nucleic acid system comprises a region encoding a first effector moiety, wherein the region encoding the first effector moiety comprises the nucleotide sequence of any one of SEQ ID NOs: 10, 14, 16, 18, 66, 68, or a sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical thereto.
[0192] In some embodiments, the nucleic acid or nucleic acid system further comprises a region encoding an NLS. In certain embodiments, the region encoding the NLS comprises the nucleotide sequence of SEQ ID NO: 63 or 64, or a sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity thereto.
[0193] In certain embodiments, the nucleic acid or nucleic acid system comprises DNA or RNA (eg, mRNA).
[0194] In one aspect, the present disclosure provides a vector comprising the nucleic acid or nucleic acid system of any one of the preceding aspects or embodiments.
[0195] In one aspect, the present disclosure provides a pharmaceutical composition comprising the expression repressor, nucleic acid, or nucleic acid system of any one of the preceding aspects or embodiments.
[0196] In some embodiments, the pharmaceutical composition comprises LNPs, for example, wherein the nucleic acid or nucleic acid system is formulated as a LNP.
[0197] In one aspect, the disclosure provides a human cell comprising: an expression repressor as described herein, a nucleic acid or nucleic acid system as described herein, or a vector as described herein.
[0198] In one aspect, the present disclosure provides a human cell having reduced expression of a CXCL gene, wherein the cell is produced by a method comprising contacting the cell with the expression repressor of any of the preceding aspects or embodiments, the nucleic acid or nucleic acid system of any of the preceding aspects or embodiments, or the vector of any of the preceding aspects or embodiments.
[0199] In some embodiments, human cells have reduced expression of the first and second CXCL genes. In certain embodiments, human cells have reduced expression of the third CXCL gene. In certain embodiments, human cells have reduced expression of the fourth CXCL gene. In certain embodiments, human cells have reduced expression of the fifth CXCL gene. In certain embodiments, human cells have reduced expression of the sixth CXCL gene. In certain embodiments, human cells have reduced expression of the seventh CXCL gene. In certain embodiments, human cells have reduced expression of the eighth CXCL gene. In certain embodiments, human cells have reduced expression of one or more (e.g., 2, 3, 4, 5, 6, 7, or 8) of CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, or IL-8. In certain embodiments, human cells have reduced expression of one or more of CXCL1, CXCL2, CXCL3, and IL8.
[0200] In one aspect, the present disclosure provides a method of reducing expression of one or more CXCL genes in a cell, the method comprising contacting the cell with the expression repressor, system, nucleic acid or nucleic acid system, or vector of any of the preceding aspects or embodiments.
[0201] In one aspect, the disclosure provides a method of reducing IL-8 expression in a cell, the method comprising contacting the cell with an expression repressor, system, nucleic acid, or nucleic acid system described herein.
[0202] In one aspect, the present disclosure provides a method of reducing the expression of one or more CXCL genes in a cell, the method comprising contacting the cell with an expression repressor or a nucleic acid comprising a sequence encoding the expression repressor, wherein the expression repressor comprises:
[0203] a first targeting moiety that binds to a target site, wherein the target site is within an El cis-acting regulatory element of the CXCL locus or within an E2 cis-acting regulatory element of the CXCL locus, and
[0204] Optionally, the first effector moiety,
[0205] This reduces CXCL gene expression.
[0206] In some embodiments, the target site is within genomic coordinates chr4:74591400-74593000 or chr4:74982639-74983600 (based on the hg19 human genome reference assembly).
[0207] In certain embodiments, the expression of one or more (e.g., 2, 3, 4, 5, 6, 7, or 8) of CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, or IL-8 is reduced.
[0208] In some embodiments, expression is reduced for at least 1, 2, 3, 4, 5, 6, 7, 10, or 14 days, or at least 1, 2, 3, 4, or 5 weeks.
[0209] In some embodiments, the cell is a cell of a subject suffering from an inflammatory disease, such as an immune-mediated inflammatory disease. In certain embodiments, the inflammatory disease is an autoimmune disorder, such as rheumatoid arthritis.
[0210] In some embodiments, the inflammatory disease is associated with a pathogenic infection, such as a viral infection, such as a SARS-CoV2 infection.
[0211] In certain embodiments, the inflammatory disease is associated with repeated infections, such as infections caused by two or more pathogens, such as infections caused by viruses and bacteria (e.g., by SARS-CoV2 and Streptococcus pneumoni), such as infections caused by viruses and fungi (e.g., by SARS-CoV2 and mucormycosis).
[0212] In some embodiments, the cell is a cell from a subject having rheumatoid arthritis, inflammation, arthritis, gout, asthma, neutrophilic asthma, neutrophilic dermatosis, swollen feet, acute respiratory disease syndrome (ARDS), COVID-19, psoriasis, inflammatory bowel disease, infection (e.g., caused by a pathogen such as a bacterium, virus, or fungus), trauma (e.g., a scrape or foreign body), effects of radiation or chemical injury, osteoarthritis, osteoarthritic joint pain, joint pain, inflammatory pain, acute pain, chronic pain, cystitis, bronchitis, dermatitis, skin disease, cardiovascular disease, neurodegenerative disease, liver disease, lung disease, kidney disease, pain, swelling, stiffness, tenderness, redness, heat, or elevated biomarkers associated with a disease state (e.g., cytokines, chemokines, growth factors, immune receptors, markers of infection, or markers of inflammation).
[0213] In some embodiments, the cell is a cell from a subject suffering from rheumatoid arthritis, psoriasis, or inflammatory bowel disease.
[0214] In certain embodiments, the cell is a cell from a subject having rheumatoid arthritis, gout, neutrophilic asthma, neutrophilic dermatoses, acute respiratory disease syndrome (ARDS), or COVID-19.
[0215] In some embodiments, the cell is a cell of a subject having cancer.
[0216] In certain embodiments, the cancer is lung cancer (e.g., non-small cell lung cancer), breast cancer, hepatocellular carcinoma (HCC), prostate cancer, colon cancer, skin cancer, cervical cancer, ovarian cancer, endometrioid carcinoma, endometrial cancer, mature B-cell lymphoma, bladder cancer, esophagogastric cancer, esophageal adenocarcinoma, bone cancer, melanoma, hepatobiliary duct cancer, thyroid cancer, mature B-cell tumors, glioma, head and neck squamous cell carcinoma, renal clear cell carcinoma, pancreatic cancer (e.g., pancreatic ductal adenocarcinoma), sarcoma, or gastric adenocarcinoma.
[0217] In some embodiments, the cell is in a subject.
[0218] In certain embodiments, the cells are ex vivo.
[0219] In some embodiments, the cell is a mammalian cell, eg, a human cell.
[0220] In certain embodiments, the cell is a somatic cell.
[0221] In some embodiments, the cells are primary cells.
[0222] In some embodiments, the contacting step is performed ex vivo.
[0223] In some embodiments, the method further comprises the step of removing cells (eg, mammalian cells) from the subject prior to the contacting step.
[0224] In some embodiments, the method further comprises the step of administering cells (eg, mammalian cells) to the subject after the contacting step.
[0225] In certain embodiments, the contacting step comprises administering to the subject a composition comprising an expression repressor.
[0226] In some embodiments, the expression repressor is administered as a monotherapy.
[0227] In certain embodiments, the expression repressor is administered in combination with a second therapeutic agent.
[0228] In one aspect, the disclosure provides a reaction mixture comprising the cell (eg, a human cell, eg, a primary human cell) of any of the preceding aspects or embodiments and an expression repressor, or system.
[0229] In one aspect, the present disclosure provides a method of treating a subject having an inflammatory disorder, the method comprising:
[0230] administering to the subject the expression repressor, system, nucleic acid, nucleic acid system, or reaction mixture of any of the foregoing aspects or embodiments in an amount sufficient to treat the disorder (e.g., an inflammatory disorder),
[0231] The disorder (eg, inflammatory disorder) is thereby treated.
[0232] In some embodiments, the inflammatory disorder is rheumatoid arthritis, psoriasis, or inflammatory bowel disease.
[0233] In some embodiments, the inflammatory disorder is rheumatoid arthritis, gout, neutrophilic asthma, neutrophilic dermatoses, acute respiratory disease syndrome (ARDS), alcoholic hepatitis, chronic obstructive pulmonary disease (COPD), or COVID-19.
[0234] In certain embodiments, the inflammatory disorder is an autoimmune disorder, such as rheumatoid arthritis.
[0235] In some embodiments, the inflammatory disease is associated with a pathogenic infection, such as a viral infection, such as a SARS-CoV2 infection.
[0236] In certain embodiments, the inflammatory disease is associated with repeated infections, such as infections caused by two or more pathogens, such as infections caused by viruses and bacteria (e.g., by SARS-CoV2 and Streptococcus pneumoni), such as infections caused by viruses and fungi (e.g., by SARS-CoV2 and mucormycosis).
[0237] In one aspect, the present disclosure provides a method of treating a subject having cancer, the method comprising:
[0238] administering to the subject the expression repressor, system, nucleic acid, nucleic acid system or reaction mixture of any one of claims 1 to 102 in an amount sufficient to treat the cancer,
[0239] thereby treating the cancer.
[0240] In certain embodiments, the cancer is lung cancer (e.g., non-small cell lung cancer), breast cancer, hepatocellular carcinoma (HCC), prostate cancer, colon cancer, skin cancer, cervical cancer, ovarian cancer, endometrioid carcinoma, endometrial cancer, mature B-cell lymphoma, bladder cancer, esophagogastric cancer, esophageal adenocarcinoma, bone cancer, melanoma, hepatobiliary duct cancer, thyroid cancer, mature B-cell tumors, glioma, head and neck squamous cell carcinoma, renal clear cell carcinoma, pancreatic cancer (e.g., pancreatic ductal adenocarcinoma), sarcoma, or gastric adenocarcinoma.
[0241] In some embodiments, the subject has an El cis-acting regulatory element sequence comprising the sequence of SEQ ID NO: 162 or a sequence having no more than 8, 7, 6, 5, 4, 3, 2, or 1 alterations thereto.
[0242] In certain embodiments, the subject has an E2 cis-acting regulatory element sequence comprising the sequence of SEQ ID NO: 163 or a sequence having no more than 8, 7, 6, 5, 4, 3, 2, or 1 alterations thereto.
[0243] In some aspects, the disclosure relates to nucleic acids encoding a first expression repressor, a second expression repressor, both or components thereof (e.g., gRNA, mRNA). In some embodiments, the nucleic acid encoding the expression repressor system is a polycistronic sequence. In some embodiments, the polycistronic sequence is a bicistronic sequence.
[0244] In some aspects, the present disclosure provides an expression repressor comprising a targeting moiety that targets an enhancer operably linked to a plurality of genes. In some aspects, the present disclosure provides a method for reducing the expression of a plurality of genes, the method comprising contacting a cell comprising the plurality of genes with an expression repressor comprising a targeting moiety that targets an enhancer operably linked to the plurality of genes. In some embodiments, the plurality of genes comprises a CXCL gene. In some embodiments, the expression repressor targets the E1 cRE of the CXCL locus.
[0245] On the one hand, expression repressors or systems comprising expression repressors can be used in combination with site-specific disruptors as described herein. For example, expression repressors targeting the cis-acting regulatory elements of the CXCL locus can be used in combination with site-specific disruptors targeting the anchor sequence of the CXCL locus. In some embodiments, the site-specific disruptor is a site-specific disruptor as described in any one of Examples B1-B232. In some embodiments, the site-specific disruptor is a site-specific disruptor as described herein. In some embodiments, the site-specific disruptor is a site-specific disruptor described in International Application PCT / US2021 / 052720, which is incorporated herein by reference in its entirety.
[0246] On the one hand, the site-specific destructive agent comprises a targeting portion that specifically binds to the first anchor sequence in ASMC or the proximal end of the first anchor sequence. In some embodiments, the binding of the site-specific destructive agent occurs in an amount sufficient to regulate (e.g., reduce) the expression of multiple target genes (e.g., the first gene and the second gene). In some embodiments, the site-specific destructive agent further comprises an effector portion. Typically, the regulation of the expression of multiple target genes by the site-specific destructive agent involves the binding of the site-specific destructive agent to the first anchor sequence or to the proximal end of the first anchor sequence. In some embodiments, the binding of the site-specific destructive agent to the first anchor sequence can destroy the binding of the nucleating polypeptide (e.g., CTCF) to the first anchor sequence, for example, thereby destroying the formation and / or maintenance of ASMC, for example, thereby regulating (e.g., reducing) the expression of multiple genes. In some embodiments, the site-specific destructive agent binds to the first anchor sequence or to the proximal end of the first anchor sequence and can locate the function of the effector portion to the first anchor sequence and / or ASMC, for example, thereby destroying the formation and / or maintenance of ASMC, for example, thereby regulating (e.g., reducing) reducing the expression of multiple genes. In some embodiments, the site-specific destructive agent binds to the first anchor sequence or binds to the proximal end of the first anchor sequence to locate the function of the effector portion to the first anchor sequence and / or ASMC, for example, thereby regulating (e.g., reducing) the expression of multiple genes. Without wishing to be bound by theory, in some embodiments, it is believed that targeting multiple genes within the same ASMC can more effectively regulate (e.g., reduce) the expression of multiple genes and / or more effectively achieve therapeutic effects related to the functions of multiple genes. For example, in some embodiments, the multiple genes targeted may all be pro-inflammatory genes; as taught herein, targeting multiple pro-inflammatory genes to regulate (e.g., reduce) expression can reduce inflammation more effectively than targeting a single gene. Compared to the effects of targeting individual genes in multiple genes, targeting multiple genes contained within the same genomic complex (e.g., ASMC) (e.g., by targeting ASMC or ASMC's anchor sequence) can have a greater superposition or synergistic effect (e.g., with respect to expression regulation or regulation stability / duration).
[0247] In some embodiments, the methods described herein comprise reducing the expression of a first gene and a second gene in a cell. In some embodiments, the method comprises contacting the cell with a site-specific disrupting agent comprising a targeting moiety that specifically binds to a first anchor sequence or a site located proximal to the first anchor sequence in an amount sufficient to reduce the expression of the first and second genes, the first and second genes being within an anchor sequence-mediated linkage comprising the first and second anchor sequences. In some embodiments, the first and second genes are pro-inflammatory genes. In some embodiments, the first and second genes are CXCL genes.
[0248] In some embodiments, the systems described herein comprise or the methods described herein involve the use of a DNA binding moiety, such as a targeting moiety, that specifically binds to a first anchor sequence in a cell or binds proximal to a first anchor sequence in a cell. In some embodiments, the first anchor sequence is part of an anchor sequence-mediated linker that further comprises a second anchor sequence, a first gene, and a second gene. In some embodiments, the first gene and the second gene are CXCL genes.
[0249] In some embodiments, the systems described herein include, or the methods described herein involve the use of, a site-specific disrupting agent comprising: a targeting portion that specifically binds to a first anchor sequence in a cell or binds proximal to a first anchor sequence in a cell, wherein the first anchor sequence is part of an anchor sequence-mediated linker that further comprises a second anchor sequence, a first gene, and a second gene, wherein the first gene and the second gene are CXCL genes.
[0250] In some embodiments, the methods described herein comprise reducing expression of a first gene and a second gene in a cell, the method comprising: contacting the cell with a site-specific disrupting agent comprising a targeting portion that specifically binds to a first anchor sequence or a site proximal to the first anchor sequence, in an amount sufficient to reduce expression of the first and second genes, the first and second genes being in an anchor sequence-mediated association comprising the first anchor sequence and the second anchor sequence, wherein the first and second genes are CXCL genes; thereby reducing expression of the first and second genes.
[0251] In another aspect, the disclosure relates to a reaction mixture comprising a cell described herein (e.g., a human cell, e.g., a primary human cell), a system (e.g., a system comprising an expression repressor described herein and optionally further comprising a site-specific disrupting agent described herein).
[0252] In another aspect, the disclosure relates to a method of treating a subject having an inflammatory disorder, the method comprising administering to the subject a system described herein (e.g., a system comprising an expression repressor described herein and, optionally, further comprising a site-specific disrupting agent described herein) in an amount sufficient to treat the inflammatory disorder.
[0253] In another aspect, the disclosure relates to a method of treating inflammation (e.g., localized inflammation) in a subject having an infection (e.g., a viral infection, such as COVID-19), the method comprising administering to the subject a system described herein (e.g., a system comprising an expression repressor described herein and, optionally, further comprising a site-specific disrupting agent described herein) in an amount sufficient to treat the inflammation.
[0254] In another aspect, present disclosure relates to a human cell with reduced expression of a first gene and a second gene, wherein the first gene and the second gene are proinflammatory genes, wherein the cell comprises a destroyed (e.g., completely destroyed) anchor sequence-mediated linker comprising the first gene and the second gene. In some embodiments, the human cell is previously contacted with a system described herein (e.g., a system comprising an expression repressor described herein and optionally further comprising a site-specific destructive agent described herein). In some embodiments, the human cell no longer comprises a system described herein.
[0255] In some embodiments, the human cells described herein comprise a mutation at genomic coordinates chr4:74595464-74595486, chr4:74595457-74595479, chr4:74595460-74595482, chr4:74595472-74595494, chr4:75000088-75000110, chr4:75000091-75000113, chr4:75000085-75000107, chr4:75000157- 75000179, chr4:75000156-75000178, chr4:74595215-74595237, chr4:74595370-74595392, chr4:74595560-74595582, c hr4:74595642-74595664, chr4:74595787-74595809, chr4:74528428-74528450, chr4:74528567-74528589, chr4:7452860 9-74528631、chr4:74789132-74789154、chr4:74789250-74789272、chr4:74789312-74789334、chr4:74964853-74964875 , chr4:74964906-74964928, chr4:74965538-74965560, chr4:74965737-74965759, chr4:75000031-75000053, chr4:75000 70526-74570548, or within 5, 10, 15, 20, 30, 40, or 50 nucleotides of said region.
[0256] Numbered Example B
[0257] B1. A method for reducing the expression of a first gene and a second gene in a cell, the method comprising:
[0258] contacting the cell with a site-specific disrupting agent comprising a targeting moiety that specifically binds to the first anchor sequence or a site proximal to the first anchor sequence in an amount sufficient to reduce expression of the first and second genes,
[0259] The first and second genes are located in an anchor sequence-mediated linkage, the linkage comprising the first anchor sequence and the second anchor sequence,
[0260] wherein optionally, the first gene and the second gene are pro-inflammatory genes;
[0261] Thereby reducing the expression of the first and second genes.
[0262] B2. A site-specific disrupting agent comprising:
[0263] A DNA binding moiety, for example, a targeting moiety that specifically binds to the first anchor sequence or its proximal end in the cell,
[0264] wherein the first anchor sequence is part of an anchor sequence-mediated linkage, the anchor sequence-mediated linkage further comprising a second anchor sequence, a first gene, and a second gene,
[0265] Optionally, the first gene and the second gene are pro-inflammatory genes.
[0266] B3. A site-specific disrupting agent as described in embodiment B2, wherein the first or second anchor sequence is located between IL-8 and RASSF6; between the IL-8 enhancer and RASSF6; between CXCL1 and CXCL4; between CXCL2 and EPGN; or between the E2 enhancer and EPGN.
[0267] B4. The site-specific disrupting agent of embodiment B2 or B3, wherein the site-specific disrupting agent further comprises an effector portion.
[0268] B5. A site-specific disruptor as described in any of embodiments B2-B4, wherein the targeting moiety comprises a TAL effector molecule, a CRISPR / Cas molecule (e.g., a catalytically inactive CRISPR / Cas protein), a zinc finger domain, a tetR domain, a large-range nuclease, or an oligonucleotide.
[0269] B6. A site-specific disrupting agent as described in any one of embodiments B2-B5, wherein the effector portion comprises an effector described herein, e.g., MQ1, DNMT1, DNMT3A1, DNMT3A2, DNMT3B1, DNMT3B2, DNMT3B3, DNMT3B4, DNMT3B5, DNMT3B6, DNMT3L, EZH2, HDAC8, KRAB, MeCP2, HP1, RBBP4, REST, FOG1, SUZ12, SETDB1, SETDB2, EHMT2 (i.e., G9 A), EHMT1 (i.e., GLP), SUV39H1, HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, HDAC10, HDAC11, SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, SIRT7, SIRT8, SIRT9, EZH1, SUV39H2, SETD8, SUV420H1, SUV420H2, or DNMT3, or a functional variant or fragment of any one thereof.
[0270] B7. The site-specific disrupting agent of any one of embodiments B2-B6, wherein the effector moiety is linked to the targeting moiety via a linker.
[0271] B8. The site-specific disrupting agent of any one of embodiments B2-B7, wherein the effector moiety is at the C-terminus of the targeting moiety.
[0272] B9. The site-specific disrupting agent of any one of embodiments B2-B7, wherein the effector moiety is the N-terminus of the targeting moiety.
[0273] B10. A site-specific disrupting agent as described in any of embodiments B2-B9, wherein the effector portion is encoded by a nucleotide sequence selected from any one of SEQ ID NO: 10, 14, 16, 18, 66, 68, or a sequence that is at least 80%, 85%, 90%, 95%, 99% or 100% identical thereto, or differs from it at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 position.
[0274] B11. A site-specific disrupting agent as described in any of embodiments B2-B10, wherein the effector portion comprises an amino acid sequence according to any one of SEQ ID NO: 11, 12, 13, 15, 17, 19, 67, or a sequence that is at least 80%, 85%, 90%, 95%, 99% or 100% identical thereto, or differs therefrom at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 position.
[0275] B12. A site-specific disrupting agent as described in any of embodiments B2-B11, wherein the effector portion is MQ1 or a functional variant or fragment thereof, for example, wherein the effector portion comprises the amino acid sequence of SEQ ID NO: 11 or 12, or a sequence that is at least 80%, 85%, 90%, 95%, 99% or 100% identical thereto or differs from it at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 position, wherein optionally the effector portion is at the C-terminus of the targeting portion.
[0276] B13. A site-specific disrupting agent as described in any of embodiments B2-B11, wherein the effector portion is KRAB or a functional variant or fragment thereof, for example, wherein the effector portion comprises the amino acid sequence of SEQ ID NO: 13, or a sequence that is at least 80%, 85%, 90%, 95%, 99% or 100% identical thereto, or differs therefrom at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 position, wherein optionally the effector portion is at the C-terminus of the targeting portion.
[0277] B14. A site-specific disrupting agent as described in any of embodiments B2-B11, wherein the effector portion is DNMT3a / 3L or a functional variant or fragment thereof, for example, wherein the effector portion comprises the amino acid sequence of SEQ ID NO: 15, or a sequence that is at least 80%, 85%, 90%, 95%, 99% or 100% identical thereto, or differs therefrom at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 position, wherein optionally the effector portion is at the C-terminus of the targeting portion.
[0278] B15. A site-specific disrupting agent as described in any of embodiments B2-B11, wherein the effector portion is EZH2 or a functional variant or fragment thereof, for example, wherein the effector portion comprises the amino acid sequence of SEQ ID NO: 17, or a sequence that is at least 80%, 85%, 90%, 95%, 99% or 100% identical thereto, or differs therefrom at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 position.
[0279] B16. A site-specific disrupting agent as described in any one of embodiments B2-B11, wherein the effector moiety is HDAC8 or a functional variant or fragment thereof, for example, wherein the effector moiety comprises the amino acid sequence of SEQ ID NO: 19, or a sequence that is at least 80%, 85%, 90%, 95%, 99% or 100% identical thereto, or differs therefrom at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 position, wherein optionally the effector moiety is at the C-terminus of the targeting moiety.
[0280] B17. A site-specific disrupting agent as described in any of embodiments B2-B11, wherein the effector portion is G9A or a functional variant or fragment thereof, for example, wherein the effector portion comprises the amino acid sequence of SEQ ID NO: 67, or a sequence that is at least 80%, 85%, 90%, 95%, 99% or 100% identical thereto, or differs therefrom at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 position, wherein optionally the effector portion is the N-terminus of the targeting portion.
[0281] B18. The site-specific disrupting agent of any one of embodiments B2-B17, further comprising a second effector moiety.
[0282] B19. The site-specific disrupting agent of embodiment B18, wherein the targeting moiety is located between the first effector moiety and the second effector moiety.
[0283] B20. The site-specific disruption agent of any one of embodiments B2-B19, wherein the effector moiety comprises a polymer, e.g., an oligonucleotide; e.g., a gRNA.
[0284] B21. The site-specific destroying agent of embodiment B20, wherein the oligonucleotide has a sequence comprising the complement of the anchor sequence or the complement of a sequence proximal to the anchor sequence.
[0285] B22. The site-specific disrupting agent of any one of embodiments B2-B21, wherein the targeting moiety further comprises a gRNA, e.g., a gRNA that binds to a genomic locus comprising at least 14, 15, 16, 17, 18, 19, or 20 nucleotides of the sequence of any one of SEQ ID NOs: 20-62, e.g., wherein the gRNA comprises a sequence comprising at least 14, 15, 16, 17, 18, 19, or 20 nucleotides of the sequence of any one of SEQ ID NOs: 20-62.
[0286] B23. The site-specific disruption agent of any one of embodiments B2-B22, wherein the targeting domain comprises a CRISPR / Cas molecule, e.g., a catalytically inactive CRISPR / Cas protein, and a gRNA, e.g., a gRNA that binds to a genomic locus comprising at least 14, 15, 16, 17, 18, 19, or 20 nucleotides of the sequence of any one of SEQ ID NOs: 20-62, e.g., wherein the gRNA comprises a sequence comprising at least 14, 15, 16, 17, 18, 19, or 20 nucleotides of the sequence of any one of SEQ ID NOs: 20-62 and the effector portion comprises an effector selected from DNMT3a / 31, MQ1, KRAB, G9A, HDAC8, or EZH2.
[0287] B24. The site-specific disruption agent of embodiment B23, wherein the targeting domain comprises a CRISPR / Cas molecule, e.g., a catalytically inactive CRISPR / Cas protein, and a gRNA, e.g., a gRNA that binds to a genomic locus comprising at least 14, 15, 16, 17, 18, 19, or 20 nucleotides of the sequence of any one of SEQ ID NOs: 20-62, e.g., wherein the gRNA comprises a sequence comprising at least 14, 15, 16, 17, 18, 19, or 20 nucleotides of the sequence of any one of SEQ ID NOs: 20-62, the first effector portion comprises an effector selected from DNMT3a / 31, MQ1, KRAB, G9A, HDAC8, or EZH2, and the second effector portion comprises an effector selected from DNMT3a / 31, MQ1, KRAB, G9A, HDAC8, or EZH2.
[0288] B25. The site-specific disrupting agent of any one of embodiments B2-B24, wherein the targeting domain binds to a genomic locus comprising at least 14, 15, 16, 17, 18, 19, or 20 nucleotides of the sequence of any one of SEQ ID NOs: 20-62.
[0289] B26. The site-specific disrupting agent of any one of embodiments B2-B25, wherein the targeting domain binds to a genomic locus within 50 nucleotides (e.g., upstream or downstream) of the sequence of any one of SEQ ID NOs: 20-62.
[0290] B27. The site-specific disrupting agent of any one of embodiments B2-B26, wherein the targeting domain binds to a genomic locus within 100 nucleotides (e.g., upstream or downstream) of the sequence of any one of SEQ ID NOs: 20-62.
[0291] B28. The site-specific disrupting agent of any one of embodiments B2-B27, wherein the targeting domain binds to a genomic locus within 200 (eg, upstream or downstream) nucleotides of the sequence of any one of SEQ ID NOs: 20-62.
[0292] B29. The site-specific disrupting agent of any one of embodiments B2-B28, wherein the targeting domain binds to a genomic locus within 300 nucleotides (e.g., upstream or downstream) of the sequence of any one of SEQ ID NOs: 20-62.
[0293] B30. The site-specific disrupting agent of any one of embodiments B2-B29, which: (i) comprises one or more nuclear localization signal sequences (NLS), or (ii) does not comprise an NLS, optionally wherein the NLS comprises the amino acid sequence of SEQ ID NO: 63 and / or 64.
[0294] B31. The site-specific disruptor of any one of embodiments B18-B30, wherein the first effector moiety and / or the second effector moiety comprises a recruiting agent for a DNA methyltransferase, a histone methyltransferase, a histone deacetylase, a histone demethylase, or a histone modification complex.
[0295] B32. The site-specific disruptor of embodiments B2-B31, wherein the ASMC comprises two rings.
[0296] B33. The site-specific disrupting agent of any one of embodiments B2-B32 or the method of embodiment B1, wherein the first gene is located in the first loop of the ASMC and the second gene is located in the second loop of the ASMC.
[0297] B34. The site-specific disrupting agent or method of embodiment B33, wherein the first anchor sequence is located between the first loop and the second loop.
[0298] B35. A nucleic acid encoding the site-specific disrupting agent of any one of embodiments B2-B34.
[0299] B36. The method of embodiment B1 or the site-specific disrupting agent of any one of embodiments B2-B36, wherein the anchor sequence-mediated junction further comprises a third gene, and optionally wherein the method results in decreased expression of the third gene.
[0300] B37. The method or site-specific disrupting agent of embodiment B36, wherein the anchor sequence-mediated junction further comprises a fourth gene, and optionally wherein the method results in decreased expression of the fourth gene.
[0301] B38. The method or site-specific disrupting agent of embodiment B37, wherein the anchor sequence-mediated linkage further comprises a fifth gene, and optionally wherein the method results in decreased expression of the fifth gene.
[0302] B39. The method or site-specific disrupting agent of embodiment B38, wherein the anchor sequence-mediated junction further comprises a sixth gene, and optionally wherein the method results in decreased expression of the sixth gene.
[0303] B40. The method or site-specific disrupting agent of embodiment B39, wherein the anchor sequence-mediated linkage further comprises a seventh gene, and optionally wherein the method results in decreased expression of the seventh gene.
[0304] B41. The method or site-specific disrupting agent of embodiment B40, wherein the anchor sequence-mediated junction further comprises an eighth gene, and optionally wherein the method results in decreased expression of the eighth gene.
[0305] B42. A human cell having reduced expression of a first gene and a second gene,
[0306] wherein the first gene and the second gene are pro-inflammatory genes,
[0307] wherein the cell comprises a disrupted (eg, completely disrupted) anchor sequence-mediated junction comprising the first and second genes.
[0308] B43. A human cell as described in embodiment B42, which has reduced CTCF binding to the anchor sequence comprised by the linker mediated by the anchor sequence, for example, by at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100%.
[0309] B44. The human cell of any one of embodiments B42 or B43, wherein the human cell has reduced expression of a third pro-inflammatory gene.
[0310] B45. The human cell of embodiment B44, wherein the human cell has reduced expression of a fourth pro-inflammatory gene.
[0311] B46. The human cell of embodiment B45, wherein the human cell has reduced expression of a fifth pro-inflammatory gene.
[0312] B47. The human cell of embodiment B46, wherein the human cell has reduced expression of a sixth pro-inflammatory gene.
[0313] B48. The human cell of embodiment B47, wherein the human cell has reduced expression of a seventh pro-inflammatory gene.
[0314] B49. The human cell of embodiment B48, wherein the human cell has reduced expression of an eighth pro-inflammatory gene.
[0315] B50. The human cell of any one of embodiments B42-B49, wherein the human cell comprises a mutation at chr4:74595464-74595486, chr4:74595457-74595479, chr4:74595460-74595482, chr4:74595472-74595494, chr4:75000088-75000110, chr4:75000091-75000113, chr4:75000085-75000107, chr4:74595464-74595486, chr4:74595457-74595479, 5000157-75000179, chr4:75000156-75000178, chr4:74595215-74595237, chr4:74595370-74595392, chr4:74595560-7459 5582, chr4:74595642-74595664, chr4:74595787-74595809, chr4:74528428-74528450, chr4:74528567-74528589, chr4:74 528609-74528631, chr4:74789132-74789154, chr4:74789250-74789272, chr4:74789312-74789334, chr4:74964853-74964 875, chr4:74964906-74964928, chr4:74965538-74965560, chr4:74965737-74965759, chr4:75000031-75000053, chr4:750 70526-74570548, or within 5, 10, 15, 20, 30, 40, or 50 nucleotides of said region.
[0316] B51. A human cell comprising a mutation at chr4:74595464-74595486, chr4:74595457-74595479, chr4:74595460-74595482, chr4:74595472-74595494, chr4:75000088-75000110, chr4:75000091-75000113, chr4:75000085-75000107, chr4:75000157-7500017 9. chr4:75000156-75000178, chr4:74595215-74595237, chr4:74595370-74595392, chr4:74595560-74595582, chr4:74 595642-74595664, chr4:74595787-74595809, chr4:74528428-74528450, chr4:74528567-74528589, chr4:74528609-745 28631, chr4:74789132-74789154, chr4:74789250-74789272, chr4:74789312-74789334, chr4:74964853-74964875, chr 4:74964906-74964928, chr4:74965538-74965560, chr4:74965737-74965759, chr4:75000031-75000053, chr4:75000115 or within 5, 10, 15, 20, 30, 40 or 50 nucleotides of the region.
[0317] B52. The human cell of any one of embodiments B27 or B28, wherein the mutation comprises a deletion, substitution, or insertion (e.g., 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, or 1-2 nucleotides).
[0318] B53. The human cell of any one of embodiments B50-B52, which has reduced binding to the mutated CTCF, e.g., by at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% compared to a human cell with undisrupted ASMC.
[0319] B54. The human cell of any one of embodiments B42-B53, wherein expression of the first gene and the second gene is reduced by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90% compared to a human cell having undisrupted ASMCs.
[0320] B55. A system comprising:
[0321] a first site-specific disrupting agent comprising a first targeting moiety and optionally a first effector moiety, wherein the first site-specific disrupting agent specifically binds to a first anchor sequence of an anchor sequence-mediated junction (ASMC), wherein the ASMC comprises a first gene and a second gene, and
[0322] A second site-specific disruption agent comprises a second targeting moiety and optionally a second effector moiety, wherein the second site-specific disruption agent binds to a second anchor sequence of the ASMC.
[0323] B56. The system of embodiment B55, wherein the first anchor sequence is between IL-8 and RASSF6; between the IL-8 enhancer and RASSF6; between CXCL1 and CXCL4; between CXCL2 and EPGN; or between the E2 enhancer and EPGN.
[0324] B57. The system of embodiment B55 or B56, wherein the second anchor sequence is between IL-8 and RASSF6; between the IL-8 enhancer and RASSF6; between CXCL1 and CXCL4; between CXCL2 and EPGN; or between the E2 enhancer and EPGN.
[0325] B58. The system of any one of embodiments B55-B57, wherein the first anchor sequence is between the IL-8 enhancer and RASSF6 and the second anchor sequence is between CXCL1 and CXCL4.
[0326] B59. The system of any one of embodiments B55-B58, wherein the first anchor sequence is between the IL-8 enhancer and RASSF6 and the second anchor sequence is between the E2 enhancer and EPGN.
[0327] B60. The system of any one of embodiments B55-B59, wherein the first anchor sequence is between CXCL1 and CXCL4, and the second anchor sequence is between the E2 enhancer and EPGN.
[0328] B61. The system of any one of embodiments B55-B60, wherein the first site-specific destroying agent is a site-specific destroying agent described herein, eg, the site-specific destroying agent of any one of embodiments B2-B9.
[0329] B62. The system of any one of embodiments B55-B61, wherein the second site-specific destroying agent is a site-specific destroying agent described herein, eg, the site-specific destroying agent of any one of embodiments B2-B9.
[0330] B63. The system of any one of embodiments B55-B62, wherein the first targeting moiety and the second targeting moiety each independently comprise a TAL effector molecule, a CRISPR / Cas molecule, a zinc finger domain, a tetR domain, a meganuclease, or an oligonucleotide.
[0331] B64. The system of any one of embodiments B55-B63, wherein the first effector and the second effector each independently comprise an effector described herein, e.g., MQ1, EZH2, HDAC8, KRAB, G9A, or DNMT3a / 31, or a functional variant or fragment of any one thereof.
[0332] B65. The system of any one of embodiments B55-B62, wherein the first effector and the second effector each independently comprise a protein selected from SETDB1, SETDB2, EHMT2 (i.e., G9A), EHMT1 (i.e., GLP), SUV39H1, EZH2, EZH1, SUV39H2, SETD8, SUV420H1, SUV420H2, or a functional variant or fragment of any one thereof.
[0333] B66. The system of any one of embodiments B55-B65, wherein the first effector and the second effector each independently comprise a protein selected from the group consisting of HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, HDAC10, HDAC11, SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, SIRT7, SIRT8, SIRT9, or a functional variant or fragment of any one thereof.
[0334] B67. The system of any one of embodiments B55-B43, wherein the first effector and the second effector each independently comprise a protein selected from: MQ1, DNMT1, DNMT3A1, DNMT3A2, DNMT3B1, DNMT3B2, DNMT3B3, DNMT3B4, DNMT3B5, DNMT3B6, DNMT3L, DNMT3a / 31, or a functional variant or fragment of any one thereof.
[0335] B68. The system of any one of embodiments B55-B67, wherein the first effector and the second effector each independently comprise a protein selected from KRAB, MeCP2, HP1, RBBP4, REST, FOG1, SUZ12, or a functional variant or fragment of any one thereof.
[0336] B69. The system of any one of embodiments B55-B68, wherein the first effector and the second effector each independently comprise a polymer, eg, an oligonucleotide.
[0337] B70. The system of any one of embodiments B55-B69, wherein the first oligonucleotide and the second oligonucleotide are identical.
[0338] B71. The system of any one of embodiments B55-B70, wherein the first oligonucleotide and the second oligonucleotide are different.
[0339] B72. The system of any one of embodiments B55-B71, wherein the first oligonucleotide has a sequence comprising the complement of the first anchor sequence or the complement of a sequence proximal to the first anchor sequence and the second oligonucleotide has a sequence comprising the complement of the second anchor sequence or the complement of a sequence proximal to the second anchor sequence.
[0340] B73. The system of any one of embodiments B55-B72, wherein the anchor sequence-mediated junction further comprises a third gene.
[0341] B74. The system of any one of embodiments B55-B73, wherein the anchor sequence-mediated junction further comprises a fourth gene.
[0342] B75. The system of any one of embodiments B55-B74, wherein the anchor sequence-mediated junction further comprises a fifth gene.
[0343] B76. The system of any one of embodiments B55-B75, wherein the anchor sequence-mediated junction further comprises a sixth gene.
[0344] B77. The system of any one of embodiments B55-B76, wherein the anchor sequence-mediated junction further comprises a seventh gene.
[0345] B78. The system of any one of embodiments B55-B77, wherein the anchor sequence-mediated junction further comprises an eighth gene.
[0346] B79. The system of any one of embodiments B55-B78, wherein the ASMC comprises two rings.
[0347] B80. A nucleic acid composition encoding the system of any one of embodiments B55-B79.
[0348] B81. The nucleic acid of embodiment B80, wherein a single nucleic acid encodes both the first site-specific disrupting agent and the second site-specific disrupting agent.
[0349] B82. The nucleic acid of embodiment B81, wherein the first nucleic acid encodes the first site-specific disrupting agent and the second nucleic acid encodes the second site-specific disrupting agent.
[0350] B83. A method of reducing expression of a first gene and a second gene in a cell, the method comprising contacting the cell with a system as described in any of embodiments B55-B79 and a nucleic acid composition as described in any of embodiments B80-B82.
[0351] B84. The method of embodiment B83, wherein the cell is contacted with the first site-specific disrupting agent and the second site-specific disrupting agent simultaneously.
[0352] B85. The method of embodiment B83, wherein the cell is contacted sequentially with the first site-specific disrupting agent and the second site-specific disrupting agent simultaneously.
[0353] B86. The method, human cell, site-specific disruptive agent or system of any one of embodiments B1-B85, wherein the first gene is CXCL1 and the second gene is CXCL2.
[0354] B87. The method, human cell, site-specific disruptive agent or system of any one of embodiments B1-B85, wherein the first gene is CXCL1 and the second gene is CXCL3.
[0355] B88. The method, human cell, site-specific destructive agent or system of any one of embodiments B1-B85, wherein the first gene is CXCL1 and the second gene is IL-8.
[0356] B89. The method, human cell, site-specific disruptive agent or system of any one of embodiments B1-B85, wherein the first gene is CXCL1 and the second gene is CXCL4.
[0357] B90. The method, human cell, site-specific disruptive agent or system of any one of embodiments B1-B85, wherein the first gene is CXCL1 and the second gene is CXCL5.
[0358] B91. The method, human cell, site-specific disruptive agent or system of any one of embodiments B1-B85, wherein the first gene is CXCL1 and the second gene is CXCL6.
[0359] B92. The method, human cell, site-specific disruptive agent or system of any one of embodiments B1-B85, wherein the first gene is CXCL1 and the second gene is CXCL7.
[0360] B93. The method, human cell, site-specific disruptive agent or system of any one of embodiments B1-B85, wherein the first gene is CXCL2 and the second gene is CXCL3.
[0361] B94. The method, human cell, site-specific destructive agent or system of any one of embodiments B1-B85, wherein the first gene is CXCL2 and the second gene is IL-8.
[0362] B95. The method, human cell, site-specific disruptive agent or system of any one of embodiments B1-B85, wherein the first gene is CXCL2 and the second gene is CXCL4.
[0363] B96. The method, human cell, site-specific disruptive agent or system of any one of embodiments B1-B85, wherein the first gene is CXCL2 and the second gene is CXCL4.
[0364] B97. The method, human cell, site-specific disruptive agent or system of any one of embodiments B1-B85, wherein the first gene is CXCL2 and the second gene is CXCL5.
[0365] B98. The method, human cell, site-specific disruptive agent or system of any one of embodiments B1-B85, wherein the first gene is CXCL2 and the second gene is CXCL6.
[0366] B99. The method, human cell, site-specific disruptive agent or system of any one of embodiments B1-B85, wherein the first gene is CXCL2 and the second gene is CXCL7.
[0367] B100. The method, human cell, site-specific destructive agent or system of any one of embodiments B1-B85, wherein the first gene is CXCL3 and the second gene is IL-8.
[0368] B101. The method, human cell, site-specific disruptive agent or system of any one of embodiments B1-B85, wherein the first gene is CXCL3 and the second gene is CXCL4.
[0369] B102. The method, human cell, site-specific disruptive agent or system of any one of embodiments B1-B85, wherein the first gene is CXCL3 and the second gene is CXCL5.
[0370] B103. The method, human cell, site-specific disruptive agent or system of any one of embodiments B1-B85, wherein the first gene is CXCL3 and the second gene is CXCL6.
[0371] B104. The method, human cell, site-specific disruptive agent or system of any one of embodiments B1-B85, wherein the first gene is CXCL3 and the second gene is CXCL7.
[0372] B105. The method, human cell, site-specific disruptive agent or system of any one of embodiments B1-B85, wherein the first gene is CXCL4 and the second gene is CXCL5.
[0373] B106. The method, human cell, site-specific disruptive agent or system of any one of embodiments B1-B85, wherein the first gene is CXCL4 and the second gene is CXCL6.
[0374] B107. The method, human cell, site-specific disruptive agent or system of any one of embodiments B1-B85, wherein the first gene is CXCL4 and the second gene is CXCL7.
[0375] B108. The method, human cell, site-specific destructive agent or system of any one of embodiments B1-B85, wherein the first gene is CXCL4 and the second gene is IL-8.
[0376] B109. The method, human cell, site-specific disruptive agent or system of any one of embodiments B1-B85, wherein the first gene is CXCL5 and the second gene is CXCL6.
[0377] B110. The method, human cell, site-specific disruptive agent or system of any one of embodiments B1-B85, wherein the first gene is CXCL5 and the second gene is CXCL7.
[0378] B111. The method, human cell, site-specific destructive agent or system of any one of embodiments B1-B85, wherein the first gene is CXCL5 and the second gene is IL-8.
[0379] B112. The method, human cell, site-specific disruptive agent or system of any one of embodiments B1-B85, wherein the first gene is CXCL6 and the second gene is CXCL7.
[0380] B113. The method, human cell, site-specific destructive agent or system of any one of embodiments B1-B85, wherein the first gene is CXCL6 and the second gene is IL-8.
[0381] B114. The method, human cell, site-specific destructive agent or system of any one of embodiments B1-B85, wherein the first gene is CXCL7 and the second gene is IL-8.
[0382] B115. The method, human cell, site-specific disruptive agent, or system of any one of embodiments B36-B85, wherein the first gene is CXCL1, the second gene is CXCL2, and the third gene is CXCL3.
[0383] B116. The method, human cell, site-specific disruptive agent or system of any one of embodiments B36-B85, wherein the first gene, second gene and third gene are selected from CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, or IL-8.
[0384] B117. The method, human cell, site-specific disrupting agent or system of any one of embodiments B36-B85, wherein the first gene, second gene, third gene and fourth gene are selected from CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, or IL-8.
[0385] B118. The method, human cell, site-specific disrupting agent or system of any one of embodiments B36-B85, wherein the first gene, second gene, third gene, fourth gene and fifth gene are selected from CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, or IL-8.
[0386] B119. The method, human cell, site-specific disrupting agent or system of any one of embodiments B36-B85, wherein the first gene, second gene, third gene, fourth gene, fifth gene and sixth gene are selected from CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, or IL-8.
[0387] B120. The method, human cell, site-specific disruptive agent or system of any one of embodiments B36-B85, wherein the first gene, second gene, third gene, fourth gene, fifth gene, sixth gene and seventh gene are selected from CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, or IL-8.
[0388] B121. The method, human cell, site-specific disrupting agent or system of any one of embodiments B36-B85, wherein the first gene, second gene, third gene, fourth gene, fifth gene, sixth gene, seventh gene and eighth gene are CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, or IL-8.
[0389] B122. The method, human cell, site-specific destructive agent or system of any preceding embodiment, wherein the first gene is a cytokine.
[0390] B123. The method, human cell, site-specific disruptive agent or system of any preceding embodiment, wherein the second gene is a cytokine.
[0391] B124. The method, human cell, site-specific destructive agent or system of any preceding embodiment, wherein the third gene is a cytokine.
[0392] B125. The method, human cell, site-specific disruptive agent or system of any preceding embodiment, wherein the fourth gene is a cytokine.
[0393] B126. The method, human cell, site-specific destructive agent or system of any preceding embodiment, wherein the fifth gene is a cytokine.
[0394] B127. The method, human cell, site-specific destructive agent or system of any preceding embodiment, wherein the sixth gene is a cytokine.
[0395] B128. The method, human cell, site-specific destructive agent or system of any preceding embodiment, wherein the seventh gene is a cytokine.
[0396] B129. The method, human cell, site-specific destructive agent or system of any preceding embodiment, wherein the eighth gene is a cytokine.
[0397] B130. The method, human cell, site-specific disruptive agent or system of any preceding embodiment, wherein the anchor sequence-mediated junction comprises 3, 4 or 5 pro-inflammatory genes.
[0398] B131. A method, site-specific destructive agent or system as described in any of the preceding embodiments, wherein the site-specific destructive agent comprises a nucleic acid (e.g., DNA or RNA) comprising a nucleotide sequence selected from SEQ ID NOs: 20-62, or a sequence that is at least 90%, 95%, 98% or 99% identical thereto, or a sequence that differs therefrom at no more than 1, 2, 3, 4 or 5 positions.
[0399] B132. A method or site-specific destructive agent as described in any of the preceding embodiments, wherein the site-specific destructive agent comprises a nucleic acid (e.g., DNA or RNA) comprising a nucleotide sequence selected from SEQ ID NO: 21, 22, 24, 40, or a sequence having at least 90%, 95%, 98% or 99% identity thereto, or a sequence having differences therefrom at no more than 1, 2, 3, 4 or 5 positions.
[0400] B133. A method or site-specific disruptor as described in any of the preceding embodiments, wherein the site-specific disruptor binds to a sequence that at least partially overlaps with a region having genomic coordinates selected from Tables 4, 5, 6, 7, or binds to a sequence within 5, 10, 15, 20, 30, 40, 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 nucleotides of said region.
[0401] B134. The method of any preceding embodiment, which results in a decrease in the level of a cytokine, such as a chemokine, eg, after stimulation of the cells with TNF-α, eg, measured as described in Examples 2-11.
[0402] B135. The method or human cell of any preceding embodiment, wherein the level of a cytokine (eg, a chemokine) is reduced, eg, after stimulation of the cell with TNF-α, eg, measured as described in Example 2-11.
[0403] B136. The method or human cell of any of the preceding embodiments, wherein transcript levels of one or more (e.g., 2, 3, or all) of CXCL1, CXCL2, CXCL3, and IL8 are reduced, e.g., after stimulation of the cells with TNF-α, e.g., as measured as described in Example 2 or 4-11.
[0404] B137. The method or human cell of any of the preceding embodiments, wherein transcript levels of one or more (e.g., 2, 3, or all) of CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, and IL8 are reduced, e.g., after stimulation of the cells with TNF-α.
[0405] B138. The method or human cell of any one of embodiments B132-B137, wherein the reduction is at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90% compared to pre-treatment levels or to human cells with undamaged ASMCs.
[0406] B139. The method or human cell of any of the preceding embodiments, wherein protein levels (e.g., secreted protein levels) of one or more (e.g., 2, 3, or all) of CXCL1, CXCL2, CXCL3, and IL8 are reduced, e.g., after stimulation of the cells with TNF-α, e.g., measured as described in Example 3.
[0407] B140. The method or human cell of any preceding embodiment, wherein protein levels (e.g., secreted protein levels) of one or more (e.g., 2, 3, or all) of CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, and IL8 are reduced, e.g., after stimulation of the cell with TNF-α.
[0408] B141. The method or human cell of embodiment B140, wherein the reduction is at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90% compared to pre-treatment levels or to human cells with undamaged ASMCs.
[0409] B142. The method of any of the preceding embodiments, which results in reduced binding of CTCF to the first anchor sequence, e.g., complete loss of binding or at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% loss compared to human cells with undisrupted ASMCs, e.g., as measured by ChIP and quantitative PCR.
[0410] B143. The method of any preceding embodiment, which results in disruption of the anchor sequence-mediated linker.
[0411] B144. The method of any of the preceding embodiments, wherein the population of cells is contacted with the site-specific disrupting agent, and wherein the first anchor sequence is edited in at least 50%, 60%, 70%, 80%, 90% or 95% of the cells in the population.
[0412] B145. The method of any one of the preceding embodiments, wherein the effect (eg, reduction in cytokine levels) is additive or synergistic compared to the effect of inhibiting the first gene or the second gene alone.
[0413] B146. The method of any one of the preceding embodiments, wherein the decreased expression persists for at least 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days, or 14 days, or at least 1 week, 2 weeks, 3 weeks, 4 weeks, or 5 weeks.
[0414] B147. The method, human cell, site-specific destructive agent or system of any preceding embodiment, wherein the cell is a cell of a subject suffering from an inflammatory disease (eg, an immune-mediated inflammatory disease).
[0415] B148. The method, human cell, site-specific destructive agent or system of any preceding embodiment, wherein the inflammatory disease is an autoimmune disorder, such as rheumatoid arthritis.
[0416] B149. The method, human cell, site-specific destructive agent or system of any preceding embodiment, wherein the inflammatory disease is associated with a pathogenic infection (e.g., a viral infection, such as a SARS-CoV2 infection).
[0417] B150. The method, human cell, site-specific destructive agent or system of any preceding embodiment, wherein the inflammatory disease is associated with repeated infections, such as infections caused by two or more pathogens, such as infections caused by viruses and bacteria (e.g., by SARS-CoV2 and Streptococcus pneumoni), such as infections caused by viruses and fungi (e.g., by SARS-CoV2 and mucormycosis).
[0418] B151. A method, human cell, site-specific destructive agent or system as described in any of the preceding embodiments, wherein the cell is a cell of a subject suffering from: rheumatoid arthritis, inflammatory arthritis, gout, asthma, neutrophilic asthma, neutrophilic dermatosis, paw edema, acute respiratory disease syndrome (ARDS), COVID-19, psoriasis, inflammatory bowel disease, infection (e.g., caused by a pathogen, e.g., bacteria, virus or fungus), external injury (e.g., a scrape or foreign body), the effects of radiation or chemical injury, osteoarthritis, osteoarthritis joint pain, joint pain, inflammatory pain, acute pain, chronic pain, cystitis, bronchitis, dermatitis, skin disease, cardiovascular disease, neurodegenerative disease, liver disease, lung disease, kidney disease, pain, swelling, stiffness, tenderness, redness, fever or elevated biomarkers associated with the disease state (e.g., cytokines, chemokines, growth factors, immune receptors, infection markers or inflammatory markers).
[0419] B152. The method, human cell, site-specific destructive agent or system of any preceding embodiment, wherein the cell is a cell of a subject suffering from rheumatoid arthritis, psoriasis or inflammatory bowel disease.
[0420] B153. The method, human cell, site-specific destructive agent or system of any of the preceding embodiments, wherein the cell is a cell of a subject having rheumatoid arthritis, gout, neutrophilic asthma, neutrophilic dermatosis, acute respiratory disease syndrome (ARDS) or COVID-19.
[0421] B154. The method, site-specific disrupting agent or system of any preceding embodiment, wherein the anchor sequence-mediated linker comprises an internal enhancer sequence.
[0422] B155. The method, site-specific disruptor or system of any preceding embodiment, wherein the second gene (and optionally the third, fourth, fifth, sixth, seventh or eighth gene) is transcribed in the same direction as the first gene.
[0423] B156. The method, site-specific disrupting agent or system of any preceding embodiment, wherein the first anchor sequence comprises a binding motif selected from a CTCF binding motif, a USF1 binding motif, a YY1 binding motif, a TAF3 binding motif or a ZNF143 binding motif.
[0424] B157. The method, site-specific disrupting agent or system of any preceding embodiment, wherein the first anchor sequence comprises a CTCF binding motif.
[0425] B158. A method, site-specific disrupting agent or system as described in any of the preceding embodiments, wherein the site-specific disrupting agent specifically binds to the first anchor sequence or binds proximal to the first anchor sequence with an affinity sufficient to compete with an endogenous nucleating polypeptide (e.g., CTCF, USF1, YY1, TAF3 or ZNF143) in the cell.
[0426] B159. The method, site-specific destroying agent or system of any preceding embodiment, wherein the site-specific destroying agent adds, deletes or substitutes one or more nucleotides within or proximal to the first anchor sequence.
[0427] B160. The method or site-specific disruption agent of any preceding embodiment, wherein the site-specific disruption agent comprises a targeting portion or effector portion comprising a first CRISPR / Cas molecule comprising a first CRISPR / Cas protein and a first guide RNA.
[0428] B161. A method or system as described in any of the preceding embodiments, wherein the first site-specific destruction agent comprises a first targeting moiety or a first effector moiety (the first targeting moiety or the first effector moiety comprises a first CRISPR / Cas molecule comprising a first CRISPR / Cas protein) and a first guide RNA, and the second site-specific destruction agent comprises a second targeting moiety or a second effector moiety (the second targeting moiety or the second effector moiety comprises a second CRISPR / Cas molecule comprising a second CRISPR / Cas protein) and a second guide RNA.
[0429] B162. A method or site-specific disruptor as described in any of the preceding embodiments, wherein the site-specific disruptor comprises a targeting portion or an effector portion, which comprises a TAL effector molecule, a CRISPR / Cas molecule, a zinc finger domain, a tetR domain, a large-range nuclease or an oligonucleotide.
[0430] B163. A method or system as described in any of the preceding embodiments, wherein the first site-specific destructor comprises a first targeting moiety or a first effector moiety, which comprises a TAL effector molecule, a CRISPR / Cas molecule, a zinc finger domain, a tetR domain, a large-range nuclease, or an oligonucleotide, and the second site-specific destructor comprises a second targeting moiety or a second effector moiety, which comprises a TAL effector molecule, a CRISPR / Cas molecule, a zinc finger domain, a tetR domain, a large-range nuclease, or an oligonucleotide.
[0431] B164. The method or site-specific disrupting agent of any preceding embodiment, wherein the site-specific disrupting agent comprises an effector portion comprising a histone modification function, such as a histone methyltransferase, a histone demethylase, or a histone deacetylase activity.
[0432] B165. A method or system as described in any of the preceding embodiments, wherein the first site-specific disruptor and / or the second site-specific disruptor comprises an effector portion, which effector portion comprises a histone modification function, such as a histone methyltransferase, a histone demethylase or a histone deacetylase activity.
[0433] B166. The method, site-specific disrupting agent or system of embodiment B164 or B165, wherein the effector portion comprises a protein selected from the group consisting of SETDB1, SETDB2, EHMT2 (i.e., G9A), EHMT1 (i.e., GLP), SUV39H1, EZH2, EZH1, SUV39H2, SETD8, SUV420H1, SUV420H2, or a functional variant or fragment of any one thereof.
[0434] B167. The method, site-specific disruptor or system of embodiment B164 or B165, wherein the effector portion comprises a protein selected from the group consisting of HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, HDAC10, HDAC11, SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, SIRT7, SIRT8, SIRT9, or a functional variant or fragment of any one thereof.
[0435] B168. The method, site-specific disruptive agent or system of embodiment B164 or B165, wherein the effector portion comprises EZH2 or a functional variant or fragment thereof.
[0436] B169. The method, site-specific disruptive agent or system of embodiment B164 or B165, wherein the effector portion comprises HDAC8 or a functional variant or fragment thereof.
[0437] B170. The method or site-specific disrupting agent of any preceding embodiment, wherein the site-specific disrupting agent comprises an effector portion comprising a DNA modification function, such as a DNA methyltransferase.
[0438] B171. A method or system as described in any of the preceding embodiments, wherein the first site-specific disrupting agent and / or the second site-specific disrupting agent comprises an effector portion, which effector portion comprises a DNA modification function, such as a DNA methyltransferase.
[0439] B172. The method, site-specific disruptor or system of embodiment B170 or B171, wherein the effector portion comprises a protein selected from the group consisting of: MQ1, DNMT1, DNMT3A1, DNMT3A2, DNMT3B1, DNMT3B2, DNMT3B3, DNMT3B4, DNMT3B5, DNMT3B6, DNMT3L, DNMT3a / 3l, or a functional variant or fragment of any one thereof.
[0440] B173. The method, site-specific disruptive agent or system of embodiment B170 or B171, wherein the effector portion comprises MQ1 or a functional variant or fragment thereof.
[0441] B174. The method, site-specific disruptor, or system of embodiment B170 or B171, wherein the effector portion comprises DNMT3 (e.g., DNMT3a, DNMT3L, DNMT3a / 3l, DNMT3B1, DNMT3B2, DNMT3B3, DNMT3B4, DNMT3B5, or DNMT3B6), or a functional variant or fragment of any one thereof.
[0442] B175. The method or site-specific disrupting agent of any preceding embodiment, wherein the site-specific disrupting agent comprises an effector portion comprising a transcriptional repressor.
[0443] B176. The method or site-specific disrupting agent of any preceding embodiment, wherein the first and / or second site-specific disrupting agent comprises an effector portion comprising a transcriptional repressor.
[0444] B177. The method, site-specific disrupting agent, or system of embodiment B175 or B176, wherein the effector portion comprises a protein selected from KRAB, MeCP2, HP1, RBBP4, REST, FOG1, SUZ12, or a functional variant or fragment of any one thereof.
[0445] B178. The method, site-specific disruptive agent or system of embodiment B177, wherein the effector portion comprises KRAB or a functional variant or fragment thereof.
[0446] B179. The method or site-specific destroying agent of any preceding embodiment, wherein the site-specific destroying agent comprises a polymer.
[0447] B180. The method or system of any preceding embodiment, wherein the first and / or the second site-specific disrupting agent comprises a polymer.
[0448] B181. The method, site-specific disrupting agent, or system of embodiment B179 or B180, wherein the polymer comprises a polyamide.
[0449] B182. The method, site-specific disrupting agent or system of embodiment B179 or B180, wherein the polymer is an oligonucleotide.
[0450] B183. The method, site-specific destroying agent or system of embodiment B182, wherein the oligonucleotide has a sequence comprising the complement of the first anchor sequence or the complement of a sequence proximal to the first anchor sequence.
[0451] B184. The method, site-specific destroying agent or system of embodiment B182, wherein the oligonucleotide has a sequence comprising the complement of the second anchor sequence or the complement of a sequence proximal to the second anchor sequence.
[0452] B185. The method, site-specific destroyer or system of any one of embodiments B182-B184, wherein the oligonucleotide comprises a chemical modification.
[0453] B186. The method, site-specific disrupting agent, or system of embodiment B179 or B180, wherein the polymer is a peptide nucleic acid.
[0454] B187. The method, site-specific destroying agent or system of any preceding embodiment, wherein the site-specific destroying agent comprises a peptide-nucleic acid mixture.
[0455] B188. The method, site-specific disrupting agent or system of any preceding embodiment, wherein the site-specific disrupting agent (eg, the targeting portion or effector portion of the site-specific disrupting agent) comprises a peptide or polypeptide.
[0456] B189. The method, site-specific disrupting agent or system of embodiment B188, wherein the polypeptide is a zinc finger polypeptide.
[0457] B190. The method, site-specific disruption agent or system of embodiment B188, wherein the polypeptide is or comprises a transcription activator-like effector nuclease (TALEN) polypeptide.
[0458] B191. The method or site-specific disrupting agent of any preceding embodiment, wherein the site-specific disrupting agent comprises a small molecule.
[0459] B192. The method or system of any preceding embodiment, wherein the first and / or second site-specific disrupting agent comprises a small molecule.
[0460] B193. The method or site-specific disrupting agent of any preceding embodiment, wherein the site-specific disrupting agent further comprises an effector portion, eg, an epigenetic modifier, eg, a DNA methyltransferase, a histone deacetylase, or a histone methyltransferase.
[0461] B194. A method or system as described in any preceding embodiment, wherein the first site-specific disruptor and / or the second site-specific disruptor further comprises an effector portion, such as an epigenetic modifier, such as a DNA methyltransferase, a histone deacetylase or a histone methyltransferase.
[0462] B195. The method or site-specific disrupting agent of any preceding embodiment, wherein the site-specific disrupting agent comprises a fusion molecule.
[0463] B196. A method or system as described in any preceding embodiment, wherein the first and / or second site-specific disrupting agent comprises a fusion molecule.
[0464] B197. The method or site-specific disruption agent of any preceding embodiment, wherein the site-specific disruption agent comprises a targeting portion comprising a CRISPR / Cas molecule and an effector portion comprising a transcriptional repressor, e.g., as a fusion molecule.
[0465] B198. A method or system as described in any preceding embodiment, wherein the first site-specific disruptor and / or the second site-specific disruptor comprises a targeting portion comprising a CRISPR / Cas molecule and an effector portion comprising a transcriptional repressor, for example, as a fusion molecule.
[0466] B199. The method or site-specific disruptor of embodiment B198, wherein the targeting moiety comprises dCas9 and the effector moiety KRAB or a functional variant or portion thereof.
[0467] B200. The method or system of any preceding embodiment, wherein the first and / or the second targeting moiety comprises dCas9 and the effector moiety KRAB or a functional variant or portion thereof.
[0468] B201. The method or site-specific disrupting agent of any one of embodiments B1-B177, wherein the site-specific disrupting agent comprises a targeting portion comprising a CRISPR / Cas molecule and an effector portion comprising a histone methyltransferase, e.g., as a fusion molecule.
[0469] B202. A method or system as described in any preceding embodiment, wherein the first and / or the second site-specific destruction agent comprises a targeting portion comprising a CRISPR / Cas molecule and an effector portion comprising a histone methyltransferase, for example, as a fusion molecule.
[0470] B203. The method, site-specific disruption agent, or system of embodiment B201, wherein the targeting moiety comprises dCas9 and the effector moiety comprises EZH2 or a functional variant or portion thereof.
[0471] B204. The method, site-specific disruptor or system of any one of embodiments B1-B196, wherein the site-specific disruptor comprises a targeting portion comprising a CRISPR / Cas molecule and an effector portion comprising a DNA methyltransferase, e.g., as a fusion molecule.
[0472] B205. The method, site-specific disruption agent, or system of embodiment B204, wherein the targeting moiety comprises dCas9 and the effector moiety comprises MQ1 or a functional variant or portion thereof.
[0473] B206. The method, site-specific disruption agent, or system of embodiment B203, wherein the targeting moiety comprises dCas9 and the effector moiety comprises DNMT3, e.g., DNMT3a / 31 or a functional variant or portion thereof.
[0474] B207. A method, site-specific disruptor or system as described in any of the preceding embodiments, wherein the site-specific disruptor comprises a targeting portion comprising a CRISPR / Cas molecule, a first effector portion comprising a histone methyltransferase, and a second effector portion comprising a transcriptional repressor, for example, as a fusion molecule.
[0475] B208. The method, site-specific destruction agent or system of embodiment B207, wherein the targeting moiety comprises dCas9, the first effector moiety comprises EZH2 or a functional variant or portion thereof, and the second effector moiety comprises KRAB or a functional variant or portion thereof.
[0476] B209. The method, site-specific disrupting agent or system of any preceding embodiment, wherein the site-specific disrupting agent comprises a targeting portion comprising a CRISPR / Cas molecule and an effector portion comprising a histone deacetylase, e.g., as a fusion molecule.
[0477] B210. The method, site-specific destruction agent, or system of embodiment B209, wherein the targeting moiety comprises dCas9 and the effector moiety comprises HDAC8 or a functional variant or portion thereof.
[0478] B211. A method, site-specific disruptor or system as described in any of the preceding embodiments, wherein the site-specific disruptor comprises a targeting portion comprising a CRISPR / Cas molecule, a first effector portion comprising a histone methyltransferase, and a second effector portion comprising a histone deacetylase, for example, as a fusion molecule.
[0479] B212. The method, site-specific destruction agent or system of embodiment B211, wherein the targeting moiety comprises dCas9, the first effector moiety comprises EZH2 or a functional variant or portion thereof, and the second effector moiety comprises HDAC8 or a functional variant or portion thereof.
[0480] B213. The method, site-specific destroying agent, or system of any one of embodiments B195-B212, wherein the site-specific destroying agent comprises an amino acid sequence encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NOs: 69, 71, 85, 201, 202, 204, 205, 207, 209, 211, 213, 215, 217, or 219-242, the complement or reverse complement of any one thereof, or a sequence at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one thereof.
[0481] B214. The method, site-specific disrupting agent, or system of any one of embodiments B195-B213, wherein the site-specific disrupting agent comprises an amino acid sequence selected from any one of SEQ ID NOs: 70, 72, 82, 84, 86, 203, 206, 208, 210, 212, 214, 216, or 218, or an amino acid sequence encoded by a sequence selected from any one of SEQ ID NOs: 219-242, or a sequence at least 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one thereof.
[0482] B215. The method, site-specific destructive agent or system of any preceding embodiment, wherein the cell is located in the subject.
[0483] B216. The method or site-specific destructive agent of any one of embodiments B1-B215, wherein the cell is isolated.
[0484] B217. The method, site-specific destructive agent, or system of any preceding embodiment, wherein the cell is a mammalian cell, eg, a human cell.
[0485] B218. The method, site-specific destructive agent or system of any preceding embodiment, wherein the cell is a somatic cell.
[0486] B219. The method, site-specific destructive agent or system of any preceding embodiment, wherein the cell is a primary cell.
[0487] B220. The method of any one of the preceding embodiments, wherein the contacting step is performed ex vivo.
[0488] B221. The method of embodiment B220, further comprising the step of removing the cell (eg, mammalian cell) from the subject prior to the contacting step.
[0489] B222. The method of any one of embodiments B220 or B221, further comprising (b) administering the cells (eg, mammalian cells) to the subject after the contacting step.
[0490] B223. The method of any one of embodiments B1-B222, wherein the contacting step comprises administering to the subject a composition comprising the site-specific disrupting agent.
[0491] B224. The method of embodiment B223, wherein the site-specific disrupting agent is administered as a monotherapy.
[0492] B225. The method of embodiment B223, wherein the site-specific disrupting agent is administered in combination with a second therapeutic agent.
[0493] B226. A reaction mixture comprising the cell (eg, human cell, eg, primary human cell) and a site-specific destructive agent, or system of any preceding embodiment.
[0494] B227. A method of treating a subject having an inflammatory disorder, the method comprising:
[0495] administering to the subject a site-specific disrupting agent, system or reaction mixture as described in any preceding embodiment in an amount sufficient to treat the inflammatory disorder,
[0496] The inflammatory disorder is thereby treated.
[0497] B228. The method of embodiment B227, wherein the inflammatory disorder is rheumatoid arthritis, psoriasis, or inflammatory bowel disease.
[0498] B229. The method of embodiment B227 or B228, wherein the inflammatory disorder is rheumatoid arthritis, gout, neutrophilic asthma, neutrophilic dermatosis, acute respiratory disease syndrome (ARDS), or COVID-19.
[0499] B230. The method of any one of embodiments B227-B229, wherein the inflammatory disorder is an autoimmune disorder, eg, rheumatoid arthritis.
[0500] B231. The method of any one of embodiments B227-B229, wherein the inflammatory disease is associated with a pathogenic infection, e.g., a viral infection, e.g., a SARS-CoV2 infection.
[0501] B232. The method of any one of embodiments B227-B229, wherein the inflammatory disease is associated with a superinfection, e.g., an infection caused by two or more pathogens, e.g., a virus and a bacterium (e.g., SARS-CoV2 and Streptococcus pneumoniae), e.g., a virus and a fungus (e.g., SARS-CoV2 and mucormycosis).
[0502] B232. A method of treating a subject having cancer, the method comprising:
[0503] administering to the subject an expression suppressor, system, nucleic acid, nucleic acid system or reaction mixture as described in any one of the preceding embodiments in an amount sufficient to treat the cancer,
[0504] thereby treating the cancer.
[0505] B233. The method of claim B232, wherein the cancer is lung cancer (e.g., non-small cell lung cancer), breast cancer, hepatocellular carcinoma (HCC), prostate cancer, colon cancer, skin cancer, cervical cancer, ovarian cancer, endometrioid carcinoma, endometrial cancer, mature B-cell lymphoma, bladder cancer, esophagogastric cancer, esophageal adenocarcinoma, bone cancer, melanoma, hepatobiliary duct cancer, thyroid cancer, mature B-cell tumors, glioma, head and neck squamous cell carcinoma, renal clear cell carcinoma, pancreatic cancer (e.g., pancreatic ductal adenocarcinoma), sarcoma, or gastric adenocarcinoma.
[0506] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the disclosure described herein.
[0507] All publications, patent applications, patents, and other references (e.g., sequence database reference numbers) mentioned herein are incorporated by reference in their entirety. For example, all GenBank, Unigene, and Entrez sequences mentioned herein (e.g., in any of the tables herein) are incorporated by reference. Unless otherwise indicated, sequence accession numbers specified herein (included in any of the tables herein) refer to current database entries as of March 30, 2022. When a gene or protein references multiple sequence accession numbers, all sequence variants are encompassed.
[0508] definition
[0509] A / an, the: As used herein, the singular forms "a / an," and "these" include plural referents unless the context clearly dictates otherwise.
[0510] Anchor sequence: As used herein, the term "anchor sequence" refers to a nucleic acid sequence that is recognized by a nucleating agent and that binds sufficiently to form an anchor sequence-mediated linkage, such as a complex. In some embodiments, the anchor sequence comprises one or more CTCF binding motifs. In some embodiments, the anchor sequence is not located within a gene coding region. In some embodiments, the anchor sequence is located within an intergenic region. In some embodiments, the anchor sequence is not located within an enhancer or promoter. In some embodiments, the anchor sequence is located at least 400 bp, at least 450 bp, at least 500 bp, at least 550 bp, at least 600 bp, at least 650 bp, at least 700 bp, at least 750 bp, at least 800 bp, at least 850 bp, at least 900 bp, at least 950 bp, or at least 1 kb from any transcription start site. In some embodiments, the anchor sequence is located in a region not associated with genomic imprinting, monoallelic expression, and / or monoallelic epigenetic markers. In some embodiments, the anchor sequence has one or more functions selected from the following: binding to an endogenous nucleating polypeptide (e.g., CTCF), interacting with a second anchor sequence to form an anchor sequence-mediated linker, or isolating an enhancer outside the anchor sequence-mediated linker. In some embodiments of the present disclosure, a technique is provided that can specifically target one or more specific anchor sequences without targeting other anchor sequences (e.g., sequences that may contain nucleating agents (e.g., CTCF) binding motifs in different contexts); such targeted anchor sequences may be referred to as "target anchor sequences." In some embodiments, the sequence and / or activity of the target anchor sequence is regulated, while the sequence and / or activity of one or more other anchor sequences that may be present in the same system as the targeted anchor sequence (e.g., in the same cell and / or in some embodiments on the same nucleic acid molecule (e.g., the same chromosome)) are not regulated. In some embodiments, the anchor sequence comprises or is a nucleating polypeptide binding motif. In some embodiments, the anchor sequence is adjacent to the nucleating polypeptide binding motif.
[0511] Anchor sequence-mediated linker: As used herein, the term "anchor sequence-mediated linker" refers to a DNA structure, in some cases a complex, that is generated and / or maintained through physical interaction or binding of at least two anchor sequences in DNA by one or more polypeptides (such as nucleating polypeptides) or one or more proteins and / or nucleic acid entities (such as RNA or DNA) that bind to the anchor sequences to achieve spatial proximity and functional connection between the anchor sequences.
[0512] Associated: Two events or entities are "associated" with each other, as the term is used herein, if the presence, level, form, and / or function of one event or entity is associated with another event or entity. For example, in some embodiments, a particular entity (e.g., a polypeptide, a genetic signature, a metabolite, a microorganism, etc.) is considered to be associated with a particular disease, disorder, or condition if its presence, level, form, and / or function are correlated with the incidence and / or susceptibility of the disease, disorder, or condition (e.g., in a related population). In some embodiments, two or more entities are physically "associated" with each other if they interact, directly or indirectly, so that they are physically close to each other and / or remain in physical proximity to each other. In some embodiments, two or more entities that are physically associated with each other are covalently linked to each other; in some embodiments, two or more entities that are physically associated with each other are not covalently linked to each other, but are non-covalently bound, for example, by hydrogen bonds, van der Waals interactions, hydrophobic interactions, magnetism, and combinations thereof. In some embodiments, a DNA sequence is "associated with" a target genome or transcription complex when the nucleic acid is at least partially located within the target genome or transcription complex and expression of genes in the DNA sequence is affected by the formation or disruption of the target genome or transcription complex.
[0513] CXCL locus: As used herein, the term "CXCL locus" refers to the portion of the human genome encoding CXCL1-7 and IL-8, enhancers E1 and E2, and anchor sequences that form ASMCs containing CXCL1-7 and IL-8, or homologous regions of non-human animal genomes. In some embodiments, the CXCL locus is located on human chromosome 4.
[0514] CXCL gene: As used herein, the term "CXCL gene" refers to human CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, or IL-8, or homologous non-human genes. Human IL-8 is sometimes also referred to as CXCL8.
[0515] Site-specific disrupting agent: As used herein, the term "site-specific disrupting agent" refers to an agent or entity that specifically inhibits, dissociates, degrades, and / or modifies one or more components of a genomic complex (e.g., ASMC), thereby modulating (e.g., reducing) the expression of multiple target genes as described herein. In some embodiments, the site-specific disrupting agent interacts with one or more components of the genomic complex. In some embodiments, the site-specific disrupting agent binds (e.g., directly or, in some embodiments, indirectly) to one or more genomic complex components. In some embodiments, the site-specific disrupting agent binds to an anchor sequence, e.g., a first and / or second anchor sequence, that may be part of an ASMC that targets multiple genes. In some embodiments, the site-specific disrupting agent binds to a site that is proximal to an anchor sequence, e.g., a first and / or second anchor sequence, that may be part of an ASMC that targets multiple genes. In some embodiments, the site-specific disrupting agent modifies one or more genomic complex components. In some embodiments, the site-specific disrupting agent comprises an oligonucleotide. In some embodiments, the site-specific disrupting agent comprises a polypeptide. In some embodiments, the site-specific disrupting agent comprises an antibody (e.g., a monospecific or multispecific antibody construct) or an antibody fragment. In some embodiments, the site-specific disrupting agent is directed to a specific genomic location and / or genomic complex via a targeting moiety, as described herein. In some embodiments, the site-specific disruptor comprises a genome complex component or a variant thereof. In some embodiments, the site-specific disruptor comprises a targeting moiety. In some embodiments, the site-specific disruptor comprises an effector moiety. In some embodiments, the site-specific disruptor comprises a plurality of effector moieties. In some embodiments, the site-specific disruptor comprises a targeting moiety and one or more effector moieties. In some embodiments, the site-specific disruptor specifically binds to the first site in the genome with an affinity higher than the second site in the genome (for example, relative to any other site in the genome). In some embodiments, relative to the second genome complex (for example, relative to any other genome complex), the site-specific disruptor preferentially inhibits, dissociates, degrades and / or modifies one or more components of the first genome complex. In some embodiments, the site-specific disruptor can be an expression repressor, such as a site-specific disruptor can inhibit ASMC, thereby reducing the expression of genes in ASMC.
[0516] Domain: As used herein, the term "domain" refers to a segment or portion of an entity. In some embodiments, a "domain" is associated with a specific structural and / or functional characteristic of an entity, such that when the domain is physically separated from the rest of its parent entity, it substantially or completely retains the specific structural and / or functional characteristic. Alternatively or additionally, in some embodiments, a domain can be or comprise a portion of an entity that, when separated from the (parent) entity and attached to a different (receiving) entity, substantially retains and / or imparts to the receiving entity one or more of the structural and / or functional characteristics that characterize it in the parent entity. In some embodiments, a domain is or comprises a segment or portion of a molecule (e.g., a small molecule, a carbohydrate, a lipid, a nucleic acid, a polypeptide, etc.). In some embodiments, a domain is or comprises a segment of a polypeptide. In some such embodiments, a domain is characterized by specific structural elements (e.g., a specific amino acid sequence or sequence motif, α-helical characteristics, β-sheet characteristics, helical coil characteristics, random coil characteristics, etc.), and / or specific functional characteristics (e.g., binding activity, enzymatic activity, folding activity, signaling activity, etc.).
[0517] E1 cRE: As used herein, the terms "E1 cRE" and "E1 cRE" refer to a cRE located proximal to IL8 (e.g., approximately 14 kb upstream) in the human genome (see Figure 16B ) and is sufficiently bound to be recognized by a trans-acting factor (e.g., a transcription factor such as p65) that upregulates the expression of one or more CXCL genes.
[0518] E2 cRE: As used herein, the terms "E2 cRE" and "E2 cRE" refer to a cRE located in the human genome near CXCL2 (see Figure 16B ) and is sufficiently bound to be recognized by a trans-acting factor (e.g., a transcription factor such as p65) that upregulates the expression of one or more CXCL genes.
[0519] Effector portion: As used herein, the term "effector portion" refers to a domain having one or more functions that, when appropriately localized in the nucleus, regulates (e.g., reduces) the expression of a target plurality of genes in a cell. In some embodiments, the effector portion comprises a polypeptide. In some embodiments, the effector portion comprises a polypeptide and a nucleic acid. The function associated with the effector portion may directly affect the expression of the target plurality of genes, for example, by blocking the recruitment of transcription factors that stimulate the expression of the gene. The function associated with the effector portion may indirectly affect the expression of the target plurality of genes, for example, by introducing epigenetic modifications or recruiting other factors that introduce epigenetic modifications, thereby inducing changes in the chromosomal topology, thereby inhibiting the expression of the target plurality of genes.
[0520] Expression repressor: As used herein, the term "expression repressor" refers to an agent or entity with one or more functionalities that reduces the expression of a target gene in a cell and specifically binds to a DNA sequence (e.g., a DNA sequence associated with a target gene, or a transcriptional control element operably linked to a target gene). An expression repressor comprises at least one targeting portion and optionally an effector portion. In some embodiments, the expression repressor binds to a site near an enhancer sequence that can be operably linked to a target multiple gene. In some embodiments, the expression repressor comprises an oligonucleotide. In some embodiments, the expression repressor comprises a polypeptide. In some embodiments, the expression repressor comprises a plurality of effector portions. In some embodiments, the expression repressor comprises a targeting portion and one or more effector portions. In some embodiments, the expression repressor specifically binds to the first site in the genome with a higher affinity than a second site in the genome (e.g., relative to any other site in the genome).
[0521] Genomic complex: As used herein, the term "genomic complex" is a complex that brings together two genomic sequence elements that are separated from each other on one or more chromosomes through interactions between and among multiple proteins and / or other components (which may include genomic sequence elements). In some embodiments, the genomic sequence element is an anchor sequence to which one or more protein components of the complex bind. In some embodiments, the genomic complex may comprise an anchor sequence-mediated linker. In some embodiments, the genomic sequence element may be or comprise a CTCF binding motif, a promoter, and / or an enhancer. In some embodiments, the genomic sequence element comprises at least one or both of a promoter and / or a regulatory site (e.g., an enhancer). In some embodiments, complex formation is nucleated at one or more genomic sequence elements and / or nucleated by binding of one or more protein components to one or more genomic sequence elements. As will be understood by those skilled in the art, in some embodiments, the co-localization (e.g., binding) of genomic sites via complex formation alters the DNA topology at or near (in some embodiments, including between) one or more genomic sequence elements. In some embodiments, the genomic complex comprises an anchor sequence-mediated linker comprising one or more loops. In some embodiments, genome complexes as described herein are nucleated by nucleating polypeptides (e.g., such as CTCF and / or cohesin). In some embodiments, genome complexes as described herein may include, for example, CTCF, cohesin, non-coding RNA (e.g., eRNA), transcription machinery proteins (e.g., RNA polymerase, one or more transcription factors, such as those selected from the group consisting of TFIIA, TFIIB, TFIID, TFIIE, TFIIF, TFIIH, etc.), transcription regulators (e.g., mediators, P300, enhancer binding proteins, repressor binding proteins, histone modifiers, etc.). In some embodiments, genome complexes as described herein include one or more polypeptide components and / or one or more nucleic acid components (e.g., one or more RNA components), which in some embodiments can interact with each other and / or with one or more genomic sequence elements (e.g., anchor sequences, promoter sequences, regulatory sequences (e.g., enhancer sequences)) to restrict a section of genomic DNA to a topological structure (e.g., a loop) that would not be adopted if the complex were not formed.
[0522] Nucleic Acid: As used herein, the term "nucleic acid" in its broadest sense refers to any compound and / or substance that is or can be incorporated into an oligonucleotide chain. In some embodiments, a nucleic acid is a compound and / or substance that is or can be incorporated into an oligonucleotide chain via phosphodiester bonds. As will be clear from the context, in some embodiments, "nucleic acid" refers to a single nucleic acid residue (e.g., a nucleotide and / or nucleoside); in some embodiments, "nucleic acid" refers to an oligonucleotide chain comprising a single nucleic acid residue. In some embodiments, a "nucleic acid" is or comprises RNA; in some embodiments, a "nucleic acid" is or comprises DNA. In some embodiments, a nucleic acid is, comprises, or consists of one or more natural nucleic acid residues. In some embodiments, a nucleic acid is, comprises, or consists of one or more nucleic acid analogs. In some embodiments, a nucleic acid analog differs from a nucleic acid in that it does not utilize a phosphodiester backbone. For example, in some embodiments, a nucleic acid is, comprises, or consists of one or more "peptide nucleic acids," which are known in the art and have peptide bonds in the backbone rather than phosphodiester bonds, and are considered to be within the scope of the present invention. Alternatively or additionally, in some embodiments, the nucleic acid has one or more phosphorothioate and / or 5'-N-phosphoramidite bonds rather than phosphodiester bonds. In some embodiments, the nucleic acid is, comprises, or consists of one or more natural nucleosides (e.g., adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxyguanosine, and deoxycytidine). In some embodiments, the nucleic acid is, comprises, or consists of one or more nucleoside analogs (e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolopyrimidine, 3-methyladenosine, 5-methylcytidine, C-5 propynyl-cytidine, C-5 propynyl-uridine, 2-aminoadenosine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-propynyl-uridine, C5-propynyl-cytidine, C5-methylcytidine, 2-aminoadenosine, 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, O(6)-methylguanine, 2-thiocytidine, methylated bases, intercalated bases, and combinations thereof). In some embodiments, the nucleic acid comprises one or more modified sugars (e.g., 2'-fluororibose, ribose, 2'-deoxyribose, arabinose, and hexose) compared to those in naturally occurring nucleic acids. In some embodiments, the nucleic acid has a nucleotide sequence encoding a functional gene product (such as RNA or protein). In some embodiments, the nucleic acid comprises one or more introns. In some embodiments, the nucleic acid is prepared by one or more of isolation from a natural source, enzymatic synthesis (in vivo or in vitro) based on polymerization of a complementary template, replication in a recombinant cell or system, and chemical synthesis.In some embodiments, the nucleic acid is at least 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 20, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 600, 700, 800, 900, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000, or more residues in length. In some embodiments, the nucleic acid is partially or entirely single-stranded; in some embodiments, the nucleic acid is partially or entirely double-stranded. In some embodiments, the nucleic acid has a nucleotide sequence that comprises at least one element encoding a polypeptide or is a complementary sequence to a sequence encoding a polypeptide. In one embodiment, the nucleic acid has enzymatic activity. In some embodiments, the nucleic acid is an mRNA nucleic acid and can be a monocistronic or polycistronic (e.g., a bicistronic, a tricistronic, etc.).
[0523] Operably linked: As used herein, the phrase "operably linked" refers to a juxtaposition in which the components are in a relationship that allows them to function in their intended manner. A genomic regulatory element (e.g., a transcriptional control element) that is "operably linked" to a functional element (e.g., a gene) is associated in such a way that expression and / or activity of the functional element (e.g., a gene) is achieved under conditions compatible with the genomic regulatory element (e.g., a transcriptional control element). In some embodiments, an "operably linked" genomic regulatory element (e.g., a transcriptional control element) is adjacent (e.g., covalently linked) to a coding element of interest (e.g., a gene); in some embodiments, an operably linked genomic regulatory element (e.g., a transcriptional control element) acts in cis to the functional element (e.g., a gene of interest) or is otherwise at a distance therefrom. In some embodiments, an "operably linked" genomic regulatory element (e.g., a transcriptional control element) is adjacent (e.g., covalently linked) to a coding element of interest (e.g., a gene); in some embodiments, an operably linked genomic regulatory element (e.g., a transcriptional control element) acts in trans on a functional element of interest (e.g., a gene of interest), or otherwise acts at a distance from the functional element of interest (e.g., a gene of interest). In some embodiments, two operably linked nucleic acid sequences are contained on the same nucleic acid. In another embodiment, two operably linked nucleic acid sequences are close to each other on the same nucleic acid, e.g., within 1000, 500, 100, 50, or 10 base pairs of each other or directly adjacent to each other.
[0524] Peptide, polypeptide, protein: As used herein, the terms "peptide," "polypeptide," and "protein" refer to compounds composed of amino acid residues covalently linked by peptide bonds or by means other than peptide bonds. A protein or peptide must contain at least two amino acids, and there is no limit on the maximum number of amino acids that can comprise the sequence of a protein or peptide. Polypeptides include any peptide or protein comprising two or more amino acids linked to each other by peptide bonds or by means other than peptide bonds. As used herein, the terms refer to both short chains, which are also commonly referred to in the art as, for example, peptides or oligopeptides, and long chains, which are commonly referred to in the art as proteins, of which there are many types.
[0525] Proximal: As used herein, "proximal" refers to the proximity of two sites (e.g., nucleic acid sites) such that binding of an expression repressor or site-specific disruptor at a first site and / or modification of the first site by an expression repressor or site-specific disruptor will produce the same or substantially the same effect as binding and / or modification of the other sites. For example, a DNA targeting moiety can bind to a first site (second site) proximal to an anchor sequence, and an effector moiety associated with the DNA targeting moiety can epigenetically modify the first site such that binding of the anchor sequence to an endogenous nucleating polypeptide is modified, which is substantially the same as if the second site (anchor sequence) were bound and / or modified. In some embodiments, sites that are proximal to each other are less than 5000, 4000, 3000, 2000, 1000, 900, 800, 700, 600, 500, 400, 300, 200, 100, 50, 40, 30, 20, 10, or 5 base pairs away from each other.
[0526] Sequence-targeting polypeptide: As used herein, the term "sequence-targeting polypeptide" refers to a protein, such as a protein comprising a CRISPR / Cas domain, a TAL effector domain, or a zinc finger domain, that recognizes or specifically binds to a target nucleic acid sequence. In some embodiments, the sequence-targeting polypeptide is a catalytically inactive protein that lacks endonuclease activity, such as dCas9, a TAL effector molecule, or a Zn finger domain.
[0527] Specific binding: As used herein, the term "specific binding" refers to the ability to discriminate between possible binding partners in the context of binding. In some embodiments, a binding agent that interacts with a particular target in the presence of other potential targets is said to "specifically bind" to the target with which it interacts. In some embodiments, specific binding is assessed by detecting or determining the extent of binding between a binding agent and its partner; in some embodiments, specific binding is assessed by detecting or determining the extent of dissociation of the binding agent-partner complex. In some embodiments, specific binding is assessed by detecting or determining the ability of a binding agent to compete for selective interactions with its partner and another entity. In some embodiments, specific binding is assessed by performing such detection or determination over a range of concentrations.
[0528] Subject: As used herein, the term "subject" or "test subject" refers to any organism to which a provided compound or composition according to the present disclosure is administered, e.g., for experimental, diagnostic, prophylactic, and / or therapeutic purposes. Typical subjects include animals (e.g., mammals such as mice, rats, rabbits, non-human primates, and humans; insects; worms; etc.) and plants. In some embodiments, the subject may be suffering from or susceptible to a disease, disorder, and / or condition.
[0529] Substantially: As used herein, the term "substantially" refers to the qualitative condition of exhibiting the full or nearly full extent or degree of a characteristic or property of interest. One of ordinary skill in the art will understand that biological and chemical phenomena rarely, if ever, are completed and / or proceed to perfection or achieve or avoid an absolute result. Thus, the term "substantially" may be used in some embodiments herein to capture the potential imperfections inherent in many biological and chemical phenomena.
[0530] Symptom reduction: As used herein, the phrase "symptom reduction" may be used when the degree (e.g., intensity, severity, etc.) and / or frequency of one or more symptoms of a particular disease, disorder, or condition is reduced. In some embodiments, delaying the onset of a particular symptom is considered a form of reducing the frequency of that symptom.
[0531] Target: According to the present disclosure, an agent or entity is considered to "target" another agent or entity if it specifically binds to the targeted agent or entity under conditions in which they are in contact with each other. For example, in some embodiments, an antibody (or antigen-binding fragment thereof) targets its cognate epitope or antigen. In some embodiments, a nucleic acid having a specific sequence targets a nucleic acid of a substantially complementary sequence. In some embodiments, a targeting moiety that specifically binds to an anchor sequence targets the anchor sequence, an ASMC comprising the anchor sequence, and / or multiple genes within the ASMC.
[0532] Target multiple genes: As used herein, the term "target multiple genes" refers to a group of more than one gene (e.g., 2, 3, 4, 5, 6, 7, 8, 9 or more genes) that is targeted for regulation (e.g., regulating expression). In some embodiments, the target multiple genes are part of a targeted genomic complex. In some embodiments, each gene in the target multiple genes is operably linked to an enhancer, such as an E1 enhancer, wherein the enhancer is targeted by an expression repressor described herein. In some embodiments, regulation includes inhibiting the expression of the target multiple genes. In some embodiments, the target multiple genes are regulated by contacting the target multiple genes or genomic regulatory elements (e.g., transcriptional control elements) operably linked to one or more of the target multiple genes with an expression repressor described herein. In some embodiments, one or more of the target multiple genes are abnormally expressed (e.g., overexpressed) in a cell (e.g., a cell in a subject (e.g., a patient)). In some embodiments, the target multiple genes have related functions. For example, the genes in the target multiple genes may all have a pro-inflammatory effect when expressed; genes in such target multiple genes may be referred to herein as pro-inflammatory genes or target pro-inflammatory genes. In some embodiments, the genes of the target multiple genes encode proteins. In some embodiments, a gene in the target plurality of genes encodes a functional RNA.
[0533] Targeting moiety: As used herein, the term "targeting moiety" refers to an agent or entity that specifically interacts (e.g., targets) with a component or set of components (e.g., DNA). In some embodiments, the one or more components participate in a genomic complex as described herein (e.g., an anchor sequence-mediated linker). In some embodiments, a targeting moiety according to the present disclosure targets one or more target components of a genomic complex as described herein. In some embodiments, the targeting moiety targets a genomic regulatory element (e.g., an E1 enhancer). In some embodiments, the targeting moiety targets an anchor sequence. In some embodiments, the targeting moiety targets a genomic complex component rather than a genomic regulatory element. In some embodiments, the targeting moiety targets a plurality of genomic complex components or combinations thereof, and in some embodiments, the plurality of genomic complex components may include genomic sequence elements. In some aspects, as described herein, by targeting one or more complex components comprising one or more genomic sequence elements, effective inhibition, dissociation, degradation, and / or modification of one or more genomic complexes can be achieved. In some embodiments, the present disclosure contemplates that improved (e.g., with respect to the degree of specificity of a particular genomic complex compared to other genomic complexes that may form or exist in a given system, the effectiveness of inhibition, dissociation, degradation, or modification [e.g., in terms of the effect on the number of complexes detected in a population]) inhibition, dissociation, degradation, or modification can be achieved by targeting one or more complex components that are not genomic sequence elements, and optionally, can alternatively or additionally include targeting genomic sequence elements, wherein the improved inhibition, dissociation, degradation, or modification is relative to the inhibition, dissociation, degradation, or modification typically achieved by targeting one or more individual genomic sequence elements. In some embodiments, site-specific disrupting agents as described herein promote the inhibition, dissociation, degradation, or modification of a target genomic complex. For example, as a non-limiting example, in some embodiments, site-specific disrupting agents described herein inhibit, dissociate, degrade, and / or modify anchor sequence-mediated linkages (e.g., components thereof) by targeting at least one component of a given genomic complex (e.g., comprising an anchor sequence-mediated linkage).In some embodiments, site-specific destroyers as described herein inhibit, dissociate specific genomic complexes (i.e., target genomic complexes), degrade specific genomic complexes (i.e., target genomic complexes) (e.g., components thereof) and / or modify specific genomic complexes (i.e., target genomic complexes) (e.g., components thereof), and do not inhibit, dissociate at least one other specific genomic complex (i.e., non-target genomic complexes), do not degrade at least one other specific genomic complex (i.e., non-target genomic complexes) (e.g., components thereof) and / or do not modify at least one other specific genomic complex (e.g., components thereof), which at least one other specific genomic complex (i.e., non-target genomic complex) may, for example, be present in other cells (e.g., in non-target cells) and / or may be present at different sites in the same cell (i.e., within target cells). Expression repressors or site-specific destroyers as described herein may include a targeting moiety. In some embodiments, the targeting moiety also serves as an effector moiety (e.g., a destroying moiety); in some such embodiments, the expression repressor or site-specific destroyer provided may lack any effector moiety (e.g., a destroying effector moiety, a modifying effector moiety, or other effector moieties) that is separate (or intentionally different) from the targeting moiety.
[0534] Therapeutically effective amount: As used herein, the term "therapeutically effective amount" means an amount of a substance (e.g., a therapeutic agent, composition, and / or formulation) that, when administered as part of a treatment regimen, elicits a desired biological response. In some embodiments, a therapeutically effective amount of a substance is an amount sufficient to treat, diagnose, prevent, and / or delay the onset of a disease, disorder, and / or condition when administered to a subject suffering from or susceptible to the disease, disorder, and / or condition. As will be understood by one of ordinary skill in the art, the effective amount of a substance can vary depending on factors such as one or more desired biological endpoints, the substance to be delivered, one or more target cells, or one or more tissues. For example, in some embodiments, an effective amount of a compound in a formulation for treating a disease, disorder, and / or condition is an amount that alleviates, ameliorates, relieves, inhibits, prevents, delays the onset of, reduces the severity of, and / or reduces the incidence of one or more symptoms or features of the disease, disorder, and / or condition. In some embodiments, the therapeutically effective amount is administered in a single dose; in some embodiments, multiple unit doses are required to deliver the therapeutically effective amount.
[0535] Genomic regulatory sequence: As used herein, the term "genomic regulatory sequence" refers to a nucleic acid sequence that increases or decreases gene transcription. An "enhancing sequence" increases the likelihood of gene transcription. A "silencing or repressor sequence" reduces the likelihood of gene transcription. Examples of genomic regulatory sequences include promoters and enhancers. In certain embodiments, the genomic regulatory sequence is a cis-acting regulatory element. In certain embodiments, ASMC comprises a genomic regulatory sequence. Such a genomic regulatory sequence is referred to as an internal genomic regulatory sequence (for example, an enhancing sequence contained within an ASMC is referred to as an internal enhancing sequence). BRIEF DESCRIPTION OF THE DRAWINGS
[0536] The following detailed description of the embodiments of the present disclosure will be better understood when read in conjunction with the accompanying drawings. For the purpose of illustrating the present disclosure, exemplary embodiments of the present invention are shown in the accompanying drawings. However, it should be understood that the present disclosure is not limited to the precise arrangements and instrumentalities of the embodiments shown in the accompanying drawings.
[0537] Figure 1 The diagram shown illustrates exemplary positioning of gRNA sequences within anchor sequences. Figure 1 SEQ ID NOs 244-245 are disclosed in the order of appearance, respectively.
[0538] Figure 2 The diagram shown shows exemplary positioning of gRNA sequences within the anchor sequence and restriction site information. Figure 2 SEQ ID NOs 246-247 are disclosed in the order of appearance, respectively.
[0539] Figure 3 Shown is a graph of the expression (mRNA) of various chemokines in cells treated with TNF with and without treatment with a site-specific disruption agent comprising a CRISPR / Cas molecule and a first exemplary gRNA.
[0540] Figure 4 Shown are graphs of the expression (mRNA) of various chemokines in cells treated with TNF with and without treatment with a site-specific disruption agent comprising a CRISPR / Cas molecule and a second exemplary gRNA.
[0541] Figure 5 The figures shown depict different types of genomic complexes (eg, ASMCs, eg, rings) and a model of how the expression of genes contained therein is altered.
[0542] Figure 6A graph shows cytokine expression measured by RNA levels of CXCL1, CXCL2, CXCL3, and IL-8 in THP-1 cells treated with a site-specific disruption agent comprising a CRISPR / Cas molecule and an sgRNA targeting an anchor sequence of a genomic complex comprising cytokine-encoding genes (e.g., ASMC).
[0543] Figure 7 Shown are graphs of cytokine secretion (CXCL1 and IL-8) of THP-1 cells treated with site-specific disruptors comprising a CRISPR / Cas molecule and different sgRNAs targeting anchor sequences of genomic complexes containing cytokine-encoding genes (e.g., ASMC).
[0544] Figure 8 Shown are graphs of cytokine expression (CXCL3) measured by RNA levels in THP-1 cells treated with a site-specific disruption agent comprising a CRISPR / Cas molecule and an sgRNA targeting an anchor sequence of a genomic complex containing a cytokine-encoding gene (e.g., ASMC) (top), and a flowchart showing how the cells were treated in the experiment (bottom).
[0545] Figure 9A Shown are graphs of cytokine expression (CXCL1) measured by RNA levels in THP-1 cells 3 weeks after treatment with a site-specific disruption agent comprising a CRISPR / Cas molecule and an sgRNA targeting an anchor sequence of a genomic complex comprising a cytokine-encoding gene (e.g., ASMC) (top), and a flowchart showing how the cells were processed in the experiment (bottom). Figure 9B A graph shows cytokine expression (CXCL3) measured by RNA levels in THP-1 cells 3 weeks after treatment with a site-specific disruptor comprising a CRISPR / Cas molecule and an sgRNA targeting an anchor sequence of a genomic complex comprising a cytokine-encoding gene (e.g., ASMC).
[0546] Figure 10 Shown is a graph of cytokine expression (CXCL1) measured by RNA levels in THP-1 cells after treatment with a site-specific disruption agent comprising a catalytically inactive CRISPR / Cas molecule and a transcriptional repressor (KRAB) and an sgRNA targeting an anchor sequence of a genomic complex containing a cytokine-encoding gene (e.g., ASMC).
[0547] Figure 11Shown is a graph of cytokine expression (CXCL1) measured by RNA levels in THP-1 cells following treatment with a site-specific disruptor comprising a catalytically inactive CRISPR / Cas molecule and a histone methyltransferase (EZH2) and an sgRNA targeting an anchor sequence of a genomic complex containing cytokine-encoding genes (e.g., ASMC).
[0548] Figure 12 Shown is a graph of cytokine expression (CXCL1) measured by RNA levels in THP-1 cells following treatment with a site-specific disruption agent comprising a catalytically inactive CRISPR / Cas molecule and a DNA methyltransferase (MQ1) and an sgRNA targeting an anchor sequence of a genomic complex containing cytokine-encoding genes (e.g., ASMC).
[0549] Figure 13 Shown are graphs of cytokine expression (CXCL1) measured by RNA levels in THP-1 cells after treatment with different site-specific disrupting agents for 72 hours, 3 weeks, or 4 weeks (top panel), and a flow chart showing how the cells were treated in the experiments (bottom panel).
[0550] Figure 14 Shown are graphs of cytokine expression (CXCL3) measured by RNA levels in THP-1 cells after treatment with different site-specific disrupting agents and sgRNAs targeting anchor sequences of genomic complexes containing cytokine-encoding genes (e.g., ASMC) (top), and a flowchart showing how cells were processed in the experiments (bottom).
[0551] Figure 15 A graph shows cytokine expression (CXCL1) measured by RNA levels in THP-1 cells after treatment with different site-specific disrupting agents and sgRNAs targeting anchor sequences of genomic complexes containing cytokine-encoding genes (e.g., ASMC) (top panel).
[0552] Figure 16 shows the human CXCL IGD and gene cluster organization. Figure 16A A schematic diagram of the Insulated Genomic Domain (IGD) is shown, illustrating the two loops within the CXCL1-8 gene cluster. The CXCL8, CXCL6, and CXCL1 genes are located on the left loop of the IGD. The CXCL2-5 and CXCL7 genes are located on the right loop of the IGD. Examination of IGD data from different cell lines revealed that intermediate CTCF is only present in cells that secrete CXCLs (e.g., not in lymphocytes). Figure 16B Guides are shown designed for four different CTCF targets: Left CTCF-2, Left CTCF, Center CTCF, and Right CTCF.
[0553] Figure 17 The results show that when the dCas9-EZH2 guide 30183 targets the middle CTCF motif located within the CXCL1-8 cluster in TNF-α-treated human A549 lung cancer epithelial cells, the CXCL1-8 genes are downregulated. Cells stimulated with TNFα were treated as a control.
[0554] Figure 18 Figure 3 shows that when dCas9-EZH2 guide 30183 targets the middle CTCF motif located within the CXCL1-8 cluster in TNF-α-treated human IMR-90 normal lung fibroblasts, CXCL1, 2, 3, 8 genes are downregulated. Cells stimulated with TNFα were treated as a control.
[0555] Figure 19 Figure 3 shows that CXCL1, 2, 3, and 8 genes are downregulated when control A targets the left CTCF motif within the CXCL1-8 cluster in TNF-α-treated human monocytes. Cells stimulated with TNFα were treated as a control.
[0556] Figure 20 shows mouse CXCL IGD and gene cluster organization. Figure 20A A schematic insulated genomic domain (IGD) is shown, illustrating two loops within the CXCL gene cluster. Figure 20B Two loops within the CXCL1-5, 7, and 15 gene cluster are illustrated. The CXCL4, CXCL5, and CXCL7 genes are located on the left loop of the IGD. The CXCL1-3 and CXCL15 genes are located on the right loop of the IGD guides designed for four different CTCF targets: left (L), middle 1 (M1), middle 2 (M2), and right (R) CTCF.
[0557] Figure 21A IGD guides are shown designed for four different CTCF targets: middle 1 (M1), middle 2 (M2), and right (R) CTCF.
[0558] Figure 21B Figure 2 shows in vitro downregulation of mouse CXCL IGD in Hep 1.6 cells using dCas9-MQ1. dCas9-MQ1 was transfected with guides targeting either the right or one of the two middle CTCF motifs in the CXCL gene cluster, which showed no downregulation of any of the seven CXCL genes after TNF-α stimulation (orange). When dCas9-MQ1 was transfected with a combination of guides targeting the middle and right CTCF motifs, the entire gene cluster was downregulated (blue).
[0559] Figure 22AFigure 3 shows a schematic experimental design to determine the effect of dCas9-MQ1 on reducing leukocyte infiltration in inflamed lungs. Each mouse was treated with LNP alone or 3 mg / kg of dCas9-MQ1 targeting both middle and right CTCFs at the -2 hour time point. Mice were mock treated with 5 mg / kg of LPS at zero hours and then given a second dose of either LNP alone or 3 mg / kg of dCas9-MQ1 targeting both middle and right CTCFs at the +8 hour time point. Dexamethasone was administered intraperitoneally at a dose of 10 mg / kg at 0, 24, and 48 hours. Animals were terminated at 72 hours and bronchiolar lavage fluid was collected from the lungs for flow staining.
[0560] Figure 22B Systemic administration of dCas9-MQ1 reduced leukocyte infiltration in inflamed lungs, with significant differences in total leukocyte counts / mL in bronchial lavage fluid from dCas9-MQ1-treated mice compared to LPS+ disease animals.
[0561] Figure 23A Figure 2 shows the composition of infiltrating cells found in bronchial lavage fluid obtained from inflamed lungs of mice. The white blood cell type that makes up the majority of the infiltrating cells is neutrophils, followed by B cells, T cells, macrophages, and other types of hematopoietic cells.
[0562] Figure 23B We showed that dCas9-MQ1 reduced the number of neutrophils infiltrating the lungs, with significant differences compared to the +LPS disease group.
[0563] Figure 24 This figure demonstrates that the reduction in leukocytes in BALF is lung-specific and not due to a decrease in peripheral blood leukocytes. This figure demonstrates that the effect of dCas9-MQ1 treatment on reducing leukocyte counts in BALF is lung-specific and not due to a decrease in the mouse's own leukocyte population. Hematopoietic cell populations in peripheral blood were similar in all groups.
[0564] Figure 25A -G shows reduced expression of CXCL1-5, CXCL7, and CXCL15 genes in lung tissue. After animals were treated with LNPs alone or with dCas9-MQ1, lung tissue was processed to examine CXCL gene expression by qPCR. All CXCL genes showed downregulation upon dCas9-MQ1 treatment. CXCL2 expression was most significantly downregulated.
[0565] Figure 26A-D showed that reducing CXCL expression and cell recruitment to the site of inflammation has the beneficial downstream effect of reducing the presence of other cytokines. The secreted chemokine protein levels in BALF showed a decrease in CXCL1 and 2 protein levels. Reducing CXCL expression and cell recruitment to the site of inflammation has the beneficial downstream effect of reducing GM-CSF ( Figure 26C ) and IL6( Figure 26D )’s beneficial downstream effects.
[0566] Figure 27 and 28 The bar graphs show the % downregulation of CXCL genes using expression repressors targeting different sites in the E1 cRE (compared to cells + IL-1A). Overall, these graphs show how numerous effectors targeting two different sites in the E1 cRE can achieve downregulation of multiple genes near the E1 cRE.
[0567] Figure 29 The bar graph shows the % downregulation of CXCL genes (compared to cells + IL-1A) using expression repressors targeting sites in the E2 cRE.
[0568] Figure 30 and 31 The bar graph shows dCas9-KRAB targeting sites in the E1 cRE ( Figure 30 ) and dCas9-MQ1( Figure 31 ) How can multiple genes near E1 cRE be downregulated? *p<0.05, ***p<0.001, ****p<0.0001
[0569] Figure 32 and 33 The bar graph shows dCas9-KRAB targeting sites in the E1 cRE ( Figure 32 ) and dCas9-MQ1( Figure 33 ) How can multiple genes near E1 cRE be downregulated? *p<0.05, ***p<0.001, ****p<0.0001
[0570] Figure 34 The bar graph shows how the expression repressor (dCas9-KRAB) targeting the IL8 promoter successfully downregulated IL8 expression.
[0571] Figure 35 The bar graph shows how two expression repressors containing zinc finger domains targeting different sites within the E1 cRE can achieve downregulation of multiple genes near the E1 cRE. Furthermore, the graph shows that the dCas9-KRAB expression repressor targeting the IL8 promoter reduced IL8 expression by over 90%.
[0572] Figure 36 The bar graph shows that the E1 cRE-targeted expression repressor (zinc finger-KRAB), the IL8 promoter-targeted expression repressor (dCas9-KRAB), and the combination of the two do not interfere with each other, and the combination of expression repressors has a greater effect on IL8 than using either expression repressor alone.
[0573] Figure 37 The bar graph shows that the use of expression repressors targeted to the E1 cRE or sites in the IL8 promoter reduces the expression of IL8 as measured by IL8 mRNA one hour after IL1A stimulation.
[0574] Figure 38 and Figure 39 The bar graph shows that the use of expression repressors targeting E1 cRE or sites in the IL8 promoter reduced IL8 expression, where IL8 expression was reduced at 6 hours after IL1A stimulation ( Figure 38 ) and 24 hours ( Figure 39 ) IL8 protein levels were measured by ELISA.
[0575] Figure 40 The bar graph depicts the downregulation of CXCL1-3 and IL8 mRNA levels by two expression repressors targeting two sites in the E1 cRE (percent downregulation calculated by normalization to IL1A-treated control).
[0576] Figure 41 The bar graph shows the ability of two expression repressors (MR32105 and MR32104, containing a zinc finger targeting moiety and a KRAB effector domain) targeting two sites in the E1 cRE to increase H3Kme3 as measured by ChIP qPCR.
[0577] Figure 42 The bar graph shows downregulation of CXCL1-3 and IL8 on days 3-7 after introduction of an expression repressor targeting the E1 cRE (MR32105). The percentage of CXCL1-3 and IL8 gene downregulation was calculated by normalizing to the IL-1A-treated control. Downregulation of CXCL1, CXCL2, CXCL3, and IL8 is shown from left to right by group on days 3-7.
[0578] Figure 43 The bar graph shows downregulation of IL8 using expression repressors targeted to different sites in the IL8 promoter. Overall, this figure illustrates how multiple effectors targeting different sites in the IL8 promoter can achieve downregulation of IL8.
[0579] Figure 44A and Figure 44BThe expression repressor targeting E1 derived from MR-32105 is enriched at the E1 site (upper sub-graph), resulting in an increase in on-target DNA histone methylation (H3K9me3) (middle sub-graph) and a decrease in on-target histone acetylation (H3K27ac) (lower sub-graph) ( Figure 44A ). Figure 44B Depletion of the P65 transcription factor at the E1 locus by the expression repressor according to MR-32105 is shown.
[0580] Figure 45 The bar graph shows the downregulation of CXCL1-3 and IL8 relative to 1 hour of IL1A stimulation after the introduction of expression repressors targeting E1 cRE (MR-32104 or MR-32105).
[0581] Figure 46A and 46B is a box-and-whisker blot showing downregulation of CXCL genes after introduction of expression repressors (MR-32104 and MR-32105) targeting E1 cRE.
[0582] Figure 47 Shown is the enrichment of IL8-targeted expression repressors derived from MR-32712 at the target IL8 (upper panel), resulting in an increase in on-target DNA histone methylation (H3K9me3) (middle panel) and a decrease in on-target P65 binding according to HA-ChIP Seq (lower panel).
[0583] Figure 48 The bar graph shows CXCL gene expression in IMR-90 cells after targeted expression of a repressor of IL8 (MR-32712).
[0584] Figure 49 Shown are box and whisker plots showing RNA levels of CXCL gene expression following introduction of an IL8 targeted expression inhibitor (MR-32172). Overall, the whisker plots show a significant reduction in IL8 RNA.
[0585] Figure 50 Enrichment of the expression repressor targeting E1 was shown at 24 hours, but no signal was detected by HA-ChIP-Seq at 24 hours.
[0586] Figure 51 The bar graph shows downregulation of CXCL gene and protein in small airway epithelial cells (COPD) after introduction of an expression repressor targeting IL8 (MR-32172) and a bicistronic expression repressor targeting E1 cRE and IL8 (MR-32905).
[0587] Figure 52The bar graph shows downregulation of CXCL gene and protein in bronchial smooth muscle cells (asthma) after introduction of an expression repressor targeting IL8 (MR-32172) and a bicistronic expression repressor targeting E1 cRE and IL8 (MR-32905).
[0588] Figure 53 The bar graph shows downregulation of CXCL gene and protein in primary lung fibroblasts following introduction of an expression repressor targeting IL8 (MR-32172) and a bicistronic expression repressor targeting E1 cRE and IL8 (MR-32905).
[0589] Figure 54 The graph shows that CXCL1-3 and IL8 were downregulated within 13 days after the introduction of an expression repressor targeting IL8 (MR-32172) and a bicistronic expression repressor targeting E1 cRE and IL8 (MR-32905).
[0590] Figure 55 The graph shows that neutrophil migration is reduced after introduction of an expression repressor targeting E1 cRE (MR-32105) and / or an expression repressor targeting IL8 (MR-32712).
[0591] Figure 56A and Figure 56B The graph shows that neutrophil migration is reduced after introduction of an expression repressor targeting IL8 (MR-32712) and / or a bicistronic expression repressor targeting E1cRE and IL8 (MR-32905).
[0592] Figure 57 The image depicts the loci of functional enhancers on the CXCL cluster in mice. The three candidate E1 positions tested in Example 41 are indicated by arrows.
[0593] Figure 58 The bar graph indicates downregulation of CXCL1 and CXCL2 following introduction of expression repressors with guides targeting mouse P1 and P6 (homologous to human E1 and E2, respectively).
[0594] Figure 59 The bar graph indicates CXCL2 RNA qPCR results after introduction of an expression repressor with guides targeting the mouse homolog of human CXCL.
[0595] Figure 60 The bar graph indicates CXCL1 RNA qPCR results after introduction of an expression repressor with guides targeting the mouse homolog of human CXCL.
[0596] Figure 61The bar graph indicates the results of CXCL1 protein expression after introduction of an expression repressor with guides targeting the mouse homolog of human CXCL.
[0597] Figure 62 The bar graph indicates downregulation of CXCL1 and CXCL2, which are homologous to human CXCLs, in mice.
[0598] Figure 63 The bar graph indicates the results of CXCL1 protein expression after the introduction of an expression repressor targeting the mouse homologue of human CXCL1.
[0599] Figure 64 The bar graph shows the results of IL-8 mRNA levels after the introduction of a bicistronic expression repressor (MR-32905) targeting E1 cRE and IL8 in multiple cancer cell lines. IL-8 mRNA levels were normalized to IL-8 mRNA in cells stimulated with TNFα.
[0600] Figure 65 The bar graph shows the results of IL-8 protein expression levels after the introduction of a bicistronic expression repressor (MR-32905) targeting E1 cRE and IL8 in multiple cancer cell lines. IL-8 mRNA levels were normalized to IL-8 mRNA in cells stimulated with TNFα.
[0601] Figure 66 The bar graph shows the results of CXCL1 mRNA levels after the introduction of a bicistronic expression repressor (MR-32905) targeting E1 cRE and IL8 in multiple cancer cell lines. CXCL1 mRNA levels were normalized to CXCL1 mRNA in cells stimulated with TNFα.
[0602] Figure 67 The bar graph shows the results of endogenous IL-8 mRNA levels after the introduction of a bicistronic expression repressor (MR-32905) targeting E1 cRE and IL8 in multiple breast cancer cell lines. IL-8 mRNA levels were normalized to IL-8 mRNA in cells stimulated with TNFα.
[0603] Figure 68 The graph indicates tumor volume (mm) in the A549 NSCLC xenograft model after introduction of a bicistronic expression repressor (MR-32905) targeting E1 cRE and IL8. 3 ).
[0604] Figure 69 The graph indicates the mean weight percent change in the A549 NSCLC xenograft model mouse group. Error bars represent the standard error of the mean (SEM). The experiment was performed as described in Example 47.
[0605] Figure 70 The bar graph indicates the area under the curve (AUC) for percent weight change in the A549 NSCLC xenograft model mouse group. The AUC for percent weight change was calculated for each animal in the study up to Day 04. This calculation was performed using the trapezoidal rule transformation. Error bars represent the SEM for each group. This experiment was performed as described in Example 47.
[0606] Figure 71 Graph depicts mean tumor volume (mm) in A549 NSCLC xenograft model after introduction of bicistronic expression repressor (MR-32905) or GFP control 3 ). Average tumor volume was calculated based on length and width measurements. Group means were calculated and shown with error bars representing the SEM for each group. This experiment was performed as described in Example 47.
[0607] Figure 72 The bar graph indicates the area under the curve (AUC) of the percent weight change in the A549 NSCLC xenograft model mouse group. The AUC was calculated using the trapezoidal rule transformation of the tumor volume measured on each animal in the study. The group mean values were calculated and displayed with error bars representing the SEM of each group. The groups were compared using an ANOVA test. The experiment was performed as described in Example 47.
[0608] Figure 73 The graph indicates the average tumor volume percentage in the A549 NSCLC xenograft model after the introduction of a bicistronic expression repressor (MR-32905) or a GFP control. The average tumor volume was calculated based on the length and width measurements. Group means were calculated and displayed with error bars representing the SEM of each group. The experiment was performed as described in Example 47.
[0609] Figure 74 The bar graph indicates the area under the curve (AUC) for the percent weight change in the A549 NSCLC xenograft model mouse group. The AUC was calculated for the tumor volume measured for each animal in the study. This calculation was performed using the trapezoidal rule transformation. Group means were calculated and displayed with error bars representing the SEM of each group. An ANOVA test was used to compare the groups. The experiment was performed as described in Example 47.
[0610] Figure 75 Schematic experimental design for determining the effect of an expression suppressor in acute respiratory distress syndrome (ARDS). The experiment was performed as described in Example 48.
[0611] Figure 76 The graph shows LPS-induced changes in body weight (BW) percentage relative to baseline in C57BL / 6 mice. The experiment was performed as described in Example 48.
[0612] Figure 77 The bar graph shows the BALF cell concentration in C57BL / 6 mice. The experiment was performed as described in Example 48.
[0613] Figures 78A-78E The bar graph shows the concentration of BALF immune cells in LPS-induced C57BL / 6 mice. Figure 78A The bar graph shows the BALF mouse leukocyte concentration (cells / mL). Figure 78B The bar graph shows the concentration of alveolar macrophages in BALF mice (cells / mL). Figure 78C The bar graph shows the neutrophil concentration (cells / mL) in BALF mice. Figure 78D The bar graph shows the BALF mouse T cell concentration (cells / mL). Figure 78E The bar graph shows the BALF mouse B cell concentration (cells / mL). The experiment was performed as described in Example 48.
[0614] Figures 79A-79D The bar graph indicates the frequency of BALF immune cells in LPS-induced C57BL / 6 mice. The experiment was performed as described in Example 48.
[0615] Figures 80A-80E The bar graph indicates the blood immune cell concentration in LPS-induced C57BL / 6 mice. This experiment was performed as described in Example 48.
[0616] Figures 81A-81D The bar graph indicates the frequency of blood immune cells in LPS-induced C57BL / 6 mice. This experiment was performed as described in Example 48.
[0617] Figures 82A-82F The bar graph indicates the histological scores and evaluation in LPS-induced C57BL / 6 mice. The experiment was performed as described in Example 48. DETAILED DESCRIPTION
[0618] The present disclosure provides, for example, a technology for reducing the expression of multiple target CXCL genes in a cell (e.g., a subject or patient) by using an expression repressor, a system comprising two or more expression repressors, or a system comprising an expression repressor and a site-specific disruptor. In some embodiments, the expression repressor comprises a targeting portion. In some embodiments, the expression repressor comprises a targeting portion and an effector portion. Without wishing to be bound by theory, many diseases and disorders are associated with a group of genes having related functions associated with a common enhancer. The inhibition of enhancers can be an improved method for reducing the expression of target multiple genes (e.g., with respect to improved efficiency, efficacy, and / or stability of changes) compared to the regulation of a single target gene. Optionally, the expression repressor can be used in combination with a site-specific disruptor, such as a site-specific disruptor that destroys an anchor sequence-mediated linker. The site-specific disruptor can also suppress the expression of multiple genes (e.g., multiple genes identical to the expression repressor or overlapping multiple genes). The improvements can be converted into corresponding improvements for treating diseases and disorders associated with target multiple genes. For example, the plurality of genes can be CXCL genes, and the expression repressor can target E1 cRE operably linked to the plurality of genes to reduce the expression of the plurality of genes, thereby achieving an anti-inflammatory effect (e.g., a superior anti-inflammatory effect relative to individually targeting a gene in the plurality of genes). Examples of expression repressors, site-specific disruptors, targeting moieties, effector moieties, and target plurality of genes are provided herein.
[0619] Expression repressor can reduce the expression of target multiple genes by one or more ways.In certain embodiments, the expression repressor for target site such as E1 cRE can physically or spatially compete for the factor that combines with target site.Do not wish to be bound by theory, the physics of enhancer sequence (for example, E1 cRE) or spatial blocking, for example, makes the combination of factor and enhancer sequence suppressed (for example, prevent), is a kind of mechanism, by which, expression repressor can regulate (for example, reduce) the expression of target multiple genes. Expression repressor can for example make the interaction of factor and enhancer sequence unstable by following: change (for example, reduce) factor and the affinity and / or avidity of enhancer sequence.Blocking factor and target sequence combination or make it unstable can be realized by one or more means, including: enhancer sequence or the epigenetic modification near its sequence, enhancer sequence or the genetic modification near its sequence or expression repressor and enhancer sequence or the combination near its sequence.The inhibition of the genomic regulatory element that is operably connected to target multiple genes can be regulated, for example, reduces the expression of the gene of target multiple genes. In some embodiments, the expression repressor comprises a targeting moiety, a first effector moiety, and a second effector moiety. In some embodiments, the first effector moiety has a sequence that is different from the sequence of the second effector moiety. In some embodiments, the first effector moiety has a sequence that is identical to the sequence of the second effector moiety.
[0620] Expression repressors described herein (for example, expression repressors targeting enhancer sequences) can also be used in combination with site-specific disruptors (for example, disruptors targeting anchor sequences). In certain embodiments, site-specific disruptors include targeting moieties. In certain embodiments, site-specific disruptors include targeting moieties and effector moieties. Without wishing to be bound by theory, many diseases and disorders are relevant to the group of genes with related functions, and these genes are associated with a common genome complex such as ASMC. Compared to regulating individual target genes, regulation (for example, destruction) of a genome complex (for example, ASMC) comprising (wholly or partially) target multiple genes may be an improved method (for example, about improved efficiency, conformation and / or stability of change) for changing (for example, reducing) the expression of the multiple genes of the target. The improvement can be converted into a corresponding improvement for treating a disease and disorder related to multiple genes of the target. For example, multiple genes may be associated with proinflammatory effects, and site-specific disruptive agents can target a genomic complex (e.g., ASMC) comprising (wholly or partially) multiple genes to regulate (e.g., reduce) the expression of multiple genes, thereby achieving an anti-inflammatory effect (e.g., a better anti-inflammatory effect relative to individually targeting genes in multiple genes). Examples of site-specific disruptive agents, targeting moieties, effector moieties, and target multiple genes are provided herein.
[0621] Site-specific destroying agents can regulate, for example, reduce the expression of target multiple genes by one or more ways. In certain embodiments, site-specific destroying agents bind to target sites (for example, anchor sequences) and physically or spatially compete with the combination of other genome complex components (for example, nucleating polypeptides). Without wishing to be bound by theory, the physical or spatial blocking of anchor sequences, for example, suppresses (for example, prevents) the combination of genome complex components (for example, nucleating polypeptides) with anchor sequences, is a mechanism by which site-specific destroying agents can regulate (for example, reduce) the expression of target multiple genes. Site-specific destroying agents can make the interaction of genome complex components (for example, nucleating polypeptides) with anchor sequences unstable, for example, by changing (for example, reducing) the affinity and / or avidity of genome complex components in conjunction with anchor sequences. Blocking the combination of genome complex components (for example, nucleating polypeptides) with anchor sequences or making them unstable can be achieved by one or more means, including: epigenetic modification of anchor sequences or sequences near them, genetic modification of anchor sequences or sequences near them, or site-specific destroying agents and anchor sequences or sequences near them. Inhibiting (e.g., preventing) the binding of a genomic complex component (e.g., a nucleating polypeptide) to an anchor sequence can inhibit (e.g., destroy or prevent the formation of) a genomic complex, e.g., ASMC. Inhibiting all or part of a genomic complex (e.g., ASMC) comprising a target multiple gene can regulate (e.g., reduce) the gene expression of the target multiple genes. In some embodiments, the site-specific destructive agent comprises a targeting portion, a first effector portion, and a second effector portion. In some embodiments, the first effector portion has a sequence different from the sequence of the second effector portion. In some embodiments, the first effector portion has a sequence identical to the sequence of the second effector portion.
[0622] The present disclosure also provides, in part, a system comprising two or more expression repressors, each expression repressor comprising a targeting moiety and an optional effector moiety. In certain embodiments, the targeting moiety targets two or more different sequences (for example, each expression repressor can target different sequences). In certain embodiments, the first expression repressor is combined with a first genome regulatory element (for example, an enhancer, such as E1cRE) operably connected to target multiple genes (for example, people CXCL1-8), and the second expression repressor is combined with a second genome regulatory element (for example, an enhancer, a promoter, or a transcription start site TSS) operably connected to multiple genes (for example, people CXCL1-8). In certain embodiments, the system comprises an expression repressor and a site-specific disruptor. In certain embodiments, the expression repressor is combined with a transcriptional regulatory element (for example, an enhancer (for example, E1cRE)) operably connected to target multiple genes (for example, people CXCL1-8), and the site-specific disruptor is combined with an anchor sequence of a connector (ASMC) mediated by an anchor sequence comprising target multiple genes (for example, people CXCL1-8).
[0623] In some embodiments, the system regulates the expression of target multiple genes (e.g., human CXCL 1-8) by the first expression repressor and the second expression repressor, respectively, and the first and second DNA sequences. In some embodiments, the system regulates the expression of target multiple genes (e.g., human CXCL 1-8) by the first expression repressor and the second expression repressor, respectively, and the first and second DNA sequences. The binding of the first and second DNA sequences localizes the functions of the first and second effector moieties to those sites. Without wishing to be bound by theory, in some embodiments, the functions of both the first and second effector moieties are employed to stably repress the expression of target multiple genes associated with or comprising the first and / or second DNA sequences, for example, wherein the first and / or second DNA sequences are or include sequences of the target multiple genes or one or more operably linked genomic regulatory elements (e.g., transcriptional control elements).
[0624] Expression repressor
[0625] In some embodiments, the expression repressor comprises a targeting moiety. In some embodiments, the targeting moiety specifically binds to a DNA sequence, such as E1 cRE, thereby regulating, for example, the function of destroying a DNA sequence. In some embodiments, the expression repressor comprises a targeting moiety and an effector moiety. In some embodiments, the targeting moiety specifically binds to a DNA sequence, thereby localizing the function of the effector moiety to the DNA sequence or a region near it. In some embodiments, the expression repressor comprises a targeting moiety and an effector moiety. In some embodiments, the expression repressor comprises a targeting moiety and more than one effector moiety, such as two, three, four or five effector moieties, each effector moiety can be the same or different from another of the more than one effector moieties. In some embodiments, the expression repressor can comprise two effector moieties, wherein the first effector moiety comprises a function different from the second effector moiety. For example, the expression repressor can comprise two effector moieties, wherein the first effector moiety comprises a DNA methyltransferase function (e.g., comprising MQ1, G9A or EZH2 or its functional fragment or variant) and the second effector moiety comprises a transcription repressor function (e.g., comprising KRAB or its functional fragment or variant). In some embodiments, the expression repressor comprises an effector moiety whose functions complement each other in reducing the expression of the target multiple genes, wherein these functions together inhibit expression, and optionally, do not inhibit or weakly inhibit expression when present alone. In some embodiments, the expression repressor comprises multiple effector moieties, wherein each effector moiety complements each other effector moiety, and each effector moiety reduces the expression of the target multiple genes.
[0626] In certain embodiments, expression repressor comprises a combination of effector moieties, and the functions of these effector moieties cooperate with each other in reducing the expression of target multiple genes. Without wishing to be bound by theory, in certain embodiments, it is believed that the epigenetic modification to genomic locus is cumulative, because multiple transcription activation epigenetic markers (e.g., multiple different types of epigenetic markers and / or the wider markers of a given type) are individually more effectively suppressed together than a single modification (e.g., producing a larger expression reduction and / or a more lasting expression reduction). In certain embodiments, expression repressor comprises multiple effector moieties, wherein each effector moiety cooperates with each other effector moiety, such as each effector moiety reduces the expression of target multiple genes. In certain embodiments, expression repressor (comprising multiple effector moieties that cooperate with each other) is more effective than an expression repressor comprising a single effector moiety in suppressing target multiple gene expression. In some embodiments, the expression repressor comprising the plurality of effector portions is at least 1.05x (i.e., 1.05-fold), 1.1x, 1.15x, 1.2x, 1.25x, 1.3x, 1.35x, 1.4x, 1.45x, 1.5x, 1.55x, 1.6x, 1.65x, 1.7x, 1.75x, 1.8x, 1.85x, 1.9x, 1.95x, 2x, 3x, 4x, 5x, 6x, 7x, 8x, 9x, 10x, 20x, 30x, 40x, 50x, 60x, 70x, 80x, 90x, or 100x more effective at reducing the expression of the target plurality of genes than an expression repressor comprising a single effector portion.
[0627] In some embodiments, the expression repressor comprises one or more targeting moieties, such as a Cas domain, a TAL effector domain, or a Zn finger domain. In an embodiment, when the system comprises two or more targeting moieties of the same type, such as two or more Cas domains or two or more zinc finger domains, the targeting moiety specifically binds to two or more different sequences. As a non-limiting example, the expression repressor system comprises two or more zinc finger domains, and the two or more zinc finger domains can be selected or changed so that they only significantly bind to their target sequence (e.g., and do not significantly bind to the target sequence of another zinc finger domain). As another non-limiting example, in an expression repressor system comprising two or more Cas domains, the two or more Cas domains can be selected or changed so that they only significantly bind to the gRNA corresponding to their target sequence (e.g., and do not significantly bind to the gRNA corresponding to the target of another Cas domain).
[0628] In some embodiments, the expression repressor comprises a targeting moiety and an effector moiety, for example, covalently linked by a peptide bond. In some embodiments, the targeting moiety and the effector moiety are located on the same polypeptide chain, for example, connected by one or more peptide bonds and / or linkers. In some embodiments, the expression repressor comprises a fusion molecule, for example, the fusion molecule comprises a targeting moiety and an effector moiety connected by a peptide bond and / or linker. In some embodiments, the expression repressor comprises a targeting moiety at the N-terminus of the effector moiety arranged on the same polypeptide chain. In some embodiments, the expression repressor comprises a targeting moiety at the C-terminus of the effector moiety arranged on the same polypeptide chain. In some embodiments, the expression repressor comprises a targeting moiety and an effector moiety covalently linked by a non-peptide bond. In some embodiments, the targeting moiety is conjugated to the effector moiety by a non-peptide bond. In some embodiments, the expression repressor comprises a targeting moiety and a plurality of effector moieties, wherein the targeting moiety and the plurality of effector moieties are covalently linked, for example, by a peptide bond (for example, the targeting moiety and the plurality of effector moieties are all connected by a series of covalent bonds, although each individual moiety may not share a covalent bond with each other moiety).
[0629] In other embodiments, the expression repressor comprises a targeting moiety and an effector moiety that are not covalently linked, e.g., they are non-covalently associated with each other. In some embodiments, the expression repressor comprises a targeting moiety that is non-covalently bound to an effector moiety or vice versa. In some embodiments, the expression repressor comprises a targeting moiety and a plurality of effector moieties, wherein the targeting moiety and at least one effector moiety are not covalently linked, e.g., are non-covalently associated with each other, and wherein the targeting moiety and at least one other effector moiety are covalently linked, e.g., via a peptide bond.
[0630] In some embodiments, the expression repressor comprises a first effector portion comprising G9A and a second effector portion comprising KRAB. In some embodiments, the expression repressor comprises a first effector portion comprising G9A and a second effector portion comprising EZH2. In some embodiments, the expression repressor comprises a first effector portion comprising EZH2 and a second effector portion comprising KRAB.
[0631] In some embodiments, the expression repressor comprises a targeting moiety and an effector moiety, wherein the C-terminus of the effector moiety (e.g., selected from KRAB or MQ1 or a functional variant or fragment thereof) and the N-terminus of the targeting moiety are covalently linked. In some embodiments, the expression repressor comprises a targeting moiety and an effector moiety, wherein the N-terminus of the effector moiety (e.g., selected from HDAC8, MQ1, DNMT3a / 3L, KRAB or a functional variant or fragment thereof) and the C-terminus of the targeting moiety are covalently linked. In some embodiments, the expression repressor comprises a targeting moiety, a first effector moiety and a second effector moiety, wherein the C-terminus of the first effector moiety and the N-terminus of the targeting moiety are covalently linked, and the C-terminus of the targeting moiety and the N-terminus of the second effector moiety are covalently linked. Covalent linkage can, for example, be via a linker sequence.
[0632] In some embodiments, the expression repressor comprises a targeting moiety, a first effector moiety, and a second effector moiety, wherein the first effector moiety is EZH2 or a functional variant or fragment thereof, for example, wherein the first effector moiety comprises the amino acid sequence of SEQ ID NO: 17, or a sequence having at least 80%, 85%, 90%, 95%, 99% or 100% identity thereto, or differs therefrom at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 position, and the first effector moiety is the N-terminal end of the targeting moiety; and the second effector moiety is KRAB or a functional variant or fragment thereof, for example, wherein the second effector moiety comprises SEQ ID NO: NO:13, or a sequence that is at least 80%, 85%, 90%, 95%, 99% or 100% identical thereto or differs from it at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 position, and the second effector portion is at the C-terminus of the targeting portion.
[0633] In some embodiments, the site-specific disruption agent comprises a targeting moiety, a first effector moiety, and a second effector moiety, wherein the first effector moiety is EZH2 or a functional variant or fragment thereof, for example, wherein the first effector moiety comprises the amino acid sequence of SEQ ID NO: 17, or a sequence having at least 80%, 85%, 90%, 95%, 99% or 100% identity thereto, or differs therefrom at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 position, and the first effector moiety is N-terminal to the targeting moiety; and the second effector moiety is HDAC8 or a functional variant or fragment thereof, for example, wherein the second effector moiety comprises SEQ ID NO: NO:19, or a sequence that is at least 80%, 85%, 90%, 95%, 99% or 100% identical thereto or differs from it at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 position, and the second effector portion is at the C-terminus of the targeting portion.
[0634] In some embodiments, the site-specific disruption agent comprises a targeting moiety, a first effector moiety, and a second effector moiety, wherein the first effector moiety is G9A or a functional variant or fragment thereof, for example, wherein the first effector moiety comprises the amino acid sequence of SEQ ID NO: 67, or a sequence having at least 80%, 85%, 90%, 95%, 99% or 100% identity thereto, or a sequence that differs from it at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 position, and the first effector moiety is at the N-terminal end of the targeting moiety; and the second effector moiety is KRAB or a functional variant or fragment thereof, for example, wherein the second effector moiety comprises SEQ ID NO: NO:13, or a sequence that is at least 80%, 85%, 90%, 95%, 99% or 100% identical thereto or differs from it at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 position, and the second effector portion is at the C-terminus of the targeting portion.
[0635] In some embodiments, the site-specific disrupting agent comprises a targeting moiety, a first effector moiety, and a second effector moiety, wherein the first effector moiety is G9A or a functional variant or fragment thereof, for example, wherein the first effector moiety comprises the amino acid sequence of SEQ ID NO: 67, or a sequence having at least 80%, 85%, 90%, 95%, 99% or 100% identity thereto or differing therefrom at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 position, and the first effector moiety is at the N-terminal end of the targeting moiety; and the second effector moiety is EZH2 or a functional variant or fragment thereof, for example, wherein the second effector moiety comprises SEQ ID NO: NO:17, or a sequence that is at least 80%, 85%, 90%, 95%, 99% or 100% identical thereto or differs from it at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 position, and the second effector portion is at the C-terminus of the targeting portion.
[0636] In some embodiments, the first effector portion comprises a histone methyltransferase activity and the second effector portion comprises a different histone methyltransferase activity. In some embodiments, the first effector portion comprises a histone methyltransferase activity and the second effector portion comprises the same histone methyltransferase activity. In some embodiments, the first effector portion comprises a histone demethylase activity and the second effector portion comprises a histone deacetylase activity. In some embodiments, the first effector portion comprises a histone demethylase activity and the second effector portion comprises a DNA methyltransferase activity. In some embodiments, the first effector portion comprises a histone demethylase activity and the second effector portion comprises a DNA demethylase activity. In some embodiments, the first effector portion comprises a histone demethylase activity and the second effector portion comprises a transcriptional repressor activity. In some embodiments, the first effector portion comprises a histone demethylase activity and the second effector portion comprises a different histone demethylase activity. In some embodiments, the first effector portion comprises a histone demethylase activity and the second effector portion comprises the same histone demethylase activity. In some embodiments, the first effector portion comprises a histone deacetylase activity and the second effector portion comprises a DNA methyltransferase activity. In some embodiments, the first effector portion comprises a histone deacetylase activity and the second effector portion comprises a DNA demethylase activity. In some embodiments, the first effector portion comprises a histone deacetylase activity and the second effector portion comprises a transcriptional repressor activity. In some embodiments, the first effector portion comprises a histone deacetylase activity and the second effector portion comprises a different histone deacetylase activity. In some embodiments, the first effector portion comprises a histone deacetylase activity and the second effector portion comprises the same histone deacetylase activity. In some embodiments, the first effector portion comprises a DNA methyltransferase activity and the second effector portion comprises a DNA demethylase activity. In some embodiments, the first effector portion comprises a DNA methyltransferase activity and the second effector portion comprises a transcriptional repressor activity. In some embodiments, the first effector portion comprises a DNA methyltransferase activity and the second effector portion comprises a different DNA methyltransferase activity. In some embodiments, the first effector portion comprises a DNA methyltransferase activity and the second effector portion comprises the same DNA methyltransferase activity. In some embodiments, the first effector portion comprises a DNA demethylase activity and the second effector portion comprises a transcriptional repressor activity. In some embodiments, the first effector moiety comprises a DNA demethylase activity and the second effector moiety comprises a different DNA demethylase activity. In some embodiments, the first effector moiety comprises a DNA demethylase activity and the second effector moiety comprises the same DNA demethylase activity.In some embodiments, the first effector moiety comprises a transcriptional repressor activity and the second effector moiety comprises a different transcriptional repressor activity. In some embodiments, the first effector moiety comprises a transcriptional repressor activity and the second effector moiety comprises the same transcriptional repressor activity.
[0637] In some embodiments, the first effector moiety comprises DNMT3a / 31, MQ1, KRAB, G9A, HDAC8, or EZH2, and the second effector moiety comprises DNMT3a / 31, MQ1, KRAB, G9A, HDAC8, or EZH2.
[0638] Site-specific disruptors
[0639] In some embodiments, the site-specific disrupting agent comprises a targeting moiety. In some embodiments, the targeting moiety specifically binds to a DNA sequence, such as an anchor sequence, thereby regulating, for example, destroying a genome complex (such as ASMC) comprising the DNA sequence. In some embodiments, the site-specific disrupting agent comprises a targeting moiety and an effector moiety. In some embodiments, the targeting moiety specifically binds to a DNA sequence, thereby positioning the function of the effector moiety to the DNA sequence, thereby regulating (for example, destroying) the genome complex (for example, ASMC) comprising the DNA sequence. In some embodiments, the site-specific disrupting agent comprises a targeting moiety and an effector moiety. In some embodiments, the site-specific disrupting agent comprises a targeting moiety and an effector moiety. In some embodiments, the site-specific disrupting agent comprises a targeting moiety and more than one effector moiety, such as two, three, four or five effector moieties, each of which can be the same or different from another in the more than one effector moiety. In some embodiments, the site-specific disrupting agent may comprise two effector moieties, wherein the first effector moiety comprises a function different from the second effector moiety. For example, a site-specific destructive agent may comprise two effector moieties, wherein the first effector moiety comprises a DNA methyltransferase function (e.g., comprising G9A or EZH2 or a functional fragment or variant thereof), and the second effector moiety comprises a transcriptional repression function (e.g., comprising KRAB or a functional fragment or variant thereof). In some embodiments, the site-specific destructive agent comprises an effector moiety whose functions complement each other in reducing the expression of target multiple genes, wherein these functions together inhibit expression, and optionally, do not inhibit or weakly inhibit expression when present alone. In some embodiments, the site-specific destructive agent comprises multiple effector moieties, wherein each effector moiety complements the other effector moieties, and each effector moiety reduces the expression of target multiple genes.
[0640] In some embodiments, the site-specific destructive agent comprises a combination of effector moieties, the functionality of which synergizes with each other with respect to the reduction in expression of target multiple genes. Without wishing to be bound by theory, in some embodiments, it is believed that epigenetic modifications to genomic loci are cumulative because multiple transcriptional activation epigenetic markers (e.g., multiple different types of epigenetic markers and / or a wider range of markers of a given type) together alone are more effective than a single modification alone in suppressing expression (e.g., producing a greater reduction in expression and / or a more persistent reduction in expression). In some embodiments, the site-specific destructive agent comprises multiple effector moieties, wherein each effector moiety collaborates with each other effector moiety, for example, each effector moiety reduces the expression of target multiple genes. In some embodiments, site-specific destructive agents (comprising multiple effector moieties that synergize with each other) more effectively suppress the expression of target multiple genes than site-specific destructive agents comprising a single effector moiety. In some embodiments, the site-specific disrupting agent comprising the plurality of effector portions is at least 1.05x (i.e., 1.05-fold), 1.1x, 1.15x, 1.2x, 1.25x, 1.3x, 1.35x, 1.4x, 1.45x, 1.5x, 1.55x, 1.6x, 1.65x, 1.7x, 1.75x, 1.8x, 1.85x, 1.9x, 1.95x, 2x, 3x, 4x, 5x, 6x, 7x, 8x, 9x, 10x, 20x, 30x, 40x, 50x, 60x, 70x, 80x, 90x, or 100x more effective at reducing the expression of the target plurality of genes than a site-specific disrupting agent comprising a single effector portion.
[0641] In some embodiments, the site-specific destructive agent comprises one or more targeting moieties, such as a Cas domain, a TAL effector domain, or a Zn finger domain. In an embodiment, when the system comprises two or more targeting moieties of the same type, such as two or more Cas domains, the targeting moieties specifically bind to two or more different sequences. For example, in a site-specific destructive agent system comprising two or more Cas domains, the two or more Cas domains can be selected or altered so that they only significantly bind to the gRNA corresponding to their target sequence (e.g., without significantly binding to the gRNA corresponding to the target of another Cas domain).
[0642] In some embodiments, the site-specific destroying agent comprises a targeting moiety and an effector moiety, for example, covalently linked by a peptide bond. In some embodiments, the targeting moiety and the effector moiety are located on the same polypeptide chain, for example, connected by one or more peptide bonds and / or linkers. In some embodiments, the site-specific destroying agent comprises a fusion molecule, for example, a fusion molecule containing a targeting moiety and an effector moiety connected by a peptide bond and / or linker. In some embodiments, the site-specific destroying agent comprises a targeting moiety at the N-terminus of the effector moiety located on the same polypeptide chain. In some embodiments, the site-specific destroying agent comprises a targeting moiety at the C-terminus of the effector moiety located on the same polypeptide chain. In some embodiments, the site-specific destroying agent comprises a targeting moiety and an effector moiety covalently linked by a non-peptide bond. In some embodiments, the targeting moiety is conjugated to the effector moiety by a non-peptide bond. In some embodiments, the site-specific destroying agent comprises a targeting moiety and a plurality of effector moieties, wherein the targeting moiety and the plurality of effector moieties are covalently linked, for example, by a peptide bond (for example, the targeting moiety and the plurality of effector moieties are all connected by a series of covalent bonds, although each individual moiety may not share a covalent bond with each other moiety).
[0643] In other embodiments, the site-specific disruption agent comprises a targeting moiety and an effector moiety that are non-covalently linked, e.g., they are non-covalently bound to each other. In some embodiments, the site-specific disruption agent comprises a targeting moiety that is non-covalently bound to an effector moiety, or vice versa. In some embodiments, the site-specific disruption agent comprises a targeting moiety and a plurality of effector moieties, wherein the targeting moiety and at least one effector moiety are not covalently linked, e.g., are non-covalently associated with each other, and wherein the targeting moiety and at least one other effector moiety are covalently linked, e.g., via a peptide bond.
[0644] In some embodiments, the site-specific disrupting agent comprises a first effector moiety comprising G9A and a second effector moiety comprising KRAB. In some embodiments, the site-specific disrupting agent comprises a first effector moiety comprising G9A and a second effector moiety comprising EZH2. In some embodiments, the site-specific disrupting agent comprises a first effector moiety comprising EZH2 and a second effector moiety comprising KRAB.
[0645] In some embodiments, the site-specific destructive agent comprises a targeting portion and an effector portion, wherein the C-terminus of the effector portion (e.g., selected from the effector portion of EZH2 or G9A or its functional variant or fragment) is covalently linked to the N-terminus of the targeting portion. In some embodiments, the site-specific destructive agent comprises a targeting portion and an effector portion, wherein the N-terminus of the effector portion (e.g., selected from the effector portion of HDAC8, MQ1, DNMT3a / 3L, KRAB or its functional variant or fragment) is covalently linked to the C-terminus of the targeting portion. In some embodiments, the site-specific destructive agent comprises a targeting portion, a first effector portion and a second effector portion, wherein the C-terminus of the first effector portion (e.g., selected from the effector portion of EZH2, G9A or its functional variant or fragment) and the N-terminus of the targeting portion are covalently linked, and the C-terminus of the targeting portion and the N-terminus of the second effector portion (e.g., selected from the effector portion of HDAC8, MQ1, DNMT3a / 3L, KRAB or its functional variant or fragment) are covalently linked. Covalent attachment can be, for example, via a linker sequence.
[0646] In some embodiments, the site-specific disrupting agent comprises a targeting moiety, a first effector moiety, and a second effector moiety, wherein the first effector moiety is EZH2 or a functional variant or fragment thereof, for example, wherein the first effector moiety comprises the amino acid sequence of SEQ ID NO: 17, or a sequence having at least 80%, 85%, 90%, 95%, 99% or 100% identity thereto or differing therefrom at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 position, and the first effector moiety is N-terminal to the targeting moiety; and the second effector moiety is KRAB or a functional variant or fragment thereof, for example, wherein the second effector moiety comprises SEQ ID NO: NO:13, or a sequence that is at least 80%, 85%, 90%, 95%, 99% or 100% identical thereto or differs from it at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 position, and the second effector portion is at the C-terminus of the targeting portion.
[0647] In some embodiments, the site-specific disruption agent comprises a targeting moiety, a first effector moiety, and a second effector moiety, wherein the first effector moiety is EZH2 or a functional variant or fragment thereof, for example, wherein the first effector moiety comprises the amino acid sequence of SEQ ID NO: 17, or a sequence having at least 80%, 85%, 90%, 95%, 99% or 100% identity thereto, or differs therefrom at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 position, and the first effector moiety is N-terminal to the targeting moiety; and the second effector moiety is HDAC8 or a functional variant or fragment thereof, for example, wherein the second effector moiety comprises SEQ ID NO: NO:19, or a sequence that is at least 80%, 85%, 90%, 95%, 99% or 100% identical thereto or differs from it at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 position, and the second effector portion is at the C-terminus of the targeting portion.
[0648] In some embodiments, the site-specific disruption agent comprises a targeting moiety, a first effector moiety, and a second effector moiety, wherein the first effector moiety is G9A or a functional variant or fragment thereof, for example, wherein the first effector moiety comprises the amino acid sequence of SEQ ID NO: 67, or a sequence having at least 80%, 85%, 90%, 95%, 99% or 100% identity thereto, or a sequence that differs from it at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 position, and the first effector moiety is at the N-terminal end of the targeting moiety; and the second effector moiety is KRAB or a functional variant or fragment thereof, for example, wherein the second effector moiety comprises SEQ ID NO: NO:13, or a sequence that is at least 80%, 85%, 90%, 95%, 99% or 100% identical thereto or differs from it at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 position, and the second effector portion is at the C-terminus of the targeting portion.
[0649] In some embodiments, the site-specific disrupting agent comprises a targeting moiety, a first effector moiety, and a second effector moiety, wherein the first effector moiety is G9A or a functional variant or fragment thereof, for example, wherein the first effector moiety comprises the amino acid sequence of SEQ ID NO: 67, or a sequence having at least 80%, 85%, 90%, 95%, 99% or 100% identity thereto or differing therefrom at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 position, and the first effector moiety is at the N-terminal end of the targeting moiety; and the second effector moiety is EZH2 or a functional variant or fragment thereof, for example, wherein the second effector moiety comprises SEQ ID NO: NO:17, or a sequence that is at least 80%, 85%, 90%, 95%, 99% or 100% identical thereto or differs from it at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 position, and the second effector portion is at the C-terminus of the targeting portion.
[0650] In some embodiments, the first effector portion comprises a histone methyltransferase activity and the second effector portion comprises a different histone methyltransferase activity. In some embodiments, the first effector portion comprises a histone methyltransferase activity and the second effector portion comprises the same histone methyltransferase activity. In some embodiments, the first effector portion comprises a histone demethylase activity and the second effector portion comprises a histone deacetylase activity. In some embodiments, the first effector portion comprises a histone demethylase activity and the second effector portion comprises a DNA methyltransferase activity. In some embodiments, the first effector portion comprises a histone demethylase activity and the second effector portion comprises a DNA demethylase activity. In some embodiments, the first effector portion comprises a histone demethylase activity and the second effector portion comprises a transcriptional repressor activity. In some embodiments, the first effector portion comprises a histone demethylase activity and the second effector portion comprises a different histone demethylase activity. In some embodiments, the first effector portion comprises a histone demethylase activity and the second effector portion comprises the same histone demethylase activity. In some embodiments, the first effector portion comprises a histone deacetylase activity and the second effector portion comprises a DNA methyltransferase activity. In some embodiments, the first effector portion comprises a histone deacetylase activity and the second effector portion comprises a DNA demethylase activity. In some embodiments, the first effector portion comprises a histone deacetylase activity and the second effector portion comprises a transcriptional repressor activity. In some embodiments, the first effector portion comprises a histone deacetylase activity and the second effector portion comprises a different histone deacetylase activity. In some embodiments, the first effector portion comprises a histone deacetylase activity and the second effector portion comprises the same histone deacetylase activity. In some embodiments, the first effector portion comprises a DNA methyltransferase activity and the second effector portion comprises a DNA demethylase activity. In some embodiments, the first effector portion comprises a DNA methyltransferase activity and the second effector portion comprises a transcriptional repressor activity. In some embodiments, the first effector portion comprises a DNA methyltransferase activity and the second effector portion comprises a different DNA methyltransferase activity. In some embodiments, the first effector portion comprises a DNA methyltransferase activity and the second effector portion comprises the same DNA methyltransferase activity. In some embodiments, the first effector portion comprises a DNA demethylase activity and the second effector portion comprises a transcriptional repressor activity. In some embodiments, the first effector moiety comprises a DNA demethylase activity and the second effector moiety comprises a different DNA demethylase activity. In some embodiments, the first effector moiety comprises a DNA demethylase activity and the second effector moiety comprises the same DNA demethylase activity.In some embodiments, the first effector moiety comprises a transcriptional repressor activity and the second effector moiety comprises a different transcriptional repressor activity. In some embodiments, the first effector moiety comprises a transcriptional repressor activity and the second effector moiety comprises the same transcriptional repressor activity.
[0651] In some embodiments, the first effector moiety comprises DNMT3a / 31, MQ1, KRAB, G9A, HDAC8, or EZH2, and the second effector moiety comprises DNMT3a / 31, MQ1, KRAB, G9A, HDAC8, or EZH2.
[0652] connector
[0653] Expression repressor and / or site-specific disruptor can comprise one or more linkers.Linker can connect targeting moiety to effector moiety, connect effector moiety to another effector moiety, or connect targeting moiety to another targeting moiety.Linker can be a chemical bond, such as one or more covalent bonds or non-covalent bonds. In certain embodiments, linker is covalent. In certain embodiments, linker is non-covalent. In certain embodiments, linker is a peptide linker. Such linkers can be between 2-30, 5-30, 10-30, 15-30, 20-30, 25-30, 2-25, 5-25, 10-25, 15-25, 20-25, 2-20, 5-20, 10-20, 15-20, 2-15, 5-15, 10-15, 2-10, 5-10, or 2-5 amino acids in length, or greater than or equal to 2, 5, 10, 15, 20, 25, or 30 amino acids in length (and optionally up to 50, 40, 30, 25, 20, 15, 10, or 5 amino acids in length). In some embodiments, a linker can be used to separate a first portion from a second portion, e.g., to separate a targeting moiety from an effector moiety. In some embodiments, for example, a linker can be positioned between a targeting moiety and an effector moiety, e.g., to provide molecular flexibility of the secondary and tertiary structures. In some embodiments, the site-specific disrupting agent can include a first effector moiety connected to a targeting moiety via a first joint and a second effector moiety connected to a targeting moiety via a second joint. In some embodiments, the first joint has a sequence identical to the sequence of the second joint. In some embodiments, the first joint has a sequence different from the sequence of the second joint. In some embodiments, the first effector moiety is at the N-terminal end of the targeting moiety. In some embodiments, the C-terminal end of the targeting moiety. In some embodiments, the C-terminal end of the first effector moiety is connected to the N-terminal end of the targeting moiety via the first joint, and the N-terminal end of the second effector moiety is connected to the C-terminal end of the targeting moiety via the second joint.
[0654] The linker can include flexible, rigid and / or cleavable linkers as described herein. In some embodiments, the linker includes at least one glycine, alanine, and serine amino acid to provide flexibility. In some embodiments, the linker is a hydrophobic linker, such as including a negatively charged sulfonate group, a polyethylene glycol (PEG) group, or a pyrophosphate diester group. In some embodiments, the linker is cleavable to selectively release the moiety (e.g., polypeptide) from the modulator, but is sufficiently stable to prevent premature cleavage.
[0655] In some embodiments, one or more portions of an expression repressor described herein are linked to one or more linkers. In some embodiments, one or more portions of a site-specific disrupting agent described herein are linked to one or more linkers.
[0656] As known to those skilled in the art, the most commonly used flexible linkers have sequences consisting primarily of stretches of Gly and Ser residues ("GS" linkers). Flexible linkers can be useful for connecting domains / parts that require a certain degree of mobility or interaction and can include small, non-polar (e.g., Gly) or polar (e.g., Ser or Thr) amino acids. The incorporation of Ser or Thr can also maintain the stability of the linker in aqueous solution by forming hydrogen bonds with water molecules, thereby reducing adverse interactions between the linker and the part / domain.
[0657] Rigid linkers are useful for maintaining a fixed distance between domains / parts and maintaining their independent functions. Rigid linkers can also be useful when the spatial separation of domains is crucial to maintaining the stability or biological activity of one or more components in the fusion. Rigid linkers can have alpha helical structures or proline-rich sequences (XP). n , wherein X represents any amino acid, preferably Ala, Lys or Glu.
[0658] Cleavable linkers can release free functional domains / parts in vivo. In some embodiments, the linker can be cleaved under specific conditions (e.g., in the presence of a reducing agent or protease). In vivo cleavable linkers can utilize the reversible nature of disulfide bonds. One example includes a thrombin-sensitive sequence (e.g., PRS) between two Cys residues. In vitro thrombin treatment of CPRSC (SEQ ID NO: 243) results in cleavage of the thrombin-sensitive sequence, while the reversible disulfide bond remains intact. Such linkers are known and are described, for example, in Chen et al., 2013. Fusion protein linkers: properties, design, and function. Adv Drug Deliv Rev. [Advanced Drug Delivery Reviews] 65(10): 1357-1369. In vivo cleavage of linkers in fusion proteins can also be performed by proteases, which are expressed in vivo under certain conditions, in specific cells or tissues, or in certain restricted cell compartments. The specificity of many proteases provides slow cleavage of the linker in a restricted compartment.
[0659] Examples of molecules suitable for use in linkers as described herein include negatively charged sulfonic acid groups; lipids, such as poly(--CH2--) hydrocarbon chains, such as polyethylene glycol (PEG) groups, unsaturated variants thereof, hydroxylated variants thereof, amidated or other N-containing variants thereof; non-carbon linkers; carbohydrate linkers; phosphodiester linkers, or other molecules capable of covalently linking two or more components of a site-specific disrupting agent. Non-covalent linkers (e.g., hydrophobic lipid globules to which a polypeptide is linked) may also be included, for example, through a hydrophobic region of a polypeptide or a hydrophobic extension of a polypeptide, such as a series of residues rich in leucine, isoleucine, valine, or possibly alanine, phenylalanine, or even tyrosine, methionine, glycine, or other hydrophobic residues. The components of the site-specific disrupting agent can be linked using charge-based chemistry such that a positively charged component of the site-specific disrupting agent is linked to a negative charge on another component.
[0660] Nucleic Acids
[0661] On the one hand, the present disclosure provides nucleic acid sequences encoding expression repressors and / or site-specific disruptors, systems, targeting moieties and / or effector moieties as described herein. Technicians know that the nucleic acid sequence of RNA is identical to the corresponding DNA sequence, except that thymine (T) is generally replaced by uracil (U). It should be understood that when the nucleotide sequence is represented by a DNA sequence (e.g., including A, T, G, C), the present disclosure also provides a corresponding RNA sequence (e.g., including A, U, G, C), wherein "U" replaces "T". Conventional symbols are used herein to describe polynucleotide sequences: the left-hand end of a single-stranded polynucleotide sequence is the 5' end; the left-hand direction of a double-stranded polynucleotide sequence is referred to as the 5' direction.
[0662] Those skilled in the art will appreciate that due to the degeneracy of the genetic code, a large number of nucleotide sequences encoding site-specific disruptive agents comprising a DNA targeting moiety and / or an effector moiety as described herein can be generated, some of which have similarity, e.g., 90%, 95%, 96%, 97%, 98%, or 99% identity, to the nucleic acid sequences disclosed herein. For example, the codons AGA, AGG, CGA, CGC, CGG, and CGU all encode the amino acid arginine. Thus, at each position where arginine is specified by a codon in the nucleic acids disclosed herein, the codon can be changed to any of the corresponding codons described above without altering the encoded polypeptide.
[0663] In some embodiments, the nucleic acid sequence encoding the expression repressor comprising a targeting moiety and / or one or more effector moieties can be a portion or all of a codon-optimized coding region, optimized for mammalian, e.g., human, codon usage. In some embodiments, the nucleic acid sequence encoding the targeting moiety and / or one or more effector moieties is codon-optimized to increase protein expression and / or increase the duration of protein expression. In some embodiments, the protein produced by the codon-optimized nucleic acid sequence is at least 1%, at least 2%, at least 5%, at least 10%, at least 15%, at least 20%, at least 30%, at least 40%, or at least 50% higher than the protein level when encoded by a non-codon-optimized nucleic acid sequence.
[0664] In some embodiments, the nucleic acid is an mRNA. In some embodiments, the nucleic acid is a monocistronic or polycistronic. In some embodiments, the nucleic acid is a monocistronic. In certain embodiments, the nucleic acid is a polycistronic (e.g., a bicistronic, a tricistronic, a tetracistronic, etc.). In certain embodiments, the nucleic acid is a bicistronic. In certain embodiments, the nucleic acid is a tricistronic. In certain embodiments, the nucleic acid is a tetracistronic.
[0665] Effector part
[0666] In some embodiments, the systems described herein comprise, or the methods described herein comprise, the use of a polypeptide comprising one or more (e.g., one) DNA targeting moiety and one or more effector moieties, for example, wherein the effector moiety is or comprises MQ1 (e.g., bacterial MQ1) or a functional variant or fragment thereof. In some embodiments, MQ1 is Spiroplasma monobiae MQ1, for example, MQ1 from strain ATCC 33825 and / or corresponding to Uniprot IDP15840. In some embodiments, the MQ1 effector moiety is encoded by the nucleotide sequence of SEQ ID NO: 10. In some embodiments, the nucleotide sequence described herein comprises the sequence of SEQ ID NO: 10, or a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity thereto, or a sequence that differs therefrom at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 position.
[0667] MQ1
[0668]
[0669] In some embodiments, MQ1 comprises the amino acid sequence of SEQ ID NO: 11. In some embodiments, MQ1 comprises the amino acid sequence of SEQ ID NO: 12. In some embodiments, an effector domain described herein comprises SEQ ID NO: 11 or 12, or a sequence that is at least 80%, 85%, 90%, 95%, 99%, or 100% identical thereto, or differs therefrom in no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 position.
[0670] MQ1
[0671] MSKVENKTKKLRVFEAFAGIGAQRKALEKVRKDEYEIVGLAEWYVPAIVMYQAIHNNFHTKLEYKSVSREEMIDYLENKTLSWNSKNPVSNGYWKRKKDDELKIIYNAIKLSEKEGNIFDIRDLYKRTLKNIDLLTYSFPCQDLSQQGIQKGMKRGSGTRSGLLWEIERALDSTEKNDLPKYLLMENVGALLHKK NEEELNQWKQKLESLGYQNSIEVLNAADFGSSQARRRVFMISTLNEFVELPKGDKKPKSIKKVLNKIVSEKDILNNLLKYNLTEFKKTKSNINKASL IGYSKFNSEGYVYDPEFTGPTLTASGANSRIKIKDGSNIRKMNSDETFLYIGFDSQDGKRVNEIEFLTENQKIFVCGNSISVEVLEAIIDKIGG(SEQ ID NO:11)
[0672] MQ1
[0673] SKVENKTKKLRVFEAFAGIGAQRKALEKVRKDEYEIVGLAEWYVPAIVMYQAIHNNFHTKLEYKSVSREEMIDYLENKTLSWNSKNPVSNGYWKRKKDDELKIIYNAIKLSEKEGNIFDIRDLYKRTLKNIDLLTYSFPCQDLSQQGIQKGMKRGSGTRSGLLWEIERALDSTEKNDLPKYLLMENVGALLHKK NEEELNQWKQKLESLGYQNSIEVLNAADFGSSQARRRVFMISTLNEFVELPKGDKKPKSIKKVLNKIVSEKDILNNLLKYNLTEFKKTKSNINKASL IGYSKFNSEGYVYDPEFTGPTLTASGANSRIKIKDGSNIRKMNSDETFLYIGFDSQDGKRVNEIEFLTENQKIFVCGNSISVEVLEAIIDKIGG(SEQ ID NO:12)
[0674] In some embodiments, the MQ1 used in the expression repressors described herein is a variant, e.g., comprising one or more mutations relative to wild-type MQ1 (e.g., SEQ ID NO: 11 or SEQ ID NO: 12). In some embodiments, the MQ1 variant comprises one or more amino acid substitutions, deletions, or insertions relative to wild-type MQ1. In some embodiments, the MQ1 variant comprises a K297P substitution. In some embodiments, the MQ1 variant comprises an N299C substitution. In some embodiments, the MQ1 variant comprises an E301Y substitution. In some embodiments, the MQ1 variant comprises a Q147L substitution (e.g., and has reduced DNA methyltransferase activity relative to wild-type MQ1). In some embodiments, the MQ1 variant comprises a K297P, N299C, and E301Y substitution (e.g., and has reduced DNA binding affinity relative to wild-type MQ1). In some embodiments, the MQ1 variant comprises a Q147L, K297P, N299C, and E301Y substitution (e.g., and has reduced DNA methyltransferase activity and DNA binding affinity relative to wild-type MQ1).
[0675] In some embodiments, the expression repressor comprises one or more linkers described herein, for example, connecting a portion / domain to another portion / domain. In some embodiments, the expression repressor comprises a targeting portion, which is or comprises a CRISPR / Cas molecule, for example, a CRISPR / Cas protein, such as a dCas9 protein. In some embodiments, the expression repressor is a fusion protein, which comprises an effector portion and a DNA targeting portion, the effector portion being or comprising MQ1 and the DNA targeting portion being or comprising a CRISPR / Cas molecule, for example, a CRISPR / Cas protein, such as a dCas9 protein; for example, dCas9m4. In some embodiments, the expression repressor comprises another portion as described herein. In some embodiments, the expression repressor reduces the expression of a target gene or multiple target genes (e.g., a target gene or multiple target genes described herein). In some embodiments, the expression repressor can be used in methods for regulating (e.g., reducing) gene expression, methods for treating a disease, or methods for epigenetically modifying a target gene or genomic regulatory element (e.g., a transcriptional control element) described herein. In some embodiments, the system comprises two or more expression repressors.
[0676] In some embodiments, the systems described herein comprise, or the methods described herein comprise the use of an expression repressor or a polypeptide comprising one or more (e.g., one) targeting moieties and one or more effector moieties, wherein the effector moiety is or comprises a Krueppel-associated box (KRAB) domain of zinc finger protein 10, e.g., a protein encoded according to NP_056209.2 or by NM_015394.5, or a functional variant or fragment thereof. In some embodiments, KRAB is a synthetic KRAB construct. In some embodiments, the KRAB used in the expression repressor described herein is, for example, a variant comprising one or more mutations relative to wild-type KRAB (e.g., a protein encoded according to NP_056209.2 or by NM_015394.5). In some embodiments, the KRAB variant comprises one or more amino acid substitutions, deletions, or insertions relative to wild-type KRAB. In some embodiments, the KRAB variant comprises an L37P substitution. In some embodiments, KRAB comprises the amino acid sequence of SEQ ID NO: 13:
[0677] KRAB
[0678] DAKSLTAWSRTLVTFKDVFVDFTREEWKLLDTAQQILYRNVMLENYKNLVSLGYQLTKPDVILRLEKGEEPWLVEREIHQETHPDSETAFEIKSSV(SEQ ID NO:13)
[0679] In some embodiments, the KRAB effector portion is encoded by the nucleotide sequence of SEQ ID NO: 14. In some embodiments, the nucleotide sequence described herein comprises the sequence of SEQ ID NO: 14, or a sequence that is at least 80%, 85%, 90%, 95%, 99%, or 100% identical thereto, or differs therefrom at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 position.
[0680] KRAB
[0681] GACGCCAAGAGCCTGACCGCCTGGAGCCGGACCCTGGTGACCTTCAAGGACGTGTTCGTGGACTTCACCCGGGAGGAGTGGAAGCTGCTGGACACCGCCCAGCAGATCCTGTACCGGAACGTGATGCTGGAGAACTACAAGAACCT GGTGAGCCTGGGCTACCAGCTGACCAAGCCCGACGTGATCCTGCGGCTGGAGAAGGGCGAGGAGCCCTGGCTGGTGGAGCGGGAGATCCACCAGGAGACCCACCCCGACAGCGAGACCGCCTTCGAGATCAAGAGCAGCGTG(SEQ IDNO:14)
[0682] In some embodiments, the KRAB used in the polypeptides or expression repressors described herein is a variant, for example, comprising one or more mutations relative to the KRAB sequence of SEQ ID NO: 13. In some embodiments, the KRAB variant comprises one or more amino acid substitutions, deletions, or insertions relative to SEQ ID NO: 13.
[0683] In some embodiments, the polypeptide or expression repressor is a fusion protein comprising an effector portion (the effector portion is or comprises KRAB) and a targeting portion (e.g., a zinc finger domain or a Crisper / Cas protein). In some embodiments, the polypeptide or expression repressor comprises another portion as described herein. In some embodiments, the polypeptide or expression repressor reduces the expression of a target gene or multiple target genes. In some embodiments, the polypeptide or expression repressor can be used for methods of regulating (e.g., reducing) gene expression, methods of treating a disease, or methods of epigenetically modifying one or more target genes (e.g., genomic regulatory elements (e.g., transcriptional control elements) described herein).
[0684] In some embodiments, the systems described herein comprise, or the methods described herein comprise, the use of an expression repressor or polypeptide comprising one or more (e.g., one) targeting moiety and one or more effector moieties, wherein the effector moiety is or comprises a DNMT3a / 3L complex or a functional variant or fragment thereof. In some embodiments, the DNMT3a / 3L complex is a fusion construct. In some embodiments, the DNMT3a / 3L complex comprises DNMT3A, e.g., human DNMT3A, e.g., a protein encoded by NP_072046.2 or NM_022552.4, or a protein encoded by NM_022552.4, or a functional variant or fragment thereof, e.g., aa 679-912 of human DNMT3A, e.g., a protein encoded by NP_072046.2 or NM_022552.4. In some embodiments, the DNMT3a / 3L complex comprises human DNMT3L or a functional fragment or variant thereof (e.g., a protein encoded according to NP_787063.1 or by NM_175867.3, or a functional variant or fragment thereof, e.g., aa 274-386 of human DNMT3L, such as a protein encoded according to NP_787063.1 or by NM_175867.3). In some embodiments, DNMT3a / 3L comprises the amino acid sequence of SEQ ID NO: 15. In some embodiments, the effector portion described herein comprises SEQ ID NO: 15, or a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity thereto, or a sequence that differs therefrom at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 position.
[0685] DNMT3A / 3l(h)
[0686] (SEQ ID NO: 15)
[0687] In some embodiments, DNMT3a / 3L is encoded by the nucleotide sequence of SEQ ID NO: 16. In some embodiments, the nucleic acids described herein comprise the sequence of SEQ ID NO: 16, or a sequence that is at least 80%, 85%, 90%, 95%, 99%, or 100% identical thereto, or that differs therefrom at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 position.
[0688] DNMT3A / 3l(h)
[0689]
[0690] In some embodiments, the systems described herein comprise, or the methods described herein comprise, the use of an expression repressor or polypeptide comprising one or more (e.g., one) targeting moiety and one or more effector moieties, wherein the effector moiety is or comprises EZH2, e.g., as a protein encoded by NP-004447.2 or NP_001190176.12 or by NM_004456.5 or NM_001203247.2, or a functional variant or fragment thereof. In some embodiments, the EZH2 used in the expression repressors described herein is, e.g., a variant comprising one or more mutations relative to EZH2 (e.g., a protein encoded by NP-004447.2 or NP 001190176.12 or by NM 004456.5 or NM 001203247.2). In some embodiments, the EZH2 variant comprises one or more amino acid substitutions, deletions, or insertions relative to wild-type EZH2. In some embodiments, EZH2 comprises the amino acid sequence of SEQ ID NO: 17:
[0691] EZH2
[0692] (SEQ ID NO: 17)
[0693] In some embodiments, the EZH2 effector portion is encoded by the nucleotide sequence of SEQ ID NO: 18. In some embodiments, the nucleotide sequence described herein comprises the sequence of SEQ ID NO: 18, or a sequence that is at least 80%, 85%, 90%, 95%, 99%, or 100% identical thereto, or differs therefrom at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 position.
[0694] EZH2
[0695]
[0696] In some embodiments, the EZH2 used in the polypeptides or expression repressors described herein is a variant, for example, comprising one or more mutations relative to the EZH2 sequence of SEQ ID NO: 17. In some embodiments, the EZH2 variant comprises one or more amino acid substitutions, deletions, or insertions relative to SEQ ID NO: 17.
[0697] In certain embodiments, polypeptide or expression repressor is a fusion protein comprising an effector portion and a targeting portion as or containing EZH2. In certain embodiments, polypeptide or expression repressor comprises another portion as described herein. In certain embodiments, polypeptide or expression repressor reduces the expression of a target gene or multiple target genes. In certain embodiments, polypeptide or expression repressor can be used for methods of regulating (e.g., reducing) gene expression, methods for treating a disease, or epigenetic modification of one or more target genes (e.g., genome regulatory elements (e.g., transcriptional control elements) described herein).
[0698] In some embodiments, the systems described herein comprise, or the methods described herein comprise, the use of an expression repressor or polypeptide comprising one or more (e.g., one) targeting moiety and one or more effector moieties, wherein the effector moiety is or comprises HDAC8, e.g., as a protein encoded by NP_001159890 or NP_060956.1 or by NM_001166418 or NM_018486.3, or a functional variant or fragment thereof. In some embodiments, HDAC8 comprises the amino acid sequence of SEQ ID NO: 19:
[0699] HDAC8
[0700] EEPEEPADSGQSLVPVYIYSPEYVSMCDSLAKIPKRASMVHSLIEAYALHKQMRIVKPKVASMEEMATFHTDAYLQHLQKVSQEGDDDHPDSIEYGLGYDCPATEGIFDYAAAIGGATITAAQCLIDGMCKVAINWSGGWHHAKKDEASGFCYLNDAVLGILRLRRKFERILYVDLDLHHGDGVEDAFSF TSKVMTVSLHKFSPGFFPGTGDVSDVGLGKGRYYSVNVPIQDGIQDEKYYQICESVLKEVYQAFNPKAVVLQLGADTIAGDPMCSFNMTPVGIGKCLKYILQWQLATLILGGGGYNLANTARCWTYLTGVILGKTLSSEIPDHEFFTAYGPDYVLEITPSCRPDRNEPHRIQQILNYIKGNLKHVV(SEQ ID NO:19)
[0701] In some embodiments, the HDAC8 effector portion is encoded by the nucleotide sequence of SEQ ID NO: 66. In some embodiments, the nucleotide sequence described herein comprises the sequence of SEQ ID NO: 66, or a sequence that is at least 80%, 85%, 90%, 95%, 99%, or 100% identical thereto, or differs therefrom at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 position.
[0702] HDAC8
[0703]
[0704] In some embodiments, the HDAC8 used in the polypeptides or expression repressors described herein is a variant, for example, comprising one or more mutations relative to the HDAC8 sequence of SEQ ID NO: 19. In some embodiments, the HDAC8 variant comprises one or more amino acid substitutions, deletions, or insertions relative to SEQ ID NO: 19.
[0705] In certain embodiments, polypeptide or expression repressor is a fusion protein comprising an effector portion and a targeting portion as or containing HDAC8. In certain embodiments, polypeptide or expression repressor comprises an additional portion as described herein. In certain embodiments, polypeptide or expression repressor reduces the expression of a target gene or multiple target genes. In certain embodiments, polypeptide or expression repressor can be used for regulating (e.g., reducing) gene expression, the method for treating a disease, or epigenetic modification of one or more target genes (e.g., genome regulatory elements (e.g., transcriptional control elements) described herein).
[0706] In some embodiments, the systems described herein comprise, or the methods described herein comprise, the use of an expression repressor or polypeptide comprising one or more (e.g., one) targeting moiety and one or more effector moieties, wherein the effector moiety is or comprises G9A, e.g., as a protein according to NP_001350618.1 or encoded by NM_001363689.1, or a functional variant or fragment thereof, e.g., comprising aa967-1250 of G9A, e.g., as a protein according to NP_001350618.1 or encoded by NM_001363689.1. In some embodiments, G9A comprises the amino acid sequence of SEQ ID NO: 67:
[0707] G9A
[0708] GNRAIRTEKIICRDVARGYENVPIPCVNGVDGEPCPEDYKYISENCETSTMNIDRNITHLQHCTCVDDCSSSNCLCGQLSIRCWYDKDGRLLQEFNKIEPPLIFECNQACSCWRNCKNRVVQSGIKVRLQLYRTAKMGWGVRA LQTIPQGTFICEYVGELISDAEADVREDDSYLFDLDNKDGEVYCIDARYYGNISRFINHLLCDPNIIPVRVFMLHQDLRFPRIAFFSSSRDIRTGEELGFDYGDRFWDIKSKYFTCQCGSEKCKHSAEAIALEQSRLARLD(SEQ ID NO:67)
[0709] In some embodiments, the G9A effector portion is encoded by the nucleotide sequence of SEQ ID NO: 68. In some embodiments, the nucleotide sequence described herein comprises the sequence of SEQ ID NO: 68, or a sequence that is at least 80%, 85%, 90%, 95%, 99%, or 100% identical thereto, or differs therefrom at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 position.
[0710] G9A
[0711] (SEQ ID NO:68)
[0712] In some embodiments, the G9A used in the polypeptides or expression repressors described herein is a variant, for example, comprising one or more mutations relative to the G9A sequence of SEQ ID NO: 67. In some embodiments, the G9A variant comprises one or more amino acid substitutions, deletions, or insertions relative to SEQ ID NO: 67.
[0713] In certain embodiments, polypeptide or expression repressor is a fusion protein comprising an effector portion and a targeting portion as or containing G9A. In certain embodiments, polypeptide or expression repressor comprises another portion as described herein. In certain embodiments, polypeptide or expression repressor reduces the expression of a target gene or multiple target genes. In certain embodiments, polypeptide or expression repressor can be used for methods of regulating (e.g., reducing) gene expression, methods of treating a disease, or methods of epigenetically modifying one or more target genes (e.g., genomic regulatory elements (e.g., transcriptional control elements) described herein).
[0714] In some embodiments, the nucleic acid sequence encoding the site-specific disrupting agent comprising a targeting moiety and / or one or more effector moieties may be part or all of a codon-optimized coding region optimized for codon usage in a mammal (e.g., a human). In some embodiments, the nucleic acid sequence encoding the targeting moiety and / or one or more effector moieties is codon-optimized to increase protein expression and / or increase the duration of protein expression. In some embodiments, the protein produced by the codon-optimized nucleic acid sequence is at least 1%, at least 2%, at least 5%, at least 10%, at least 15%, at least 20%, at least 30%, at least 40%, or at least 50% higher than the protein level when encoded by the non-codon-optimized nucleic acid sequence.
[0715] In some embodiments, the systems described herein comprise, or the methods described herein comprise, the use of a polypeptide comprising one or more (e.g., one) DNA targeting moiety and one or more effector moieties, for example, wherein the effector moiety is or comprises MQ1 (e.g., bacterial MQ1) or a functional variant or fragment thereof. In some embodiments, MQ1 is Spiroplasma monobiae MQ1, for example, MQ1 from strain ATCC 33825 and / or corresponding to Uniprot IDP15840. In some embodiments, the MQ1 effector moiety is encoded by the nucleotide sequence of SEQ ID NO: 10. In some embodiments, the nucleotide sequence described herein comprises the sequence of SEQ ID NO: 10, or a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity thereto, or a sequence that differs therefrom at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 position.
[0716] In some embodiments, MQ1 comprises the amino acid sequence of SEQ ID NO: 11. In some embodiments, MQ1 comprises the amino acid sequence of SEQ ID NO: 12. In some embodiments, an effector domain described herein comprises SEQ ID NO: 11 or 12, or a sequence that is at least 80%, 85%, 90%, 95%, 99%, or 100% identical thereto, or differs therefrom in no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 position.
[0717] In some embodiments, the MQ1 used in the site-specific destructive agents described herein is a variant, e.g., comprising one or more mutations relative to wild-type MQ1 (e.g., SEQ ID NO: 11 or SEQ ID NO: 12). In some embodiments, the MQ1 variant comprises one or more amino acid substitutions, deletions, or insertions relative to wild-type MQ1. In some embodiments, the MQ1 variant comprises a K297P substitution. In some embodiments, the MQ1 variant comprises a N299C substitution. In some embodiments, the MQ1 variant comprises an E301Y substitution. In some embodiments, the MQ1 variant comprises a Q147L substitution (e.g., and has reduced DNA methyltransferase activity relative to wild-type MQ1). In some embodiments, the MQ1 variant comprises a K297P, N299C, and E301Y substitution (e.g., and has reduced DNA binding affinity relative to wild-type MQ1). In some embodiments, the MQ1 variant comprises a Q147L, K297P, N299C, and E301Y substitution (e.g., and has reduced DNA methyltransferase activity and DNA binding affinity relative to wild-type MQ1).
[0718] In some embodiments, the site-specific disrupting agent comprises one or more linkers as described herein, which, for example, connect one part / domain to another part / domain. In some embodiments, the site-specific disrupting agent comprises a targeting portion, which is or comprises a CRISPR / Cas molecule, for example, a CRISPR / Cas protein, such as a dCas9 protein. In some embodiments, the site-specific disrupting agent is a fusion protein, which comprises an effector portion and a DNA targeting portion, which is or comprises MQ1 and the DNA targeting portion is or comprises a CRISPR / Cas molecule, for example, a CRISPR / Cas protein, such as a dCas9 protein; for example, dCas9m4. In some embodiments, the site-specific disrupting agent comprises another portion as described herein. In some embodiments, the site-specific disrupting agent reduces the expression of a target gene or multiple target genes (for example, a target gene or multiple target genes described herein). In some embodiments, the site-specific disrupting agent can be used for methods of regulating (for example, reducing) site-specific disrupting agents, methods of treating illnesses, or methods of epigenetically modifying target genes or genomic regulatory elements (for example, transcriptional control elements) described herein. In some embodiments, the system comprises two or more site-specific disrupting agents.
[0719] In some embodiments, the systems described herein include, or the methods described herein include the use of site-specific destructive agents or polypeptides comprising one or more (e.g., one) targeting moieties and one or more effector moieties, wherein the effector moiety is or comprises a Krueppel-associated box (KRAB) domain of zinc finger protein 10, for example, a protein encoded according to NP_056209.2 or by NM_015394.5, or a functional variant or fragment thereof. In some embodiments, KRAB is a synthetic KRAB construct. In some embodiments, the KRAB used for the site-specific destructive agents described herein is a variant, for example, comprising one or more mutations relative to wild-type KRAB (e.g., a protein encoded according to NP_056209.2 or by NM_015394.5). In some embodiments, the KRAB variant comprises one or more amino acid substitutions, deletions, or insertions relative to wild-type KRAB. In some embodiments, the KRAB variant comprises an L37P substitution. In some embodiments, KRAB comprises the amino acid sequence of SEQ ID NO: 13.
[0720] In some embodiments, the KRAB effector portion is encoded by the nucleotide sequence of SEQ ID NO: 14. In some embodiments, the nucleotide sequence described herein comprises the sequence of SEQ ID NO: 14, or a sequence that is at least 80%, 85%, 90%, 95%, 99%, or 100% identical thereto, or differs therefrom at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 position.
[0721] In some embodiments, the KRAB used in the polypeptides or site-specific disrupting agents described herein is a variant, e.g., comprising one or more mutations relative to the KRAB sequence of SEQ ID NO: 13. In some embodiments, the KRAB variant comprises one or more amino acid substitutions, deletions, or insertions relative to SEQ ID NO: 13.
[0722] In some embodiments, the polypeptide or site-specific disrupting agent is a fusion protein comprising an effector portion (the effector portion is or comprises KRAB) and a targeting portion (e.g., CRISPR / Cas protein). In some embodiments, the polypeptide or site-specific disrupting agent comprises another portion as described herein. In some embodiments, the polypeptide or site-specific disrupting agent reduces the expression of a target gene or multiple target genes. In some embodiments, the polypeptide or site-specific disrupting agent can be used for methods of regulating (e.g., reducing) gene expression, methods of treating a disease, or methods of epigenetically modifying one or more target genes (e.g., genomic regulatory elements (e.g., transcriptional control elements) described herein).
[0723] In some embodiments, the systems described herein or the methods described herein comprise the use of a site-specific disrupting agent or polypeptide comprising one or more (e.g., one) targeting moiety and one or more effector moieties, wherein the effector moiety is or comprises a DNMT3a / 3L complex, or a functional variant or fragment thereof. In some embodiments, the DNMT3a / 3L complex is a fusion construct. In some embodiments, the DNMT3a / 3L complex comprises DNMT3A, e.g., human DNMT3A, e.g., a protein encoded according to NP_072046.2 or by NM_022552.4) or a protein encoded by NM_022552.4, or a functional variant or fragment thereof, e.g., aa 679-912 of human DNMT3A, e.g., a protein encoded according to NP_072046.2 or by NM_022552.4). In some embodiments, the DNMT3a / 3L complex comprises human DNMT3L or a functional fragment or variant thereof (e.g., a protein encoded according to NP_787063.1 or by NM_175867.3, or a functional variant or fragment thereof, e.g., aa 274-386 of human DNMT3L, such as a protein encoded according to NP_787063.1 or by NM_175867.3). In some embodiments, DNMT3a / 3L comprises the amino acid sequence of SEQ ID NO: 15. In some embodiments, the effector portion described herein comprises SEQ ID NO: 15, or a sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identity thereto, or a sequence that differs therefrom at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 position.
[0724] In some embodiments, DNMT3a / 3L is encoded by the nucleotide sequence of SEQ ID NO: 16. In some embodiments, the nucleic acids described herein comprise the sequence of SEQ ID NO: 16, or a sequence that is at least 80%, 85%, 90%, 95%, 99%, or 100% identical thereto, or that differs therefrom at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 position.
[0725] In some embodiments, the systems described herein comprise, or the methods described herein comprise the use of a site-specific disrupting agent or polypeptide comprising one or more (e.g., one) targeting moiety and one or more effector moieties, wherein the effector moiety is or comprises EZH2, e.g., as a protein encoded by NP-004447.2 or NP_001190176.12 or by NM_004456.5 or NM_001203247.2, or a functional variant or fragment thereof. In some embodiments, the MQ1 used in the site-specific disrupting agent described herein is a variant, e.g., comprising one or more mutations relative to EZH2 (e.g., a protein encoded by NP-004447.2 or NP_001190176.12 or by NM_004456.5 or NM_001203247.2). In some embodiments, the EZH2 variant comprises one or more amino acid substitutions, deletions, or insertions relative to wild-type EZH2. In some embodiments, EZH2 comprises the amino acid sequence of SEQ ID NO: 17.
[0726] In some embodiments, the EZH2 effector portion is encoded by the nucleotide sequence of SEQ ID NO: 18. In some embodiments, the nucleotide sequence described herein comprises the sequence of SEQ ID NO: 18, or a sequence that is at least 80%, 85%, 90%, 95%, 99%, or 100% identical thereto, or differs therefrom at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 position.
[0727] In some embodiments, the EZH2 used in the polypeptides or site-specific disrupting agents described herein is a variant, e.g., comprising one or more mutations relative to the EZH2 sequence of SEQ ID NO: 17. In some embodiments, the EZH2 variant comprises one or more amino acid substitutions, deletions, or insertions relative to SEQ ID NO: 17.
[0728] In certain embodiments, the polypeptide or site-specific disrupting agent is a fusion protein comprising an effector portion that is or comprises EZH2 and a targeting portion. In certain embodiments, the polypeptide or site-specific disrupting agent comprises another portion as described herein. In certain embodiments, the polypeptide or site-specific disrupting agent reduces the expression of a target gene or multiple target genes. In certain embodiments, the polypeptide or site-specific disrupting agent can be used for methods of regulating (e.g., reducing) gene expression, methods of treating a disease, or methods of epigenetically modifying one or more target genes (e.g., genomic regulatory elements (e.g., transcriptional control elements) described herein).
[0729] In some embodiments, the systems described herein or the methods described herein comprise the use of a site-specific disrupting agent or polypeptide comprising one or more (e.g., one) targeting moiety and one or more effector moieties, wherein the effector moiety is or comprises HDAC8, e.g., a protein encoded by NP_001159890 or NP_060956.1 or by NM_001166418 or NM_018486.3, or a functional variant or fragment thereof. In some embodiments, HDAC8 comprises the amino acid sequence of SEQ ID NO: 19.
[0730] In some embodiments, the HDAC8 effector portion is encoded by the nucleotide sequence of SEQ ID NO: 66. In some embodiments, the nucleotide sequence described herein comprises the sequence of SEQ ID NO: 66, or a sequence that is at least 80%, 85%, 90%, 95%, 99%, or 100% identical thereto, or differs therefrom at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 position.
[0731] In some embodiments, the HDAC8 used in the polypeptides or site-specific disrupting agents described herein is a variant, for example, comprising one or more mutations relative to the HDAC8 sequence of SEQ ID NO: 19. In some embodiments, the HDAC8 variant comprises one or more amino acid substitutions, deletions, or insertions relative to SEQ ID NO: 19.
[0732] In certain embodiments, polypeptide or site-specific disruptive agent is a fusion protein comprising an effector portion, and the effector portion is or comprises HDAC8 and a targeting portion. In certain embodiments, polypeptide or site-specific disruptive agent comprises another portion as described herein. In certain embodiments, polypeptide or site-specific disruptive agent reduces the expression of a target gene or multiple target genes. In certain embodiments, polypeptide or site-specific disruptive agent can be used for methods of regulating (e.g., reducing) gene expression, methods for treating a disease, or epigenetic modification of one or more target genes (e.g., genome regulatory elements (e.g., transcriptional control elements) described herein).
[0733] In some embodiments, the systems described herein comprise, or the methods described herein comprise, the use of a site-specific disrupting agent or polypeptide comprising one or more (e.g., one) targeting moiety and one or more effector moieties, wherein the effector moiety is or comprises G9A, e.g., as a protein according to NP_001350618.1 or encoded by NM_001363689.1, or a functional variant or fragment thereof, e.g., comprising aa967-1250 of G9A, e.g., as a protein according to NP_001350618.1 or encoded by NM_001363689.1. In some embodiments, G9A comprises the amino acid sequence of SEQ ID NO: 67.
[0734] In some embodiments, the G9A effector portion is encoded by the nucleotide sequence of SEQ ID NO: 68. In some embodiments, the nucleotide sequence described herein comprises the sequence of SEQ ID NO: 68, or a sequence that is at least 80%, 85%, 90%, 95%, 99%, or 100% identical thereto, or differs therefrom at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 position.
[0735] In some embodiments, the G9A used in the polypeptides or site-specific disrupting agents described herein is a variant, for example, comprising one or more mutations relative to the G9A sequence of SEQ ID NO: 67. In some embodiments, the G9A variant comprises one or more amino acid substitutions, deletions, or insertions relative to SEQ ID NO: 67.
[0736] In some embodiments, the polypeptide or site-specific disrupting agent is a fusion protein comprising an effector portion that is or comprises G9A and a targeting portion. In some embodiments, the polypeptide or site-specific disrupting agent comprises another portion as described herein. In some embodiments, the polypeptide or site-specific disrupting agent reduces the expression of a target gene or multiple target genes. In some embodiments, the polypeptide or site-specific disrupting agent can be used for methods of regulating (e.g., reducing) gene expression, methods of treating a disease, or methods of epigenetically modifying one or more target genes (e.g., genomic regulatory elements (e.g., transcriptional control elements) described herein).
[0737] system
[0738] The system of the present disclosure can include two or more expression repressors. In some embodiments, the expression repressor system comprises 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more expression repressors (and optionally no more than 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3 or 2). In some embodiments, the system targets two or more different sequences (e.g., the 1st and 2nd, 3rd, 4th, 5th, 6th, 7th, 8th, 9th, 10th, 11th, 12th and / or other DNA sequences, and optionally no more than the 20th, 19th, 18th, 17th, 16th, 15th, 14th, 13th, 12th, 11th, 10th, 9th, 8th, 6th, 5th, 4th, 3rd or 2nd sequence). In some embodiments, the system comprises a plurality of expression repressors, wherein each member of the plurality of expression repressors has no detectable binding (e.g., no binding) to another member of the plurality of expression repressors. In some embodiments, the system comprises a first expression repressor and a second expression repressor, wherein the first expression repressor has no detectable binding (e.g., no binding) to the second expression repressor.
[0739] In certain embodiments, the system of the present disclosure comprises two or more expression repressors, wherein the expression repressors are present together in a composition, a pharmaceutical composition or a mixture. In certain embodiments, the system of the present disclosure comprises two or more expression repressors, wherein one or more expression repressors are not mixed with at least one other expression repressor. In certain embodiments, the system may comprise a first expression repressor and a second expression repressor, wherein the presence of the first expression repressor in the nucleus does not overlap with the presence of the second expression repressor in the nucleus of the same cell, wherein the system achieves a reduction in the expression of multiple genes by the non-overlapping presence of the first and second expression repressors. In certain embodiments, the first expression repressor and the second expression repressor can work simultaneously or successively.
[0740] In some embodiments, the expression repressors of the system each comprise a different targeting moiety (e.g., the first, second, third, or additional expression repressors each comprise a different targeting moiety from one another). For example, a system can comprise a first expression repressor and a second expression repressor, wherein the first expression repressor comprises a first targeting moiety (e.g., a zinc finger domain, a Cas9 domain, or a TAL effector domain), and the second expression repressor comprises a second targeting moiety that is different from the first targeting moiety (e.g., a zinc finger domain, a Cas9 domain, or a TAL effector domain). In some embodiments, different can refer to comprising different types of targeting moieties, e.g., the first targeting moiety comprises a Cas9 domain and the second DNA targeting moiety comprises a Zn finger domain. In other embodiments, different can refer to comprising different variants of the same type of targeting moiety, e.g., the first targeting moiety comprises a first Cas9 domain (e.g., from a first species) and the second targeting moiety comprises a second Cas9 domain (e.g., from a second species).
[0741] In one aspect, the systems of the present disclosure can include one or more expression repressors and one or more site-specific disruptors. In some embodiments, the systems comprise one or more expression repressors (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more (and optionally no more than 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, or 2). In some embodiments, the systems comprise one or more site-specific disruptors (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more (and optionally no more than 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, or 2). In some embodiments, the systems target two or more different sequences (e.g., the 1st and 2nd, 3rd, 4th, 5th, 6th, 7th, 8th, 9th, 10th, 11th, 12th, 13th, or 2). 2 and / or additional DNA sequences, and optionally no more than the 20th, 19th, 18th, 17th, 16th, 15th, 14th, 13th, 12th, 11th, 10th, 9th, 8th, 6th, 5th, 4th, 3rd, or 2nd sequence. In some embodiments, the system comprises one or more expression repressors and one or more site-specific disrupting agents, wherein each of the one or more expression repressors and each of the one or more site-specific disrupting agents has no detectable binding (e.g., no binding) to another expression repressor and / or site-specific disrupting agent. In some embodiments, the system comprises an expression repressor and a site-specific disrupting agent, wherein each of the expression repressor and the site-specific disrupting agent has no detectable binding (e.g., no binding) to each other.
[0742] In some embodiments, the system comprises one or more expression repressors and one or more site-specific disrupting agents, wherein each of the one or more expression repressors and each of the one or more site-specific disrupting agents independently binds to a different target. In some embodiments, the system comprises an expression repressor and a site-specific disrupting agent, wherein the expression repressor and the site-specific disrupting agent each independently bind to a different target.
[0743] In some embodiments, the system of the present disclosure comprises one or more expression repressors and one or more site-specific disruptors, wherein the expression repressor and the site-specific disruptor are present together in a composition, a pharmaceutical composition or a mixture. In some embodiments, the system of the present disclosure comprises one or more expression repressors and one or more site-specific disruptors, wherein the one or more expression repressors and the one or more site-specific disruptors are not mixed with at least one other expression repressor and / or site-specific disruptor. In some embodiments, the system may comprise an expression repressor and a site-specific disruptor, wherein the presence of the expression repressor in the nucleus does not overlap with the presence of the site-specific disruptor in the same nucleus, wherein the system achieves the reduction of multiple gene expressions by the non-overlapping presence of expression repressors and site-specific disruptors. In some embodiments, the expression repressor and the site-specific disruptor can work simultaneously or successively.
[0744] In some embodiments, the expression repressor and the site-specific destroying agent of the system each comprise a different targeting moiety (e.g., the first, second, third or additional expression repressor each comprises a different targeting moiety from each other and / or the first, second, third or additional site-specific destroying agent each comprises a different targeting moiety from each other). In some embodiments, one or more expression repressors comprise different targeting moieties from one or more site-specific destroying agents. For example, a system may comprise an expression repressor and a site-specific destroying agent, wherein the expression repressor comprises a first targeting moiety (e.g., a zinc finger domain, a Cas9 domain or a TAL effector domain), and the site-specific destroying agent comprises a second targeting moiety different from the first targeting moiety (e.g., a zinc finger domain, a Cas9 domain or a TAL effector domain). In some embodiments, different may refer to comprising different types of targeting moieties, e.g., the first targeting moiety comprises a Cas9 domain and the second DNA targeting moiety comprises a Zn finger domain. In other embodiments, different may refer to comprising different variants of the same type of targeting moiety, e.g., the first targeting moiety comprises a first Cas9 domain (e.g., from a first species) and the second targeting moiety comprises a second Cas9 domain (e.g., from a second species).
[0745] In an embodiment, when a system comprises two or more targeting moieties of the same type, such as two or more Cas9 or Zn finger domains, the targeting moiety specifically binds to two or more different sequences. For example, in a system comprising two or more Cas9 molecules, the two or more Cas9 domains can be selected or altered so that they only significantly bind to the gRNA corresponding to their target sequence (e.g., without significantly binding to the gRNA corresponding to the target of another Cas9 domain). In another example, in a system comprising two or more effector moieties, two or more effector moieties can be selected or altered so that they only significantly bind to their target sequence (e.g., without significantly binding to the target sequence of another effector moiety).
[0746] In some embodiments, the system comprises three or more site-specific destructive agents, and two or more site-specific destructive agents comprise the same targeting moiety. For example, a system may comprise three site-specific destructive agents, wherein the first site-specific destructive agent and the second site-specific destructive agent both comprise the first targeting moiety and the third site-specific destructive agent comprises a second different targeting moiety. For another example, a system may comprise four site-specific destructive agents, wherein the first and second site-specific destructive agents both comprise the first targeting moiety and the third and fourth site-specific destructive agents comprise different second targeting moieties. For another example, a system may comprise five site-specific destructive agents, wherein the first site-specific destructive agent and the second site-specific destructive agent both comprise the first targeting moiety, the third site-specific destructive agent and the fourth site-specific destructive agent both comprise the second different targeting moiety, and the fifth site-specific destructive agent comprises the third different targeting moiety. As described above, different can refer to comprising different types of targeting moieties or comprising different variants of the same type of targeting moieties.
[0747] In some embodiments, the site-specific disrupting agents of the system each bind to a different DNA sequence (e.g., the first, second, third, or additional site-specific disrupting agents each bind to a different DNA sequence from one another). For example, a system can include a first site-specific disrupting agent and a second site-specific disrupting agent, wherein the first site-specific disrupting agent binds to a first DNA sequence and the second site-specific disrupting agent binds to a second DNA sequence. In some embodiments involving different DNA sequences, there is at least one position that is different between the DNA sequence bound by one site-specific disrupting agent and the DNA sequence bound by another site-specific disrupting agent, or there is at least one position that is present in the DNA sequence bound by one site-specific disrupting agent but not in the DNA sequence bound by another site-specific disrupting agent.
[0748] In some embodiments, the first DNA sequence may be located on a first genomic DNA strand and the second DNA sequence may be located on a second genomic DNA strand. In some embodiments, the first DNA sequence may be located on the same genomic DNA strand as the second DNA sequence.
[0749] In some embodiments, the system comprises three or more expression repressors, and two or more expression repressors bind to the same DNA sequence. For example, a system may comprise three expression repressors, wherein a first expression repressor and a second expression repressor both bind to a first DNA sequence, and a third expression repressor binds to a second, different DNA sequence. For another example, a system may comprise four expression repressors, wherein a first expression repressor and a second expression repressor both bind to a first DNA sequence, and a third expression repressor and a fourth expression repressor both bind to a second DNA sequence. For another example, a system may comprise five expression repressors, wherein a first and a second expression repressor both bind to a first DNA sequence, a third and a fourth expression repressor both bind to a second DNA sequence, and a fifth expression repressor binds to a third DNA sequence. As described above, different can mean that at least one position is different between the DNA sequence bound by one expression repressor and the DNA sequence bound by another expression repressor, or that there is at least one position in the DNA sequence bound by one expression repressor that is not present in the DNA sequence bound by another expression repressor. Similarly, in some embodiments, the system includes one or more expression repressors and one or more site-specific disrupting agents.
[0750] In certain embodiments, system comprises two or more (such as two) expression repressors and multiple (such as two) expression repressors comprise the targeting moiety in conjunction with different dna sequences.In such embodiment, the first targeting moiety can be in conjunction with the first dna sequence dna and the second targeting moiety can be in conjunction with the second dna sequence dna, and wherein the first and second dna sequence dna are different and do not overlap.In some such embodiments, the first dna sequence dna and the second dna sequence dna are separated by at least 1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,25,30,35,40,45,50,55,60,65,70,75,80,85,90,95 or 100 base pairs (optionally, no more than 500,400,300,200,100,95,90,85,80,75,70,65,60,55 or 50 base pairs). In some such embodiments, the first DNA sequence is separated from the second DNA sequence by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 base pairs (optionally, no base pairs, e.g., the first and second sequences are directly adjacent to each other). In some embodiments, the first DNA sequence is separated from the second DNA sequence by at least 1 kb, 2 kb, 3 kb, 4 kb, or 5 kb.
[0751] In some embodiments, the system comprises two or more (e.g., two) site-specific disruption agents, and the plurality (e.g., two) site-specific disruption agents comprise targeting moieties that bind to different DNA sequences. In such embodiments, the first targeting moiety can bind to a first DNA sequence and the second DNA targeting moiety can bind to a second DNA sequence, wherein the first and second DNA sequences are different and do not overlap. In some such embodiments, the first DNA sequence is separated from the second DNA sequence by at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 base pairs (optionally, no more than 500, 400, 300, 200, 100, 95, 90, 85, 80, 75, 70, 65, 60, 55, or 50 base pairs). In some such embodiments, the first DNA sequence is separated from the second DNA sequence by no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 base pairs (optionally, no base pairs are separated, e.g., the first and second sequences are directly adjacent to each other).
[0752] In some embodiments, the expression repressor and / or site-specific destructive agent of the system each independently comprises a different effector portion (e.g., the first, second, third or additional expression repressor each independently comprises an effector portion different from one another and / or the first, second, third or additional site-specific destructive agent each independently comprises an effector portion different from one another). For example, the system can comprise a first expression repressor and a second expression repressor, wherein the first expression repressor comprises a first effector portion, and the second expression repressor comprises a second effector portion different from the first effector portion. In addition, the system can comprise an expression repressor and a site-specific destructive agent, wherein the expression repressor comprises a first effector portion, and the site-specific destructive agent comprises a second effector portion different from the first effector portion. In some embodiments, different effector portions comprise different types of effector portions. In other embodiments, different effector portions comprise different variants of the same type of effector portion.
[0753] In some embodiments, the present disclosure provides an expression repression system comprising a first expression repressor and a second expression repressor. In some embodiments, the first expression repressor comprises a first targeting moiety. In some embodiments, the first targeting moiety comprises a zinc finger domain. In some embodiments, the first targeting moiety comprises a CRISPR / Cas (e.g., Cas9 or dCas9) domain. In some embodiments, the first targeting moiety comprises a TAL effector domain. In some embodiments, the first expression repressor comprises a first effector moiety. In some embodiments, the first effector moiety comprises a DNA methyltransferase, such as MQ1 or a functional fragment thereof, and / or KRAB, such as a KRAB domain. In some embodiments, the second expression repressor comprises a second targeting moiety. In some embodiments, the second targeting moiety comprises a zinc finger domain. In some embodiments, the second expression repressor comprises a second effector moiety. In some embodiments, the second effector moiety comprises a DNA methyltransferase, such as MQ1 or a functional fragment thereof, and / or KRAB, such as a KRAB domain.
[0754] In some embodiments, the expression repressor system is encoded by a first nucleic acid encoding a first expression repressor (e.g., a first targeting moiety and a first effector moiety, wherein expression is driven by a first promoter or IRES) and a second nucleic acid encoding a second expression repressor (e.g., a second targeting moiety and a second effector moiety, wherein expression is driven by a second promoter or IRES). In some embodiments, the expression repressor system is encoded by a nucleic acid (e.g., mRNA) in which expression is not driven by a promoter or IRES. In some embodiments, a monocistronic sequence is used. In some embodiments, the nucleic acid encoding the expression repressor system is a polycistronic sequence. In some embodiments, the polycistronic sequence is a bicistronic sequence. In some embodiments, the polycistronic sequence comprises a sequence encoding the first expression repressor and a sequence encoding the second expression repressor. In some embodiments, the polycistronic sequence encodes a self-cleavable peptide sequence, such as a 2A peptide sequence, such as a T2A peptide sequence, a P2A sequence. In some embodiments, the polycistronic sequence encodes a T2A peptide sequence and a P2A peptide sequence. In some embodiments, the polycistronic sequence encodes a tandem 2A sequence, such as a tPT2A sequence. In some embodiments, the bicistronic construct further comprises a poly A tail. In some embodiments, after transcription of the bicistronic gene construct, a single mRNA transcript encoding the first expression repressor and the second expression repressor is produced, which is cut after translation, for example, after the glycine residue in the 2A peptide, to produce the first expression repressor and the second expression repressor as two independent proteins. In some embodiments, the first and second expression repressors are separated by "ribosome jumping". In some embodiments, the first expression repressor and / or the second expression repressor retain a fragment of the 2A peptide after ribosome jumping. In some embodiments, the expression levels of the first and second expression repressors are equal. In some embodiments, the expression levels of the first and second expression repressors are different. In some embodiments, the protein level of the first expression repressor is within (greater than or less than) 1%, 2%, 5% or 10% of the protein level of the second expression repressor.
[0755] In another aspect, the present disclosure provides a system comprising at least one expression repressor as described herein and at least one site-specific disruptor (e.g., any site-specific disruptor described herein). In some embodiments, the system includes a first expression repressor and a first site-specific disruptor. In some embodiments, the first expression repressor includes a first targeting moiety. In some embodiments, the first targeting moiety includes a zinc finger domain. In some embodiments, the first expression repressor includes a first effector moiety. In some embodiments, the first effector moiety includes a DNA methyltransferase, such as MQ1 or a functional fragment thereof, and / or KRAB, such as a KRAB domain. In some embodiments, the site-specific disruptor includes a second targeting moiety, wherein the second targeting moiety targets an anchor sequence of a CXCL site. In some embodiments, the site-specific disruptor includes a second effector moiety (e.g., a site-specific disruptor effector moiety). In some embodiments, the second effector moiety (e.g., a site-specific disruptor effector moiety) includes a DNA methyltransferase (e.g., MQ1 or a functional fragment thereof) and / or KRAB (e.g., a KRAB domain). In some embodiments, the expression repressor effector moiety is identical to the site-specific disruptor effector moiety. In some embodiments, the first effector moiety (e.g., an expression repressor effector moiety) is different from the second effector moiety (e.g., a site-specific disruptor effector moiety). In some embodiments, the first effector moiety (e.g., an expression repressor effector moiety) and the second effector moiety (e.g., a site-specific disruptor moiety) each independently comprise a methyltransferase activity, e.g., a DNA methyltransferase activity.
[0756] In some embodiments, the expression repressor system is encoded by a first nucleic acid encoding a first expression repressor (e.g., a first targeting moiety and a first effector moiety, wherein expression is driven by a first promoter or IRES) and a second nucleic acid encoding a site-specific disruptor (e.g., a second targeting moiety and a second effector moiety, wherein expression is driven by a second promoter or IRES). In some embodiments, the expression repressor system is encoded by a nucleic acid (e.g., mRNA) in which expression is not driven by a promoter or IRES. In some embodiments, a monocistronic sequence is used. In some embodiments, the nucleic acid encoding the expression repressor system is a polycistronic sequence. In some embodiments, the polycistronic sequence is a bicistronic sequence. In some embodiments, the polycistronic sequence includes a sequence encoding the first expression repressor and a sequence encoding a site-specific disruptor. In some embodiments, the polycistronic sequence encodes a peptide sequence that can be self-cleaved, such as a 2A peptide sequence, such as a T2A peptide sequence, a P2A sequence. In some embodiments, the polycistronic sequence encodes a T2A peptide sequence and a P2A peptide sequence. In some embodiments, the polycistronic sequence encodes a tandem 2A sequence, such as a tPT2A sequence. In some embodiments, the bicistronic construct further comprises a poly A tail. In some embodiments, after transcription of the bicistronic gene construct, a single mRNA transcript encoding the first expression repressor and the site-specific destructive agent is produced, which is cut after translation, for example, after the glycine residue in the 2A peptide, to produce the first expression repressor and the site-specific destructive agent as two independent proteins. In some embodiments, the first expression repressor and the site-specific destructive agent are separated by "ribosome jumping". In some embodiments, the first expression repressor and / or the site-specific destructive agent retain a fragment of the 2A peptide after ribosome jumping. In some embodiments, the expression levels of the first expression repressor and the site-specific destructive agent are equal. In some embodiments, the expression levels of the first expression repressor and the site-specific destructive agent are different. In some embodiments, the protein level of the first expression repressor is within 1%, 2%, 5% or 10% (greater than or less than) of the protein level of the site-specific destructive agent.
[0757] Targeting moiety
[0758] The targeting portion can specifically bind to a DNA sequence, such as a DNA sequence associated with target multiple genes, such as a genomic regulatory element or an anchor sequence of an ASMC comprising target multiple genes. Any molecule or compound that specifically binds to a DNA sequence can be used as a targeting portion. In some embodiments, the targeting portion comprises a nucleic acid, such as a sequence complementary to an enhancer sequence, such as a sequence operably connected to target multiple genes. In some embodiments, the targeting portion of the site-specific destructive agent comprises a nucleic acid, such as a sequence complementary to an anchor sequence (such as an anchor sequence of an ASMC comprising target multiple genes). In some embodiments, the nucleic acid is an oligonucleotide that binds to a physical / steric blocking factor (such as a transcription factor, such as P65, or a nucleating polypeptide, such as CTCF) and a sequence (such as an enhancer sequence or an anchor sequence). In some embodiments, the nucleic acid comprises a guide RNA (gRNA), such as a guide RNA compatible with a CRISPR / Cas molecule. In some embodiments, the targeting portion comprises a CRISPR / Cas molecule, a TAL effector molecule, a zinc finger molecule, a tetR domain, a large-range nuclease, a peptide nucleic acid (PNA) or a nucleic acid.
[0759] In some embodiments, the targeting moiety specifically binds to a nucleic acid sequence within the E1 or E2 cRE of the CXCL locus. In some embodiments, the targeting moiety specifically binds to a nucleic acid sequence within the E1 cRE of the CXCL locus. In certain embodiments, the targeting moiety (e.g., a portion targeting E1) specifically binds to a region within the nucleic acid sequence of SEQ ID NO: 162, or a nucleic acid sequence with at least 80%, 85%, 90%, 95%, 99% or 100% identity thereto, or a nucleic acid sequence with no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 position of difference therewith. In some embodiments, the targeting moiety specifically binds to a nucleic acid sequence with the E2 cRE of the CXCL locus. In certain embodiments, the targeting moiety (e.g., an E2-targeting moiety) specifically binds to a region within the nucleic acid sequence of SEQ ID NO: 163, or a nucleic acid sequence that is at least 80%, 85%, 90%, 95%, 99%, or 100% identical thereto, or a nucleic acid sequence that differs therefrom at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 position.
[0760] An exemplary sequence of E1 cRE of the CXCL locus, SEQ ID NO: 162:
[0761]
[0762] An exemplary sequence of the E2 cRE of the CXCL locus, SEQ ID NO: 163:
[0763] GTTAGGTTTTATTTCACCAAGTTTATAAAGTAAACCACATATCGTTTTCTCTTTTGTAGATGCTGAAAGCAAAGTTCATGTGGGAAATGTTTGGCAATAGCTGATTTATCCTCAGGGTAACAATATTCTATAACTCCTTTGATCTTGAGGCCTCTGTGATGGAAATGCTTGGAGAAAGGGATTTTAAAGGGAGATTCTGAAGTCCTTGGGAAAGTCCACAAGTGGACGGGGCTTCATAGCCATGACAACAAATGACATTGTCTAGGAAACAGTGAGTCATGGCATGCTGAGCTTAGAATGGAGCCAACAGAAGGAACCTGGCCTCGGACACAGAATCTTTTGGCTGCTGACCCAGAATGACTGTGAAAGACTAACACTGTTTAGCAGATTTTTCTTGAGTGTTTACTATGTGTGAGGTTCCTGGGATTCAGATTCAGCTACTATTGTTAAGAGGAAATCAACCAGGAAGTCAGTTAAGAAAAGGTACAGTGGGTTTTCAGGCTGCAGGGTACAGAAATGTTCCCAGGCCTGGAGAACAAACCTTCAGATCTTAATCTGTACAGGGAGGTGGAGGGTGAAAGAATGATCTTTCAGGAAGCGTTCAAGTAGGGCTGCTGCTTGGATTGAATTTTAAAGAATGCATAGGTTATATGCAGGATCTATATATAGATCAATAGCTTCCCTGAGCACATGTTCAAAGGTTCAAACATTTGGGGTCATTTCTTTGCAAGAAGAGTCACTCAGTGGCCTGAAAGTCCATGCAGCAACTTCCCTCATGAGAGCTGCTTCCGCAGCAGGCCCAGGGTTTCTAAAGGAGAGAGCACACAGATGTAAACACTCTGTGGTTCTGAGGACTGTCACCTCTTCTTTTCACCCATCACTTTTGTCTTAAGAACTCTATGCTCAACCCTAATTCTCAGTCTCTATATCAATTCCCACCAAACAGATGCAAAGTCCTGTCC
[0764] In some embodiments, the targeting moiety specifically binds to a nucleic acid sequence within the IL8 promoter. In some embodiments, the target site (e.g., a target site within the IL8 promoter) is within genomic coordinates chr4:74606112-74606462 (hg19). In some embodiments, the target site (e.g., a target site within the IL8 promoter) is located within 1 kb of chr:74606112-74606462 (e.g., chr4:74606112-74606662, chr4:74606112-74606862, chr4:74606112-74607062, chr4:74606112-74607262, chr4:74606112-74607462, chr4:74605912-74606462, chr4:74605712-74606862). 4606462, chr4:74605512-74606462, chr4:74605312-74606462, chr4:74605112-74606462, chr4:74605912-74606662, chr4:7460 5912-74606862, chr4:74605912-74607062, chr4:74605912-74607262, chr4:74605912-74607462, chr4:74605712-74606662, chr 4:74605712-74606862, chr4:74605712-74607062, chr4:74605712-74607262, chr4:74605712-74607462, chr4:74605512-74606 662, chr4:74605512-74606862, chr4:74605512-74607062, chr4:74605512-74607262, chr4:74605512-74607462, chr4:74605312 -74606662, chr4:74605312-74606862, chr4:74605312-74607062, chr4:74605312-74607262, chr4:74605312-74607462, chr4:74605112-74606662, chr4:74605112-74606862, chr4:74605112-74607062, chr4:74605112-74607262 or chr4:74605112-74607462).
[0765] In certain embodiments, the target site (e.g., target site within the IL8 promoter) is located 500bp upstream of the transcription start site. In certain embodiments, the target site (e.g., target site within the IL8 promoter) is located at chr4:74605723-74606223. In some embodiments, the target site (e.g., a target site within the IL8 promoter) is located at chr4:74605723-74606426, chr4:74605723-74606626, chr4:74605723-74606826, chr4:74605723-74607026, chr4:74605723-74607226, chr4:74605523-74606226, chr4:74605323-74606226, chr4:74605123-74606826. 6226, chr4:74604923-74606226, chr4:74604723-74606226, chr4:74605523-74606426, chr4:74605523-74606626, chr4:74 605523-74606826, chr4:74605523-74607026, chr4:74605523-74607226, chr4:74605323-74606426, chr4:74605323-746066 26. chr4:74605323-74606826, chr4:74605323-74607026, chr4:74605323-74607226, chr4:74605123-74606426, chr4:7460 5123-74606626, chr4:74605123-74606826, chr4:74605123-74607026, chr4:74605123-74607226, chr4:74604923-7460642 6. chr4:74604923-74606626, chr4:74604923-74606826, chr4:74604923-74607026, chr4:74604923-74607226, chr4:74604723-74606426, chr4:74604723-74606626, chr4:74604723-74606826, chr4:74604723-74607026 or chr4:74604723-74607226.
[0766] In certain embodiments, the target site (e.g., target site within the IL8 promoter) is located 1000bp upstream of the transcription start site. In certain embodiments, the target site (e.g., target site within the IL8 promoter) is located at chr4:74605223-74606223. In some embodiments, the target site (e.g., a target site within the IL8 promoter) is located at chr4:74605226-74606426, chr4:74605226-74606626, chr4:74605226-74606826, chr4:74605226-74607026, chr4:74605226-74607226, chr4:74605026-74606226, chr4:74604826-74606226, chr4:74604626-7460 6226, chr4:74604426-74606226, chr4:74604226-74606226, chr4:74605026-74606426, chr4:74605026-74606626, chr4:74 605026-74606826, chr4:74605026-74607026, chr4:74605026-74607226, chr4:74604826-74606426, chr4:74604826-746066 26. chr4:74604826-74606826, chr4:74604826-74607026, chr4:74604826-74607226, chr4:74604626-74606426, chr4:7460 4626-74606626, chr4:74604626-74606826, chr4:74604626-74607026, chr4:74604626-74607226, chr4:74604426-7460642 6. chr4:74604426-74606626, chr4:74604426-74606826, chr4:74604426-74607026, chr4:74604426-74607226, chr4:74604226-74606426, chr4:74604226-74606626, chr4:74604226-74606826, chr4:74604226-74607026 or chr4:74604226-74607226.
[0767] In some embodiments, the targeting moiety has a K of less than or equal to 500, 450, 400, 350, 300, 250, 200, 150, 100, 50, 40, 30, 20, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1, 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1, 0.09, 0.08, 0.07, 0.06, 0.05, 0.04, 0.03, 0.02, 0.01, 0.005, 0.002, or 0.001 nM. D (and optionally, a K of at least 50, 40, 30, 20, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1, 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1, 0.09, 0.08, 0.07, 0.06, 0.05, 0.04, 0.03, 0.02, 0.01, 0.005, 0.002, or 0.001 nM D ) binds to its target sequence. In some embodiments, the targeting moiety is present at a K of 0.001 nM to 500 nM, such as 0.1 nM to 5 nM, such as about 0.5 nM. D In some embodiments, the targeting moiety binds to its target sequence with a K of at least 500, 600, 700, 800, 900, 1000, 2000, 5000, 10,000, or 100,000 nM. D Binds to non-target sequences (and optionally, does not appreciably bind to non-target sequences). In some embodiments, the targeting moiety does not bind to non-target sequences.
[0768] In some embodiments, the targeting portion of the expression repressor or site-specific disrupting agent comprises a nucleic acid comprising a sequence complementary to a sequence selected from Table 8 or Table 8A, or a sequence having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity thereto, or a sequence that differs from it at no more than 1, 2, 3, 4, or 5 positions. In some embodiments, the targeting portion of the expression repressor or site-specific disrupting agent comprises a nucleic acid comprising a sequence selected from Table 8 or Table 8A, or a sequence having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity thereto, or a sequence that differs from it at no more than 1, 2, 3, 4, or 5 positions. In some embodiments, the targeting moiety of the expression repressor or site-specific disruptor binds to a target site having a sequence of Table 8 or 8A. It should be understood that in some embodiments, the targeting moiety comprises an RNA sequence in which each position indicated as T in Table 8 or Table 8A is occupied by a U.
[0769] Table 8: Exemplary sequences of gRNA spacers or target sequences
[0770] name sequence SEQ ID NO. GD-31493 TTATTCTTGAGGCATCTGTG 90 GD-31494 AAATTCCACACATGGTCAAG 91 GD-31495 GTCAGCCAAAGACATTGCAC 92 GD-31496 CTGTGTAACAGGGTCTGAAT 93 GD-31497 TATAGAATATTGTTACCCTG 94 GD-31498 TCCTTGGGAAAGTCCACAAG 95 GD-31499 GACAACAAATGACATTGTCT 96 GD-31500 GCCAAAAGATTCTGTGTCCG 97 GD-31501 TCAGTTAAGAAAAGGTACAG 98 GD-31502 TTCAGATCTTAATCTGTACA 99 GD-31503 ACTGATGGCCCATCCCCTCA 100
[0771] Table 8A: Exemplary sequences of gRNA spacers or target sequences, e.g., for use in mouse models.
[0772] name sequence SEQ ID NO. GD-33448 GTTAGCCCTAAATCGACCCT 341 GD-33449 GGTGTGCAGTTAGCACAACT 342 GD-33450 GAATTGCAGACATCAGTCTG 343 GD-33451 AGGGGTCACCAAGAAGAGTG 344 GD-33452 GGTTTCTCATTAGCAATCAG 345 GD-33453 TCCTTGGGAAATTCCACTTG 346 GD-33454 GTCATAACCCAGGAGTCACG 347 GD-33455 GTTTCTGGGCTAGAGAACTC 348 GD-33456 AATGGAACAAGTCAGCATGA 349 GD-33457 CTGGCAAGGGTGAGACAGAG 350 GD-33458 CATGGTAAACAACAGTACAC 351 GD-33459 GTTGTGGATATATCCAGGCA 352 GD-33460 TACGCATGAATGAGATCACT 353 GD-33461 TTGTTTTTAATGCTTGCATG 354 GD-33462 TCATTCCGTGACATCCAGGA 355 GD-33463 CCTCCGTGACTAAGCCAAGG 356 GD-33464 CCCCTACTCTCAGCCTGCAT 357 GD-33465 ACTCCCCCTCTGTTTTACAC 358 GD-33466 CTGAGTTTGTGTGGAGTATG 359 GD-33467 TTTAGACTACTGTCTGACTG 360 GD-33468 AGCTGTGGCAGTGATGCGAG 361 GD-33469 AACAGGAAATATTCCTCCCA 362 GD-33470 AGGATCTTCTGGAAGTGTCA 363
[0773] In some embodiments, the targeting moiety comprises a nucleic acid comprising a sequence selected from Table 9 or 9A, or a sequence having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity thereto, or a sequence that differs from it in no more than 1, 2, 3, 4, or 5 positions. In some embodiments, the targeting moiety comprises a nucleic acid comprising a spacer sequence within a sequence of Table 9 or 9A, or a sequence having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity thereto, or a sequence that differs from it in no more than 1, 2, 3, 4, or 5 positions. It should be understood that in some embodiments, the targeting moiety comprises an RNA sequence wherein each position designated as T in Table 9 or Table 9A is occupied by a U.
[0774] Table 9: Exemplary guide sequences
[0775]
[0776]
[0777]
[0778] Table 9A: Exemplary guide sequences, e.g., for use in murine models
[0779]
[0780]
[0781]
[0782]
[0783]
[0784] In some embodiments, the targeting moiety comprises a nucleic acid comprising a sequence that is complementary to at least a portion of the sequence of a cRE (e.g., E1 cRE), or has no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 positions that are not complementary thereto.
[0785] In some embodiments, the targeting moiety comprises a nucleic acid comprising a sequence that is complementary to at least a portion of a non-human cRE (e.g., non-human E1 cRE) (e.g., mouse cRE) sequence that is homologous to human cRE, or has no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 positions that are not complementary thereto.
[0786] In some embodiments, the targeting moiety comprises a nucleic acid comprising a sequence that at least partially overlaps with a region having the following genomic coordinates: GRCh37: chr4:74591768-74591790, GRCh37: chr4:74591844-74591866, GRCh37: chr4:74591892-74591914, GRCh37: chr4:74592088-74592110, GRCh37: chr4:74592748-74592790. 982770, GRCh37:chr4:74982841-74982863, GRCh37:chr4:74982882-74982904, GRCh37:chr4:74982960-74982982, GRCh37:chr4:74983108-74983130, GRCh37:chr4:74983181-74983203, or GRCh37:chr4:74606162-74606184.
[0787] In some embodiments, the targeting moiety binds to sequences at the following genomic locations: GRCh37: chr4:74591768-74591790, GRCh37: chr4:74591844-74591866, GRCh37: chr4:74591892-74591914, GRCh37: chr4:74592088-74592110, GRCh37: chr4:74982748-74982770, GR Ch37:chr4:74982841-74982863, GRCh37:chr4:74982882-74982904, GRCh37:chr4:74982960-74982982, GRCh37:chr4:74983108-74983130, GRCh37:chr4:74983181-74983203, or GRCh37:chr4:74606162-74606184.
[0788] In some embodiments, the targeting moiety binds to a cRE (eg, E1 cRE) or binds to a site proximal to a cRE (eg, E1 cRE), eg, the cRE is operably linked to multiple target genes.
[0789] Site-specific disruption agent gRNA
[0790] In some embodiments, the targeting moiety or site-specific disrupting agent comprises a nucleic acid comprising a sequence selected from Table 7 or at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical thereto, or differs from it at no more than 1, 2, 3, 4, or 5 positions. It is understood that in some embodiments, the targeting moiety comprises an RNA sequence in which every position designated as T in Table 7 is occupied by a U.
[0791] Table 7: Exemplary gRNA spacer sequences
[0792] name sequence SEQ ID NO. GD-28481 AGCCCCACCTTGTGGTCAGA 21 GD-28482 AGTGCTGCCTTCTGACCACA 22 GD-28483 GCTGCCTTCTGACCACAAGG 23 GD-28484 CCAGTATAAGCCCCACCTTG 24 GD-28485 CTGCCTGTCCCATAAGGAGG 25 GD-28486 GCACTGCCTGTCCCATAAGG 26 GD-28487 GGTCCTCCTCCTTATGGGAC 27 GD-28488 GCCTTGTTTTCGGCTCTAGA 28 GD-28489 GCCATCTAGAGCCGAAAACA 29 GD-29251 CCAATGAAGATGAAACTGGG 30 GD-29252 AACGTGCTTGCCTAAGATTC 31 GD-29253 AGCCCTTAATCATATCTAGT 32 GD-29254 CAGAGCTTAAGACCTGTACT 33 GD-29255 GCCCACCTTGACCTTCACAA 34
[0793] In some embodiments, the targeting moiety comprises a nucleic acid comprising a sequence selected from Table 6, or a sequence having at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity thereto, or a sequence that differs therefrom at no more than 1, 2, 3, 4, or 5 positions. It will be understood that in some embodiments, the targeting moiety comprises an RNA sequence in which every position designated as T in Table 6 is occupied by a U.
[0794] Table 6: Exemplary guide sequences
[0795]
[0796]
[0797]
[0798] In some embodiments, the targeting moiety comprises a nucleic acid comprising a sequence that is complementary to the sequence of an anchor sequence (e.g., an anchor sequence of an ASMC that targets multiple genes), or has no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 positions that are not complementary thereto.
[0799] In some embodiments, the targeting moiety comprises a nucleic acid comprising a sequence that at least partially overlaps with a region having the following genomic coordinates: chr4:74595464-74595486, chr4:74595457-74595479, chr4:74595460-74595482, chr4:74595472-74595494, chr4:75000088-75000110, chr4:75000091-75000113, chr4:75000085-75000107, chr4:75000157-75000179, chr4:75000156-7500018 0178、chr4:74595215-74595237、chr4:74595370-74595392、chr4:74595 560-74595582、chr4:74595642-74595664、chr4:74595787-74595809、chr 4:74528428-74528450, chr4:74528567-74528589, chr4:74528609-74528 631、chr4:74789132-74789154、chr4:74789250-74789272、chr4:7478931 2-74789334、chr4:74964853-74964875、chr4:74964906-74964928、chr4 :74965538-74965560、chr4:74965737-74965759、chr4:75000031-750000 53. chr4:75000115-75000137, chr4:75000231-75000253, chr4:74975146 -74975168、chr4:74975369-74975391、chr4:74976318-74976340、chr4:7 4570348-74570370, chr4:74570503-74570525, chr4:74570526-7457054 8. chr5:90785724-90785746, chr5:90788137-90788159, chr5:90908926- 90908948, chr5:90661492-90661514, chr5:90661646-90661668, chr5:90 661744-90661766, chr5:90785610-90785632, chr5:90909047-90909069,or chr6:113076028-113076047 or a sequence within 5, 10, 15, 20, 30, 40 or 50 nucleotides of said region, or comprising a sequence that is at least 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the sequence of said genomic region, or that differs at no more than 1, 2, 3, 4 or 5 positions therefrom.
[0800] In some embodiments, the targeting moiety binds to sequences at the following genomic locations: chr4:74595464-74595486, chr4:74595457-74595479, chr4:74595460-74595482, chr4:74595472-74595494, chr4:75000088-75000110, chr4:75000091-75000113, chr4:75000085-75000107, chr4:75000157-75000179, chr4:75000156-75000178, chr4:74595215-74 595237、chr4:74595370-74595392、chr4:74595560-74595582、chr4:7459 5642-74595664, chr4:74595787-74595809, chr4:74528428-74528450, ch r4:74528567-74528589, chr4:74528609-74528631, chr4:74789132-7478 9154、chr4:74789250-74789272、chr4:74789312-74789334、chr4:7496485 3-74964875, chr4:74964906-74964928, chr4:74965538-74965560, chr4: 74965737-74965759, chr4:75000031-75000053, chr4:75000115-7500013 7. chr4:75000231-75000253, chr4:74975146-74975168, chr4:74975369- 74975391, chr4:74976318-74976340, chr4:74570348-74570370, chr4:74 570503-74570525, chr4:74570526-74570548, chr5:90661492-90661514, chr5:90661646-90661668, chr5:90661744-90661766, chr5:90785610-90785632, chr5:90909047-90909069, chr5:90785724-90785746, chr5:90788137-90788159, chr5:90908926-90908948, or chr6:113076028-113076047.
[0801] In some embodiments, the targeting moiety binds to an anchor sequence (e.g., an anchor sequence that is part of an ASMC that fully or partially comprises the target plurality of genes) or binds to a site proximal to an anchor sequence.
[0802] CRISPR / Cas targeting moiety
[0803] In some embodiments, the targeting moiety comprises a CRISPR / Cas molecule. In some embodiments, the effector moiety comprises a CRISPR / Cas molecule. The CRISPR / Cas molecule comprises a protein involved in the clustered regulatory interspaced short palindromic repeats (CRISPR) system, such as a Cas protein, and optionally a guide RNA, such as a single guide RNA (sgRNA).
[0804] The CRISPR system is an adaptive defense system originally discovered in bacteria and archaea. The CRISPR system uses an RNA-guided nuclease (e.g., Cas9 or Cpf1) called a CRISPR-associated or "Cas" endonuclease to cut exogenous DNA. For example, in a typical CRISPR / Cas system, the endonuclease is directed to a target nucleotide sequence (e.g., a site to be sequence-edited in a genome) by targeting a sequence-specific non-coding "guide RNA" of a single-stranded or double-stranded DNA sequence. Three classes (I-III) of CRISPR systems have been identified. Class II CRISPR systems use a single Cas endonuclease (rather than multiple Cas proteins). A Class II CRISPR system includes a type II Cas endonuclease, such as Cas9, CRISPR RNA ("crRNA"), and a trans-activating crRNA ("tracrRNA"). crRNA contains a "guide RNA," i.e., an RNA sequence of about 20 nucleotides generally corresponding to the target DNA sequence. crRNA also includes a region that binds to tracrRNA to form a partially double-stranded structure cut by RNase III, producing a crRNA / tracrRNA hybrid. Then, the crRNA / tracrRNA hybrid guides the Cas9 endonuclease to recognize and cut the target DNA sequence. The target DNA sequence must be generally adjacent to a "protospacer adjacent motif" ("PAM") that is specific for a given Cas endonuclease; however, PAM sequences appear to be spread throughout a given genome. CRISPR endonucleases identified from different prokaryotic species have unique PAM sequence requirements; Examples of PAM sequences include 5'-NGG (Streptococcus pyogenes), 5'-NNAGAA (Streptococcus thermophilus CRISPR1), 5'-NGGNG (Streptococcus thermophilus CRISPR3), and 5'-NNNGATT (Neisseria meningiditis). Some endonucleases (e.g., Cas9 endonuclease) associate with G-rich PAM sites (e.g., 5'-NGG (e.g., TGG, e.g., CGG, e.g., AGG)) and perform blunt-end cleavage of the target DNA at a position 3 nucleotides upstream (5') from the PAM site. Another class II CRISPR system includes the V-type endonuclease Cpf1, which is smaller than Cas9; examples include AsCpf1 (from Acidaminococcus sp.) and LbCpf1 (from Lachnospiraceae sp.).Cpf1-related CRISPR arrays are processed into mature crRNAs without the need for tracrRNA; in other words, the Cpf1 system only requires Cpf1 nuclease and crRNA to cut the target DNA sequence. Cpf1 endonuclease is associated with T-rich PAM sites such as 5'-TTN. Cpf1 can also recognize 5'-CTA PAM motifs. Cpf1 cuts the target DNA by introducing a misplaced or staggered double-strand break with a 5' overhang of 4 or 5 nucleotides, for example, cutting the following target DNA, wherein the misplaced or staggered cutting of the 5 nucleotides in the target DNA is located at a position 18 nucleotides downstream (3') of the PAM site on the coding strand and 23 nucleotides downstream of the PAM site on the complementary strand; the 5 nucleotide overhangs produced by such misplaced cutting allow DNA insertion by homologous recombination to be more accurately edited than the insertion of DNA cut at the blunt end. See, for example, Zetsche et al. (2015) Cell [cell], 163: 759-771.
[0805] A variety of CRISPR related (Cas) genes or proteins can be used in the technology provided by the present disclosure, and the selection of Cas proteins will depend on the specific condi...
Claims
1. An expression repressor, comprising: a first targeting moiety that binds to a target site, wherein the target site is within an E1 cis-acting regulatory element of the CXCL locus or within an E2 cis-acting regulatory element of the CXCL locus, and Optionally, the first effector moiety, The expression inhibitor can reduce the expression of the CXCL gene.
2. The expression repressor of claim 1, wherein the target site is within the genomic coordinates chr4:74591400-74593000 or chr4:74982639-74983600 (based on the hg19 human genome reference assembly).
3. An expression repressor, comprising: a first targeting moiety that binds to a target site within genomic coordinates chr4:74591400-74593000 or chr4:74982639-74983600 (based on the hg19 human genome reference assembly), and Optionally, the first effector moiety, The expression inhibitor can reduce the expression of the CXCL gene.
4. The expression repressor according to any one of claims 1 to 3, wherein the target site is selected from: a) GRCh37: chr4:74591777-74591797; b)GRCh37:chr4:74591834-74591854; c)GRCh37:chr4:74591896-74591916; d)GRCh37:chr4:74592082-74592102; e)GRCh37:chr4:74592107-74592127; f)GRCh37:chr4:74592156-74592176; g)GRCh37:chr4:74592210-74592230; h)GRCh37:chr4:74592057-74592077; i)GRCh37:chr4:74591977-74591997; j)GRCh37:chr4:74591856-74591876; k)GRCh37:chr4:74591768-74591790; l)GRCh37:chr4:74591844-74591866; m)GRCh37:chr4:74591892-74591914; n)GRCh37:chr4:74592088-74592110; o)GRCh37:chr4:74982748-74982770; p)GRCh37:chr4:74982841-74982863; q)GRCh37:chr4:74982882-74982904; r)GRCh37:chr4:74982960-74982982; s) GRCh37: chr4:74983108-74983130; and t)GRCh37:chr4:74983181-74983203.
5. The expression repressor of claims 1-4, wherein the first targeting moiety binds within 500, 300, 200, 100 or 50 nucleotides upstream or downstream of a target site selected from: a) GRCh37: chr4:74591777-74591797; b)GRCh37:chr4:74591834-74591854; c)GRCh37:chr4:74591896-74591916; d)GRCh37:chr4:74592082-74592102; e)GRCh37:chr4:74592107-74592127; f)GRCh37:chr4:74592156-74592176; g)GRCh37:chr4:74592210-74592230; h)GRCh37:chr4:74592057-74592077; i)GRCh37:chr4:74591977-74591997; j)GRCh37:chr4:74591856-74591876; k)GRCh37:chr4:74591768-74591790; l)GRCh37:chr4:74591844-74591866; m)GRCh37:chr4:74591892-74591914; n)GRCh37:chr4:74592088-74592110; o)GRCh37:chr4:74982748-74982770; p)GRCh37:chr4:74982841-74982863; q)GRCh37:chr4:74982882-74982904; r)GRCh37:chr4:74982960-74982982; s) GRCh37: chr4:74983108-74983130; and t)GRCh37:chr4:74983181-74983203.
6. An expression repressor, comprising: a first targeting moiety that binds to a target site comprising at least 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28 or 29 nucleotides of the sequence of any one of SEQ ID NO: 162 or 163, and Optionally, the first effector moiety, The expression inhibitor can reduce the expression of the CXCL gene.
7. An expression repressor, comprising: a first targeting moiety that binds to a target site, wherein the target site is within the IL-8 promoter, and Optionally, the first effector moiety, The expression inhibitor can reduce the expression of IL-8.
8. An expression repressor, comprising: A first targeting moiety that binds to a target site within the following genomic coordinates: GRCh37:chr4:74606162-74606184, or GRCh37:chr4:74605723-74606223 (based on the hg19 human genome reference assembly) Optionally, the first effector moiety, The expression inhibitor can reduce the expression of IL-8.
9. An expression repressor comprising: A first targeting moiety that binds to a target site within the following genomic coordinates: GRCh37: chr4:74605223-74606223 (based on the hg19 human genome reference assembly) Optionally, the first effector moiety, The expression inhibitor can reduce the expression of IL-8.
10. The expression repressor of any one of claims 1-4, wherein the target sequence comprises a sequence according to SEQ ID NO:
134.
11. The expression repressor of any of the preceding claims, wherein the first effector portion comprises an effector as described herein, e.g., KRAB, MQ1, DNMT1, DNMT3A1, DNMT3A2, DNMT3B1, DNMT3B2, DNMT3B3, DNMT3B4, DNMT3B5, DNMT3B6, DNMT3L, EZH2, HDAC8, MeCP2, HP1, RBBP4, REST, FOG1, SUZ12, SETDB1, SETDB2, EHMT2 (i.e., G9A ), EHMT1 (i.e., GLP), SUV39H1, HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9, HDAC10, HDAC11, SIRT1, SIRT2, SIRT3, SIRT4, SIRT5, SIRT6, SIRT7, SIRT8, SIRT9, EZH1, SUV39H2, SETD8, SUV420H1, SUV420H2 or DNMT3, or a functional variant or fragment of any one thereof.
12. The expression repressor of any one of the preceding claims, wherein the first effector moiety is linked to the targeting moiety via a linker.
13. The expression repressor of any one of the preceding claims, wherein the first effector moiety is at the C-terminal end of the targeting moiety.
14. The expression repressor of any one of the preceding claims, wherein the first effector moiety is N-terminal to the targeting moiety.
15. The expression repressor of any of the preceding claims, wherein the first effector portion is encoded by a nucleotide sequence selected from any one of SEQ ID NOs: 10, 14, 16, 18, 66, 68, or a sequence that is at least 80%, 85%, 90%, 95%, 99% or 100% identical thereto or differs therefrom at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 position.
16. An expression repressor as described in any of the preceding claims, wherein the first effector portion comprises an amino acid sequence according to any of SEQ ID NOs: 11, 12, 13, 15, 17, 19, 67, or a sequence that is at least 80%, 85%, 90%, 95%, 99% or 100% identical thereto or differs therefrom at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 position.
17. An expression repressor as described in any of the preceding claims, wherein the first effector portion is MQ1 or a functional variant or fragment thereof, for example, wherein the first effector portion comprises the amino acid sequence of SEQ ID NO: 11 or 12, or a sequence having at least 80%, 85%, 90%, 95%, 99% or 100% identity thereto or differing therefrom by no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 position, wherein optionally the first effector portion is at the C-terminus of the first targeting portion.
18. An expression repressor as claimed in any of the preceding claims, wherein the first effector moiety is KRAB or a functional variant or fragment thereof, for example, wherein the first effector moiety comprises the amino acid sequence of SEQ ID NO: 13, or a sequence having at least 80%, 85%, 90%, 95%, 99% or 100% identity thereto, or differing therefrom at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 position, wherein optionally the first effector moiety is at the C-terminus of the first targeting moiety.
19. The expression repressor of any preceding claim, wherein the effector moiety comprises a DNA methyltransferase, such as MQ1 or a fragment or variant thereof.
20. The expression repressor of any preceding claim, wherein the effector moiety comprises a transcriptional repressor, such as comprising KRAB or a fragment or variant thereof.
21. The expression repressor of any of the preceding claims, wherein the target site has a length of 15-20, 20-25, 25-30 or 30-35 nucleotides.
22. The expression repressor of any of the preceding claims, wherein the first targeting moiety comprises a zinc finger domain or a TAL domain.
23. The expression repressor of claim 22, wherein the zinc finger domain comprises 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 zinc fingers (and optionally no more than 11, 10, 9, 8, 7, 6 or 5 zinc fingers).
24. The expression repressor of claim 22 or 23, wherein the zinc finger domain comprises 1-10, 1-9, 1-8, 1-7, 1-6, 1-5, 1-4, 1-3, 1-2, 2-10, 2-9, 2-8, 2-7, 2-6, 2-5, 2-4, 2-3, 3-10, 3-9, 3-8, 3-7, 3-6, 3-5, 3-4, 4-10, 4-9, 4-8, 4-7, 4-6, 4-5, 5-10, 5-9, 5-8, 5-7, 5-6, 6-10, 6-9, 6-8, 6-7, 7-10, 7-9, 7-8, 8-10, 8-9, or 9-10 zinc fingers.
25. The expression repressor of any one of claims 22-24, wherein the zinc finger domain comprises 3, 7 or 9 zinc fingers.
26. The expression repressor of any one of claims 1-21, wherein the first targeting moiety comprises a CRISPR-Cas domain.
27. The expression repressor of any one of the preceding claims, which is capable of reducing the expression of multiple CXCL genes (eg, 2, 3, 4, 5, 6, 7 or 8 CXCL genes).
28. The expression suppressor of claim 27, which is capable of reducing the expression of one or more (e.g., 2, 3, 4, 5, 6, 7 or 8) of CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7 or IL-8.
29. The expression repressor of any one of claims 1-28, wherein the first effector moiety is a persistent effector moiety or a transient effector moiety.
30. The expression repressor of any one of the preceding claims, wherein the first targeting moiety comprises a zinc finger domain and the first effector moiety comprises a transcriptional repressor, such as KRAB or a fragment or variant thereof.
31. The expression repressor of any of the preceding claims, wherein the first targeting moiety comprises a zinc finger domain and the first effector moiety comprises an epigenetic modification moiety, such as a DNA methyltransferase, such as MQ1 or a fragment or variant thereof.
32. The expression repressor of any of the preceding claims, wherein the first targeting moiety comprises an amino acid sequence according to SEQ ID NO: 114, or a sequence at least 80%, 85%, 90%, 95% or 99% identical thereto.
33. The expression repressor of any one of the preceding claims, comprising the amino acid sequence of SEQ ID NO: 306, or a sequence at least 80%, 85%, 90%, 95% or 99% identical thereto.
34. An expression repressor as described in any of the preceding claims, comprising the amino acid sequence of any one of SEQ ID NOs: 152-161 or 164-169, or a sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identity thereto, or a sequence that differs therefrom at no more than 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 position.
35. The expression repressor of any one of the preceding claims, which: (i) comprises one or more nuclear localization signal sequences (NLS), or (ii) does not comprise an NLS.
36. The expression repressor of any one of the preceding embodiments, comprising a first NLS at the N-terminus, eg, wherein the first NLS has the sequence of SEQ ID NO: 63 or 64.
37. The expression repressor of any preceding embodiment, comprising an NLS at the C-terminus, such as a second NLS, such as having a sequence of SEQ ID NO: 63 or 64.
38. The expression repressor of any preceding embodiment, wherein the first and the second NLS have the same sequence.
39. The expression repressor of any one of embodiments 36-38, wherein the first and the second NLS have different sequences.
40. The expression repressor of any one of the preceding embodiments, wherein binding of the expression repressor to the target site increases methylation at a site in the CXCL locus, for example, increases methylation at the E1 cis-acting regulatory element of the CXCL locus or the E2 cis-acting regulatory element of the CXCL locus.
41. A system comprising: a) a first expression repressor according to any one of claims 1 to 40, and b) a second expression suppressor, for example, a second expression suppressor that reduces the expression of a CXCL gene.
42. The system of claim 41, wherein the second expression repressor comprises: a second targeting moiety that binds to a second target site within the CXCL locus, and Optionally, a second effector moiety.
43. The system of claim 42, wherein the second expression repressor binds to the El cis-acting regulatory element of the CXCL locus, the E2 cis-acting regulatory element of the CXCL locus, or the IL8 promoter.
44. The system of claim 42 or 43, wherein the second target site is within the following coordinates: GRCh37: chr4:74606162-74606184, GRCh37: chr4:74605723-74606223 or GRCh37: chr4:74605223-74606223, or within 1 kb of the 5' or 3' thereof.
45. The system of any one of claims 42-44, wherein the second target site is GRCh37: chr4:74606162-74606184 or chr4:74606039-74606056.
46. The system of any one of claims 42-45, wherein the second targeting moiety is a clustered regulatory interspaced short palindromic repeat (CRISPR) Cas domain.
47. The system of any one of claims 42-46, wherein the second targeting moiety comprises an amino acid sequence according to SEQ ID NO: 268, or a sequence at least 80%, 85%, 90%, 95% or 99% identical thereto.
48. The system of any one of claims 42-47, wherein the second expression repressor comprises an amino acid sequence according to SEQ ID NO: 307, or a sequence at least 80%, 85%, 90%, 95% or 99% identical thereto.
49. The system of any one of claims 42-48, wherein: The target site comprises a sequence according to SEQ ID NO: 134; The first effector portion comprises a KRAB sequence; The second target site comprises a sequence according to SEQ ID NO: 292; and The second effector moiety comprises a KRAB sequence.
50. A nucleic acid encoding the expression repressor of any one of claims 1-40.
51. A nucleic acid encoding: a first expression repressor as described in any one of claims 1-40, and a second expression repressor, for example, a second expression repressor that reduces the expression of a CXCL gene, for example, an expression repressor of the system as described in any one of claims 41-49.
52. A nucleic acid system comprising: a) a first nucleic acid encoding the first expression repressor according to any one of claims 1 to 40, and b) a second nucleic acid encoding a second expression suppressor, such as a second expression suppressor that reduces the expression of a CXCL gene, such as an expression suppressor of the system of any one of claims 41-49.
53. A nucleic acid or nucleic acid system as described in any one of claims 50-52, comprising a region encoding the first targeting portion, wherein the region encoding the first targeting portion comprises a nucleotide sequence of any one of SEQ ID NOs: 122-131 or 194-199 or a sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity thereto.
54. The nucleic acid or nucleic acid system of any one of claims 50-53, comprising a region encoding the first effector portion, wherein the region encoding the first effector portion comprises a nucleotide sequence of any one of SEQ ID NOs: 10, 14, 16, 18, 66, 68, or a sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical thereto.
55. The nucleic acid or nucleic acid system of any one of claims 50-54, further comprising a region encoding an NLS.
56. The nucleic acid or nucleic acid system of claim 55, wherein the region encoding the NLS comprises the nucleotide sequence of SEQ ID NO: 63 or 64, or a sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical thereto.
57. The nucleic acid system of any one of claims 52-56, wherein the first nucleic acid and the second nucleic acid are separate molecules.
58. The nucleic acid system of any one of claims 52-56, wherein the first nucleic acid and the second nucleic acid are covalently linked.
59. The nucleic acid system of any one of claims 52-58, wherein the first nucleic acid comprises: a nucleotide sequence according to SEQ ID NO: 302 encoding the first targeting moiety, or a sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity thereof, and a nucleotide sequence according to SEQ ID NO: 303 encoding the first effector domain, or a sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity thereof.
60. The nucleic acid system of any one of claims 52-59, wherein the second nucleic acid comprises: a nucleotide sequence according to SEQ ID NO: 304 encoding the second targeting moiety, or a sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity thereof, and a nucleotide sequence according to SEQ ID NO: 305 encoding the first effector domain, or a sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity thereof.
61. The nucleic acid system of any one of claims 52-60, having a nucleotide sequence according to SEQ ID NO: 301 or a sequence having at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identity thereto.
62. The nucleic acid or nucleic acid system of any one of claims 50-61, comprising DNA or RNA (eg, mRNA).
63. A vector comprising the nucleic acid or nucleic acid system according to any one of claims 50 to 62.
64. A pharmaceutical composition comprising the expression repressor, nucleic acid or nucleic acid system as claimed in any one of the preceding claims.
65. pharmaceutical compositions as claimed in claim 64, comprising LNP, for example, wherein the nucleic acid or nucleic acid system is formulated as LNP.
66. A human cell comprising: the expression repressor of any one of claims 1-40, the nucleic acid or nucleic acid system of any one of claims 50-62, or the vector of claim 63.
67. A human cell with reduced CXCL gene expression, wherein the cell is produced by a method comprising contacting the cell with an expression repressor as described in any one of claims 1-40, a nucleic acid or nucleic acid system as described in any one of claims 50-62, or a vector as described in claim 63.
68. The human cell of claim 67, wherein the human cell has reduced expression of the first and second CXCL genes.
69. The human cell of claim 67 or 68, wherein the human cell has reduced expression of a third CXCL gene.
70. The human cell of any one of claims 67-69, wherein the human cell has reduced expression of a fourth CXCL gene.
71. The human cell of any one of claims 67-70, wherein the human cell has reduced expression of a fifth CXCL gene.
72. The human cell of any one of claims 67-71, wherein the human cell has reduced expression of a sixth CXCL gene.
73. The human cell of any one of claims 67-72, wherein the human cell has reduced expression of the seventh CXCL gene.
74. The human cell of any one of claims 67-73, wherein the human cell has reduced expression of an eighth CXCL gene.
75. The human cell of any one of claims 67-74, wherein the human cell has reduced expression of one or more (e.g., 2, 3, 4, 5, 6, 7, or 8) of CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, or IL-8.
76. The human cell of any one of claims 67-75, wherein the human cell has reduced expression of one or more of CXCL1, CXCL2, CXCL3, and IL8.
77. A method of reducing the expression of one or more CXCL genes in a cell, the method comprising contacting the cell with an expression repressor as described in any one of claims 1-40, a system as described in any one of claims 41-49, a nucleic acid as described in any one of claims 50-62, or a vector as described in claim 63.
78. A method of reducing the expression of one or more CXCL genes in a cell, the method comprising contacting the cell with an expression repressor or a nucleic acid comprising a sequence encoding the expression repressor, wherein the expression repressor comprises: a first targeting moiety that binds to a target site, wherein the target site is within an E1 cis-acting regulatory element of the CXCL locus or within an E2 cis-acting regulatory element of the CXCL locus, and Optionally, the first effector moiety, Thereby reducing the expression of CXCL gene.
79. The method of claim 77 or 78, wherein the target site is within genomic coordinates chr4:74591400-74593000 or chr4:74982639-74983600 (based on the hg19 human genome reference assembly).
80. The method of any one of claims 77-79, wherein the expression of one or more (e.g., 2, 3, 4, 5, 6, 7, or 8) of CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, or IL-8 is reduced.
81. The method of any one of claims 77-80, wherein the decreased expression persists for at least 1, 2, 3, 4, 5, 6, 7, 10, or 14 days, or at least 1, 2, 3, 4, or 5 weeks.
82. The expression repressor, human cell, system or method of any of the preceding claims, wherein the cell is a cell of a subject suffering from an inflammatory disease, such as an immune-mediated inflammatory disease.
83. The expression repressor, human cell, system or method of claim 82, wherein the inflammatory disease is an autoimmune disorder, such as rheumatoid arthritis.
84. The expression repressor, human cell, system or method of claim 82 or 83, wherein the inflammatory disease is associated with a pathogen infection, such as a viral infection, such as a SARS-CoV2 infection.
85. An expression repressor, human cell, system or method as described in any of claims 82-84, wherein the inflammatory disease is associated with a superinfection, which is an infection caused by two or more pathogens, such as a virus and a bacteria (e.g., SARS-CoV2 and Streptococcus pneumoniae), such as a virus and a fungus (e.g., SARS-CoV2 and mucormycosis).
86. An expression repressor, human cell, system or method as described in any of the preceding claims, wherein the cell is a cell of a subject suffering from rheumatoid arthritis, inflammation, arthritis, gout, asthma, neutrophilic asthma, neutrophilic dermatosis, swollen feet, acute respiratory disease syndrome (ARDS), COVID-19, psoriasis, inflammatory bowel disease, infection (e.g., caused by a pathogen such as a bacterium, virus or fungus), trauma (e.g., an abrasion or foreign body), the effects of radiation or chemical injury, osteoarthritis, osteoarthritic joint pain, joint pain, inflammatory pain, acute pain, chronic pain, cystitis, bronchitis, dermatitis, skin disease, cardiovascular disease, neurodegenerative disease, liver disease, lung disease, kidney disease, pain, swelling, stiffness, tenderness, redness, fever, or elevated biomarkers associated with a disease state (e.g., cytokines, chemokines, growth factors, immune receptors, markers of infection, or markers of inflammation).
87. The expression repressor, human cell, system or method of any of the preceding claims, wherein the cell is a cell of a subject suffering from rheumatoid arthritis, psoriasis or inflammatory bowel disease.
88. The expression repressor, human cell, system or method of any of the preceding claims, wherein the cell is a cell of a subject suffering from rheumatoid arthritis, gout, neutrophilic asthma, neutrophilic dermatosis, acute respiratory disease syndrome (ARDS) or COVID-19.
89. The expression repressor, human cell, system or method of any one of claims 1-81, wherein the cell is a cell of a subject suffering from cancer.
90. The expression repressor, human cell, system or method of claim 89, wherein the cancer is lung cancer (e.g., non-small cell lung cancer), breast cancer, hepatocellular carcinoma (HCC), prostate cancer, colon cancer, skin cancer, cervical cancer, ovarian cancer, endometrioid carcinoma, endometrial carcinoma, mature B-cell lymphoma, bladder cancer, esophagogastric cancer, esophageal adenocarcinoma, bone cancer, melanoma, hepatobiliary carcinoma, thyroid cancer, mature B-cell tumors, glioma, head and neck squamous cell carcinoma, renal clear cell carcinoma, pancreatic cancer (e.g., pancreatic ductal adenocarcinoma), sarcoma, or gastric adenocarcinoma.
91. The expression repressor, human cell, system or method of any of the preceding claims, wherein the cell is located in a subject.
92. The method of any one of claims 77-90, wherein the cell is ex vivo.
93. The method of any one of claims 77-92, wherein the cell is a mammalian cell, such as a human cell.
94. The method of any one of claims 77-93, wherein the cell is a somatic cell.
95. The method of any one of claims 77-94, wherein the cell is a primary cell.
96. The method of any one of claims 77-95, wherein the contacting step is performed ex vivo.
97. The method of claim 96, further comprising the step of removing the cell (eg, mammalian cell) from the subject prior to the contacting step.
98. The method of claim 96 or 87, wherein the method further comprises, after the contacting step, step (b) administering the cells (eg, mammalian cells) to a subject.
99. The method of any one of claims 77-95, wherein the contacting step comprises administering to the subject a composition comprising the expression repressor.
100. The method of claim 99, wherein the expression suppressor is administered as a monotherapy.
101. The method of claim 99, wherein the expression suppressor is administered in combination with a second therapeutic agent.
102. A reaction mixture comprising the cell (eg, human cell, eg, primary human cell) of any one of claims 1-49 and an expression repressor or system.
103. A method of treating a subject suffering from an inflammatory disorder, the method comprising: administering to the subject an expression repressor, system, nucleic acid, nucleic acid system or reaction mixture as described in any one of claims 1 to 102 in an amount sufficient to treat the disorder (e.g., an inflammatory disorder), The disorder (eg, inflammatory disorder) is thereby treated.
104. The method of claim 103, wherein the inflammatory disorder is rheumatoid arthritis, psoriasis, or inflammatory bowel disease.
105. The method of claim 103 or 104, wherein the inflammatory disorder is rheumatoid arthritis, gout, neutrophilic asthma, neutrophilic dermatosis, acute respiratory disease syndrome (ARDS), alcoholic hepatitis, chronic obstructive pulmonary disease (COPD), or COVID-19.
106. The method of any one of claims 103-105, wherein the inflammatory disorder is an autoimmune disorder, such as rheumatoid arthritis.
107. The method of any one of claims 103-106, wherein the inflammatory disease is associated with a pathogen infection, such as a viral infection, such as a SARS-CoV2 infection.
108. The method of any one of claims 103-107, wherein the inflammatory disease is associated with a superinfection, e.g., an infection caused by two or more pathogens, e.g., a virus and a bacterium (e.g., SARS-CoV2 and Streptococcus pneumoniae), e.g., a virus and a fungus (e.g., SARS-CoV2 and mucormycosis).
109. A method of treating a subject suffering from cancer, the method comprising: administering to the subject an expression repressor, system, nucleic acid, nucleic acid system or reaction mixture as described in any one of claims 1 to 102 in an amount sufficient to treat the cancer, Thereby treating the cancer.
110. The method of claim 109, wherein the cancer is lung cancer (e.g., non-small cell lung cancer), breast cancer, hepatocellular carcinoma (HCC), prostate cancer, colon cancer, skin cancer, cervical cancer, ovarian cancer, endometrioid carcinoma, endometrial carcinoma, mature B-cell lymphoma, bladder cancer, esophagogastric cancer, esophageal adenocarcinoma, bone cancer, melanoma, hepatobiliary carcinoma, thyroid cancer, mature B-cell tumors, glioma, head and neck squamous cell carcinoma, renal clear cell carcinoma, pancreatic cancer (e.g., pancreatic ductal adenocarcinoma), sarcoma, or gastric adenocarcinoma.
111. The method of any one of claims 77-101 or 103-110, wherein the subject has an El cis-acting regulatory element sequence comprising the following: a sequence of SEQ ID NO: 162 or a sequence having no more than 8, 7, 6, 5, 4, 3, 2 or 1 alterations thereto.
112. The method of any one of claims 77-101 or 103-110, wherein the subject has an E2 cis-acting regulatory element sequence comprising the sequence of SEQ ID NO: 163 or a sequence having no more than 8, 7, 6, 5, 4, 3, 2 or 1 alterations thereto.
Citation Information
Patent Citations
Apparatus and process for electrolysis using a cation-permselective membrane and turbulence inducing means
EP0002009A1
Manual folding type apparatus of display device for bus
KR101291948B1
Methods and compositions for targeted cleavage and recombination
US20050064474A1
Methods and compositions for treating neuropathic and neurodegenerative conditions
US20050267061A1
Rationally-designed meganucleases with altered sequence specificity and DNA-binding affinity
US20070117128A1
